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Abstract 
Musculoskeletal (MSK) pain is a major reason why people consult their general 
practitioner. Analgesia plays a central role in its treatment but do not always work, 
resulting in the need to switch amongst analgesia potency levels. Stronger analgesia is 
however associated with increased adverse effects.  
The aim was to investigate the use of robust statistical approaches to determine socio-
demographic and clinical factors associated with receiving and switching, prescribed 
analgesia in primary care management of MSK pain.  
The first phase reviewed statistical methods previously used in modelling medication 
switching, and established that Cox proportional hazards and logistic regression models 
were predominantly used. The second phase investigated the prevalence of prescribed 
analgesia, factors associated with being prescribed analgesia, and prescription patterns in 
the management of new MSK conditions using a general practice database. In 3236 
incident consulters, 42% were prescribed analgesia, NSAIDs being most prescribed. In a 
5 year follow-up period, three prescription patterns were identified: no analgesia or basic 
analgesia only, use of NSAIDs, and multiple-potency analgesia combinations. The main 
baseline factors associated with being prescribed analgesia, and stronger analgesia were 
increasing age and having been previously prescribed analgesia. The third phase used 
Cox and Weibull frailty models to identify factors associated with switching analgesia and 
switching to stronger analgesia. The main factors identified were age, gender and initially 
prescribed analgesia.  
The fourth phase used a prevalent cohort of 1610 patients aged 50+ with linked self-
reported and medical record data. Patient-reported factors such as level of physical 
function and pain interference were also associated with switching of analgesia. Using a 
propensity score approach to modelling outcomes suggested those who switched 
analgesia did not have better three year outcomes, but further research is required to 
establish if switching analgesia is beneficial in reducing pain and improving function.
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Chapter 1 
1 Introduction 
This thesis examines analgesia primary care prescription patterns in patients presenting 
to primary care with musculoskeletal (MSK) conditions, and the patient characteristics 
associated with variations in prescription patterns including the switching of analgesia. 
Appropriate statistical methods to determine the pharmacological, clinical and 
demographic factors associated with starting and switching pharmacological treatment of 
MSK conditions in primary care are also explored.  
The main analysis follows a cohort of patients from initial consultation for a MSK condition 
for a maximum of 5 years, modelling factors associated with being prescribed analgesia 
and the potency level prescribed, and the switching of analgesia. The impact of switching 
analgesia on patient reported outcomes is also explored. The analysis is based on the 
hierarchical analgesia categorisation (HAC), a previously developed hierarchy of 
analgesia grouped according to perceived equi-potency when managing a given level of 
pain (Bedson et al., 2009).  
Changing (switching) analgesia is a common feature in the primary care treatment of MSK 
conditions (Chou et al., 2005; Rahme et al., 2006). In this thesis, switching analgesia is 
defined as either a record of a prescription of an analgesia of a potency different from that 
previously prescribed (this may be in place of, or in addition to the initial analgesia), or a 
record of prescribed analgesia without a previous analgesia prescription on first 
consultation (Gore et al., 2012, Rahme et al., 2006; Schneider, 2010).   
There are several factors that can be associated with the need to start or switch analgesia 
ranging from the complexity of the medical condition, the severity and chronicity of pain, 
side effects of current medication and existing co-morbidity or multi-morbidity as well as a 
natural improvement in the pain resulting from the treatment (Bartsch et al., 2008; 
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Mercadante and Bruera, 2006). For example the presence of particular co-morbidities 
such as low back pain, anxiety and irritable bowel syndrome are associated with the 
initiation of stronger analgesia (opioids) in patients with fibromyalgia (Boulanger et al., 
2011; Mercadante and Bruera, 2006), while NSAIDs are not recommended in patients 
with chronic obstructive pulmonary disease (COPD), cardiovascular, chronic kidney and 
gastro-intestinal complications (Rahme and Nedjar, 2007; Hunt et al., 2007).  
The need to switch to stronger or alternative analgesia primarily occurs in three sets of 
circumstances. 1) Where the patient’s pain or condition is controlled by medication, but 
they experience intolerable adverse effects. 2) Where pain is not adequately controlled 
but the dosage of the current medication cannot be increased due to adverse effects. 3)  
When pain is not adequately controlled, even with a rapid increase in dosage that does 
not produce adverse effects, (Chou et al., 2005; Rahme et al., 2006). The switching 
between opioid analgesia can also sometimes be a calculated move by clinicians, as 
opioid rotation may be an effective strategy in the management of negative effects such 
as constipation, nausea, dizziness, dependency, hyper-analgesia and cognitive 
impairment (Joseph et al., 2009; Fitzcharles et al., 2010; Reid et al., 2010).  
While stronger analgesia has the potential to alleviate pain and improve the quality of a 
patient’s life, the stronger the analgesia, the more potential there is for the patient to 
experience adverse side effects such as psychological addiction, dependency, gastric 
toxicity, hyper-analgesia (increased sensitivity to pain) and restricted therapeutic effect 
(Benyamin et al., 2008; Reid et al., 2010). Eschewing treatment that is ineffective and 
striving to maximise the use of more effective analgesia with the least potential for 
adverse side-effects is beneficial to patients (Kroenke et al., 2009; Schneider, 2010).  An 
improved awareness of analgesic use is however only the starting point, since whatever 
prescribing algorithms are being used, it is important for the GP to understand what 
factors they might consider when choosing a therapeutic approach to their patient’s pain 
in order to optimise the cost and benefit of their prescribing.   
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1.1 Musculoskeletal conditions 
A musculoskeletal (MSK) condition is described by Littlejohn (2005) as a cardinal 
symptom of the changes in normal mechanical, physical, and biochemical functions of the 
joint and muscle processes resulting in tissue damage, disease or dysfunction of the MSK 
system. Its presence could be a manifestation of a possible underlying disease or 
condition which may or may not get better with time and medication (Affleck et al., 1999).  
The symptoms of MSK conditions include joint pain, joint stiffness, limitation of movement 
of the joint and swelling, and occur most commonly in the hands, knees, spine, hips and 
lower back (Main, 2002). MSK pain has a multi-factorial aetiology. Examples of MSK 
conditions include rheumatoid arthritis and osteoarthritis (OA) (Wood, 1999). However, in 
most cases, no specific diagnosis can be attributed to the cause of MSK pain, such as 
that which may occur in low back pain, knee pain and shoulder pain (Littlejohn, 2005). 
These may result as a manifestation of tendonitis or soft tissue inflammation (Littlejohn, 
2005). The pain can be localised to a specific section or region of the body (for example 
knee) or widespread, due to the nature and cause of the condition. Injuries may contribute 
to the development of osteoarthritis (OA) of the knee but in the majority of cases, patients 
often do not attribute their chronic pain to injury (Wood, 1999; Katz, 2002).  
MSK pain is associated with increasing age, obesity, female gender, abnormal joint 
loading during occupations involving repetitive use of joints over prolonged periods, e.g. 
professional athletes, and manual jobs based on lifting and handling of heavy loads 
(Wood, 1999; Fitzcharles et al., 2010). Exposure to low social support and low social 
participation may also be associated with higher levels of MSK pain (Jordan et al., 2008).  
Analgesics are often used to alleviate the resultant pain but they do not always work, 
giving rise to the need to switch between analgesia (Rahme et al., 2006). While switching 
analgesia can be necessary, it also brings about the complications of adverse effects 
which may complicate the management of the condition (Moulin, 2001; Bope et al., 2004).  
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1.2 Prevalence of musculoskeletal conditions in the UK  
The prevalence of MSK conditions in the UK and the world in general has far reaching 
health and economic implications (Wood, 1999; Brooks, 2005). MSK conditions were the 
most frequent self-reported longstanding illness in the UK 1995 General Household 
Survey, with a rate of 159 per 1000 adult women and 143 per 1000 adult men, with people 
who live in socially deprived areas having more MSK symptoms, (Urwin et al., 1998). In 
2006, an estimated quarter of the general practice registered population consulted at least 
once with a MSK problem during the course of the year (2405 per 10,000 persons) 
(Jordan et al., 2010) 
 In a study by Jordan et al. (2007), the annual consultation prevalence of MSK conditions 
in the UK in 2001 for adults aged 15 and above was calculated at around 2000 persons 
per 10000, based on national and regional primary care databases. The prevalence 
increases steadily with age and is much higher among females. Some of the MSK 
conditions evaluated for annual consultation prevalence within the population are 
osteoarthritis (230-280 persons per 10000), arthralgia (400 persons per 10000) and 
rheumatoid arthritis (44 persons per 10000) (Jordan et al., 2007). 
1.3 Burdens and health implications of musculoskeletal conditions 
MSK pain impacts negatively on society at large as its incidence and prevalence continue 
to increase in both the developing and the developed world (Main, 2002). It is a major 
cause of disability, loss of function and emotional stress among individuals (Brooks, 
2005). MSK also results in poor quality of life among sufferers and financial constraints 
among other burdens, posing a significant challenge to the health care system (Wood, 
1999; Brooks, 2005).  MSK pain has serious consequences, which include the physical 
and emotional distress of patients and their families as well as resulting in financial 
consequences for employers in terms of sickness absence and lost productivity (Main, 
2002; Brooks, 2006).  
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The direct health care cost of back pain in the UK in 1998 was estimated to be around 
£1.6 billion with the cost of informal care and the production losses related to back pain 
totalling £10.6 billion (Maniadakisa and Gray, 2000). To highlight the impact of MSK pain, 
back pain, which accounts for about 10% of all MSK conditions consulted for, results in 
restrictions on individuals’ social and physical activities and consequently has a 
substantial impact on their life style, the health care system and the national economy 
(Wood, 1999; Brooks, 2005).  
1.4 Management of musculoskeletal pain: WHO guidelines 
The early treatment and management of MSK pain is essential in alleviating disability and 
the resultant burdens from the MSK conditions (Ehrlich, 2003). Research shows that a 
holistic approach to managing MSK, where pharmacological and non-pharmacological 
treatments (exercise, physiotherapy, psychological support) in combination can be 
effective (Ehrlich, 2003; Kean et al., 2008; Dillard, 2011). Notwithstanding the importance 
of non-pharmacological therapies, in general practice, the fundamental treatment strategy 
available to the general practitioner (GP), however, is the prescribing of analgesia (Dillard, 
2011; Kean et al., 2008). They are essential to curb or minimise the impact of MSK pain. 
In recognition of the social and economic implications, guidelines on the pharmacological 
management of MSK pain have been formulated to ensure best practice and effective 
management. In 2003, WHO recognised MSK pain as one of the major reasons why 
people consulted their general practitioner and consequently offered health care 
professionals guidance on the use of analgesia in low back pain, which is equally 
applicable to MSK conditions in general (Ehrlich, 2003). 
1.4.1 Analgesia use in the management of musculoskeletal pain 
The WHO guidelines on the pharmacological management of MSK pain defined  an 
analgesia ladder, whereby doctors were encouraged to use basic analgesia  in the first 
instance (e.g. paracetamol), then step up to using non-steroidal anti-inflammatories 
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(NSAIDs) if basic analgesia did not control the pain, and where appropriate as a third 
step, use opioid analgesia such as codeine. The analgesia has varying levels of potency 
and side effects. Avoiding treatment which is ineffective and maximising the use of those 
giving better results without adverse side-effects is beneficial to the patients (Kroenke et 
al., 2009).  More potent analgesia that are more likely to give better pain relief are also 
more likely to have adverse side effects (Benyamin et al., 2008; Fitzcharles et al., 2010; 
Schneider, 2010; Kroenke et al., 2009).  
The WHO guidelines are the guiding principles in the formulation of the aims and structure 
of this thesis. The guidelines and the analgesia ladder are though open to varying 
interpretations as there are over 300 formulations in the UK that clinicians can prescribe in 
isolation or in combination. The most distinguishable categories of analgesia are basic 
analgesia (including paracetamol), opioids and non-steroidal anti-inflammatory drugs 
(NSAIDs), but opioids can be further subdivided (weak, moderate and strong analgesia) 
according to potency (Benyamin et al., 2008; Bedson et al., 2012).  
The hierarchical analgesia categorisation (HAC) model which has six distinguishable 
categories described in chapter 3 is the interpretation of the analgesia ladder used in this 
thesis. The HAC was used to calculate primary care prescription prevalence of analgesia 
and the effects of national guidelines on prescribing of analgesia between 2001 and 2009 
(Bedson et al., 2012). For example, while the authors showed that analgesia annual 
prescription prevalence has remained around 3100 patients prescribed analgesia per 
10,000 registered population, the prescription of moderate analgesia varied over time, 
reflecting responses to national guidelines by clinicians. 
There is evidence that the analgesia used to control MSK pain do not always work leading 
to the need to switch to different analgesia or potency levels. There is also evidence that 
the effectiveness of analgesia in relieving pain is associated with the levels of pain which 
in turn is associated with emotional, psychosocial and socio-demographic patient 
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characteristics (Fitzcharles et al., 2010; Schneider, 2010). MSK pain and disease severity 
is usually characterised by symptoms and distress (which can be subjective) rather than 
objective clinical measures of disease severity or tissue abnormality (Brown et al., 2010), 
it is essential to continue to develop ways to overcome the numerous barriers to the 
effective management of pain including patient related factors. 
Considering switching of analgesia as a symptom of the presence of the barriers, 
evaluating baseline and long term factors associated with analgesia switching can 
therefore help understand the patient specific barriers, which group of patients is at higher 
risk of exposure to adverse effects, how clinicians prescribe analgesia and potentially 
inform the future pharmacological management of MSK conditions. 
Switching analgesia is primarily an indication that the current medication is not meeting 
the expectations of the patient, the patient is not benefiting or its adverse effects exceed 
the benefits (Brown et al., 2010). In MSK conditions, it is not entirely known how patients 
come to prefer one treatment over another (Schneider, 2010). While the patient’s 
preferences and expectations of treatment benefit are affected by their experiences and 
perceptions of the treatment and their level of pain, they are willing to try treatments 
suggested by their GPs (Sarzi-Puttini et al., 2012). The patient’s expectations and general 
beliefs are strongly associated with subsequent adherence to the treatment, for example, 
a perceived level of harm such as disruption of normal life leads to taking less medicine, 
while the perceived extent to which the medicine restores normal life leads to adherence 
(Brown et al., 2010; Sarzi-Puttini et al., 2012). There are emotional aspects in the 
perception of pain and medication, for example anxiety or depression (Kroenke et al., 
2009), which may emanate from socio-demographic patient characteristics. Switching of 
analgesia is potentially an indication of poor adherence related to the presence of less 
favourable perceptions and expectations about the medication. 
8 
 
There is therefore a need to evaluate changes or switching in analgesia use in MSK 
conditions as identifying associated socio-demographic and clinical factors may help 
clinicians in understanding their patients better and lead to treatment plans tailored to 
address adherence, perceptions and beliefs from the onset of consultation for a MSK 
condition. For example, an awareness session to make the patients ‘at risk’ of switching 
analgesia aware of all their long-term treatment alternatives, their potential benefits and 
associated adverse effects may be effective. The patients may appreciate that there is 
increased exposure to adverse effects resulting from use of a wide spectrum of analgesia 
and that the exposure may eventually limit the clinicians’ choices from the available drugs 
or even increase morbidity associated with MSK pain (Lewis et al., 2002; Mercadante and 
Bruera, 2006). Clinicians may then consider treatments that may alleviate the impact of 
the adverse effects, recognise and address patients’ concerns and misconceptions from 
onset of treatment. 
Although there are prescription guidelines for clinicians, there are few studies that 
evaluate the different strategies for choosing initial treatment, such that deciding between 
first line analgesia and subsequent analgesia is more a matter of expert consensus, 
clinician’s experience and patient preference (Kroenke et al., 2009). There is also little 
evidence that following the recommended stepped approach of starting with weaker 
analgesia and then later moving to stronger analgesia is the best practice. For example 
with opioids, their long-term use is not proven to be beneficial as most studies end after 6 
months (Franklin et al., 2008; Ashworth et al., 2013) and do not suggest recognisable 
benefits, but opioid use is increasing in the UK (Bedson et al., 2012). It is also unclear 
whether this stepped approach is suitable for all patients. Clinicians need to know what is 
happening in real practice, such that if they have some idea which patients might switch 
quickly, it may be preferable instead to use a stronger painkiller immediately rather than 
using a stepped approach which may delay patient pain control. 
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Understanding the socio-demographic, clinical, pharmacologic and patient-reported 
factors associated with analgesia prescribed on initial consultation and with switching of 
analgesia will make clinicians more aware that there are patients potentially at higher risk 
of switching. This will allow better identification of these groups when they first present 
their MSK conditions. The pain management regime of such patients may be personalised 
to ensure it is robust, effective and ensures that patients constantly integrate feedback to 
successfully cope with their condition.  
1.5 Aims and Objectives of the thesis 
The aims of this thesis are therefore  
 To use robust statistical methods to identify patterns in the pharmacological 
management of MSK pain in primary care,  
 To explore and understand the pharmacologic, clinical and demographic 
factors associated with switching analgesia ,   
 To undertake an initial evaluation of the long term outcomes associated with 
switching analgesia.   
The specific objectives are: 
Phase 1 - Previous approaches to modelling medication switching 
 To identify the statistical methods previously used to model switching of 
medications/drugs in primary care  
 To evaluate the applicability of the statistical methods to model analgesia 
switching in MSK conditions in primary care 
 To identify common factors previously identified to be associated with switching of 
drugs/medication in general. 
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Phase 2 - Patterns of analgesia prescribing in new musculoskeletal consulters 
 Establish the percentage of patients prescribed analgesia at the onset of 
consulting for a MSK problem, which potency of analgesia is used and what 
factors are associated with this. 
 Determine whether latent class analysis is a feasible method for grouping patients 
newly consulting with MSK problems based on analgesia prescriptions over 5 
years  
 Determine if distinct clusters of patients can be identified based on the potency of 
the analgesia they are prescribed, and then assess their association with patient 
socio-demographic and clinical characteristics.  
Phase 3 - Switching analgesia in primary care 
 Compare Cox and Weibull models in modelling factors associated with switching 
from initial analgesia to different potency levels over time 
 Identify factors associated switching from initial analgesia potency level and 
establish if the factors associated with time to first switching vary with the potency 
level of initial analgesia. 
 Identify factors associated with switching taking into account successive switches 
from the initial analgesia potency to different potency levels  
 Identify factors associated with  change from no or low potency medication (no 
medication, basic analgesia and weak analgesia analgesia) to higher potency 
analgesia (moderate, strong  analgesia) over time 
 Identify factors associated with the incident rate of switching in multiple-event 
switches 
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Phase 4 – Association of patient-reported factors and long term outcomes with 
switching  
 Assess if the same factors identified previously to be related to switching in an 
incident MSK consulting group are also the key factors associated with switching 
in a prevalent MSK consulting group aged 50+ years 
 Investigate whether switching or progressing to stronger analgesia and having an 
increased number of analgesia switches  within 3 years is linked to reduced 
reporting of pain interference and reporting improved physical function at the end 
of the 3 year period 
1.6 Structure and Phases of the thesis 
Phase 1: Chapter 2 presents a systematic review of statistical methods previously used to 
model medication switching. The medical conditions considered are cancer, MSK 
conditions, depression, schizophrenia, epilepsy and asthma. Non-musculoskeletal 
conditions are included in order to generate a larger population of studies for review.  
The primary objective of the review is to identify commonly used statistical methods in 
modelling switching of medication and to compare and contrast the methods in order to 
understand their relevance, strengths and limitations in delivering the objectives of this 
thesis. The findings of the review will then inform the methodologies to be used in the 
phase 3 modelling. Chapter 3 then describes the datasets to be used in the study. The 
chapter also describes the hierarchical analgesia categorisation (HAC) used in this thesis 
as the primary interpretation of the WHO analgesia ladder, and looks briefly at the existing 
clinical relevance of the clinical and socio-demographic factors assessed for their 
association with switching analgesia.  
Phase 2: Chapters 4 and 5 are both exploratory and analytic and based on a high quality 
database of routinely collected consultation and prescription data (CiPCA) (described in 
Chapter 3). The patients included in the study are those who consulted for any MSK 
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condition in 2006 with no MSK consultation 12 months prior to their consultation and also 
had no prescribed pain analgesia in that period. The initial medication prescribed is 
defined as pain medication prescribed within 2 weeks of their MSK consultation.  
In Chapter 4, the data exploration and description includes frequency of prescription for 
each type of analgesia (HAC categories) at initial consultation and, variation by age, 
gender, general practice and site of MSK problem, e.g. knee, low back. The factors 
associated with prescription of any analgesia and with potency level of the initial analgesia 
are also evaluated. In Chapter 5, patterns of analgesia prescriptions over the 5 year 
follow-up period in these patients are determined using latent class analysis. Associations 
of the identified patterns with baseline factors such as patient age, gender, practice, 
previous MSK consultation and previous prescribed analgesia are examined through 
multinomial logistic regression.  
Phase 3: This phase (Chapter 6-7) examines routinely recorded clinical factors including 
region of pain, comorbidity, number of MSK consultations and prescriptions, and socio-
demographic factors like age, gender, and general practice associated with switching. The 
same cohort is used as in Phase 2 to model time to first switch (both to any and to 
stronger analgesia) and switching taking into account multiple analgesia switches.  
The models used are the Cox proportional hazards model, identified as a possible 
approach through the systematic review in Phase 1, and Weibull models as an alternative 
to the Cox. Statistical models are used in various forms, accounting for more than one 
analgesia switch per person and incorporating frailty (to address variation in switching not 
accounted for by available variables). Poisson regression is employed to evaluate factors 
associated with the relative incidence rates of switching among patients with more than 
one analgesia switch. 
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Phase 4: This phase (chapter 8-9) uses data from an older (50+) cohort (the NorStOP 
cohort) for which linked medical record and survey data has been collected. In Chapter 8, 
the objective is to validate and extend the models used in phase 3.  
The Weibull model is fitted to evaluate if the clinical and socio-demographic factors 
associated with analgesia switching identified in phase 3 are also associated in this cohort 
and when patient-reported variables are included. In Chapter 9 the effect of switching 
analgesia and the number of switches on long term pain interference and physical 
function are evaluated, with confounding factors adjusted for through application of 
propensity score modelling. 
A schematic overview summarising the objectives, structure and statistical methods of the 
thesis is illustrated in Figure 1.5.1 below. The next chapter is a systematic review of 
statistical methods used in modelling medication switching in medical research, while the 
data, analysis tools and variables considered in this thesis are introduced in chapter 3. 
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Figure 1.5.1 Schematic overview of the thesis 
 
 
Objective: To review the statistical methods previously used in 
modelling medication switching, (Chapter 2) 
Objective: To use suitable statistical techniques to evaluate 
factors associated with initial prescribed analgesia and 
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Objective: To use and evaluate suitable statistical techniques 
to determine routinely recorded factors associated with 
switching analgesia in pharmacological management of 
MSK pain (Chapter 6-7) 
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Chapter 2 
2 Statistical methods for modelling switching of medication: a 
systematic review 
2.1 Introduction     
This Chapter details a systematic review examining statistical methods previously used to 
model medication switching. Medication switching in this review is defined as the act of 
changing from one medication to another, taking additional medication, or stopping use of 
current medication. In my initial literature search, only one study (Rahme et al., 2005) 
modelling drug switching in MSK conditions in primary care was found, and no studies 
reviewing statistical methods applicable to modelling switching in medication generally 
were found. Other medical conditions where switching of medication are common were 
therefore considered for inclusion in the systematic review to enable a larger literature 
base that will allow a comprehensive review of statistical methods used in the modelling of 
medication switching. The medical conditions are cancer, epilepsy, depression, 
hypertension and MSK pain.  
Some of the medical conditions like MSK pain, depression and cancer tend to co-occur 
(Bartsch et al., 2009), which may widen the spectrum of common factors associated with 
medication switching. Inevitably each medical condition will have its own set of significant 
factors but identifying common factors for a set of conditions may help in further 
understanding the switching process.  
The need to quantify clearly the risks of switching makes the choice and use of statistical 
methods fundamental in modelling switching. The statistical modelling of socio-
demographic and clinical factors associated with switching analgesia in primary care 
treatment of MSK conditions has not been widely performed; hence a systematic review of 
16 
 
the most applicable statistical methods is necessary. The review will inform the choice of 
statistical methods to be used in later chapters of the thesis.  
The objectives of the systematic review presented in this chapter are: 
1. To identify the statistical methods previously used to model switching of 
medications/drugs in primary care  
2. To evaluate the applicability of the statistical methods to model analgesia 
switching in MSK conditions in primary care 
3. To identify common factors previously identified to be associated with switching of 
drugs/medication in general.  
2.2 Methods 
2.2.1 Literature search Strategy 
The initial search strategy was limited to EBSCOhost databases and health databases: 
which are AMED (Alternative & Complementary Medicine), British Nursing Index, 
CINAHL, MEDLINE, SPORTDiscus and PsycINFO. A manual search of the Statistics in 
Medicine journal was also conducted as it is a relevant journal which may have statistical 
papers related to modelling switching. The search was centred on publications in the 
years between 2000 and 2010 inclusive, in order to limit the modelling approaches to 
those used in the recent past. A selection of papers that had been previously identified 
opportunistically through Google Scholar was used to identify initial key words and subject 
headings as suggested by Scott et al. (2002). The reference lists of the identified papers 
were searched in attempt to locate further articles. 
The key words were the synonyms and related phrases of each medical condition, 
switching, medication and modelling or statistical analysis. Alternative spellings, acronyms 
and any closely related words were used. Some key word have asterisks, for example 
model* to allow the search engine to consider all possible derivatives of the word, while 
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some phrases are put in quotes, for example “pharmacological treatment” to enable the 
phrase to be considered as a single word. This was done because in the preliminary 
search of Google Scholar the words were found to have variations within the desired 
context and the phrases were more meaningful within the context if considered as a single 
word. 
Example search terms were: 
1. Statistical Modelling OR Model* OR Statistical  Analysis 
2. Medication OR Drugs OR Analgesia OR “Pharmacological treatment” 
3. Switching OR Switch* OR Changing OR Change* 
4. “Musculoskeletal pain” OR “Musculoskeletal disorders” OR “Musculoskeletal 
conditions” 
5. Cancer OR “Cancer pain” OR “Chronic pain” 
6. Epilepsy  
7. Depression OR Depress* 
8.  Hypertension OR “High blood pressure” 
9. 1 AND 2 AND 3 AND 4 
10. 1 AND 2 AND 3 AND 5 
11. 1 AND 2 AND 3 AND 6 
12. 1 AND 2 AND 3 AND 7 
13. 1 AND 2 AND 3 AND 8 
14. 9 OR 10 OR 11 OR 12 OR 13 
 Inclusion criteria  
The inclusion criteria was formulated with the view that it was not feasible to translate 
non-English articles into English and that the statistical methods used should be 
applicable to retrospective or prospective analyses allowing adjusting for multiple patient 
characteristics. The diseases chosen (cancer, MSK conditions, hypertension, depression 
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and epilepsy) were those where changing medications is a common feature in the 
primary care management of, and treatment of associated chronic pain (Chou et al., 
2005; Rahme et al., 2005). They are sensible choices since each involves the use of 
medications that are switched to attain some degree of control and therefore have 
commonality, e.g. hypertension drugs are often used hierarchically as in the current NICE 
guidelines, and often different drugs are targeted at different age groups, as may be the 
case in the treatment of MSK. There are several factors that can be associated with the 
need to switch medications ranging from the complexity of the medical condition, 
resultant pain and symptoms of the condition, side effects, effectiveness, co-morbidity or 
multi-morbidity and patient preference (Sarzi-Puttini et al., 2005, Lewis et al., 2002). The 
use of several common chronic problems will enable a wider selection of studies and 
more factors associated with switching to be identified. The inclusion criteria can be 
summarised as: 
i. English language journals or those with English translation available 
ii. Full text available 
iii. Observational, prospective or retrospective studies  
iv. Cohort studies  
v. Studies that used statistical modelling to model the switching of medications  
vi. Treatment or management of cancer, epilepsy, depression, hypertension and 
MSK pain.  
Exclusion criteria 
The exclusion criteria were conceived from the realisation that medication changes or 
switching in clinical trials are planned and usually specific to a particular drug or 
medication, while in this thesis some of the changes or switches to be evaluated are not 
pre-planned and are not specific to medications. The objectives of the chapter are 
primarily to identify statistical modelling techniques applicable to switching; hence the 
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studies should have comprehensive text describing the statistical modelling approaches. 
The exclusion criteria can be summarised as: 
i. Clinical trials and other randomised studies  
ii. Studies reported only in abstracts as they do not detail the modelling procedure 
employed 
2.2.2 Assessment of the quality of the studies. 
Table 2.2.1: Study quality assessment criteria 
Assessment criteria Outcome 
A. Validity of study design Y N N/A 
1. Were study objectives stated/ described?  
2. Were sampling methods clearly described?  
3. Was sample size stated and adequate for the analysis?  
4. Were participants inclusion/exclusion criteria clearly described?  
B. Statistical Methods  
1. Were the statistical methods used adequately stated or referenced?  
2. Were the statistical methods used appropriate for the data?  
3. Were the statistical methods applied correctly in data analysis?  
4. Were model assumptions reported/ tested (e.g. Cox Proportional Hazards)  
5. Were additional analysis and tests used (e.g. K-M plots, bootstrap, log 
rank)? 
 
6. Were models validated with different datasets/bootstrap?  
C. Data description and Model presentation  
1. Were outcomes and relevant characteristics of the participants adequately 
summarised? 
 
2. Were graphical illustrations used (e.g. Kaplan-Meier plots)?  
3. Were model development steps and final models stated?  
4. Were model parameters given with confidence intervals?  
5. Were missing data accounted for?  
6. Were model goodness-of-fit measures given (e.g. -2logL)  
7. Were conclusions drawn from the statistical analyses justified?  
8. Were statistical packages used stated?  
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The quality of the studies identified was assessed narratively though an assessment 
criteria derived from Mallet et al., (2010) in attempt to ensure that the synthesis process is 
credible. There is no standard tool to assess the quality of studies for the purposes of 
establishing the suitability of statistical approaches used, but there is need for a 
systematic approach to synthesising research evidence to establish relevance and 
applicability of statistical modelling approaches used in the past in modelling medication 
switching. It is essential to establish that the use of the statistical model is credible within 
the context of the research, for the outcome of the synthesis to be trusted (Rodgers et al., 
2009).  
The systematic review by Mallet et al. (2010) assessed 47 articles on prognostic models 
using time to event data with the aim of developing a new prognostic model and 
prognostic index to predict patient outcome in cancer patients. Prognostic models are 
clinical prediction models that allow multiple risk factors to be assessed systematically. 
The review found that models developed with poor methods and reporting compromise 
the reliability and clinical relevance of models derived from them. While the purpose of the 
review by Mallet et al. (2010) was different from the purpose of this review, the process of 
establishing that published statistical models have been developed through poor or good 
methods and are well reported is important in establishing the quality of the studies. A 
further similarity is that the review was dealing with studies modelling time to event data, 
which is also the core aspect of this thesis.  
A poorly developed and reported model raises doubts about the suitability of the statistical 
approach used, while well developed and reported models give credibility. The objectives 
of the study, the sample size, the type of the outcome measures and the patient 
characteristics, and available information on the patients can inform on the choice of 
statistical model to be used. For example, in order to use the Cox proportional hazards 
model, one needs to have the precise data on time to an event. 
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The study quality assessment criteria used in this review is given in Table 2.2.1 above. 
The studies were rated as satisfying the assessment items or not, or whether the item is 
not applicable to the study. Studies satisfying more than 50% (author’s choice) of the 
applicable items were considered of reasonable quality. The results were extracted, 
summarised and tabulated with columns including authors, objective, disease, population, 
data source (e.g. medical records, survey), outcome variable, risk factors assessed and 
statistical method used. The study authors’ justification for the choice of method and 
comments are discussed in the discussion section. 
2.3 Results 
401 papers were identified in the search of which 9 met the inclusion/exclusion criteria 
(see Figure 2.3.1). Of the nine studies used in this review, four used only logistic 
regression to identify the factors associated with switching of medications while four used 
only the Cox proportional hazards model. The final study (Bartch et al., 2009) used both 
the logistic and the Cox model. Three of the studies modelled medication switching in 
schizophrenia, two in MSK conditions, one in cancer, one in epilepsy, one in depression 
and one in hypertension.  
Table 2.3.1 below is a summary of the aspects of papers considered for this review which 
might help in understanding what influenced the authors’ choice of the statistical methods 
used in the modelling procedure. The factors that were not statistically significant in the 
models are in italics. 
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Figure 2.3.1: Flow chart of selecting studies for review 
 
 
 
       
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Main search of all Health databases, AMED - The Allied and 
Complementary Medicine Database; British Nursing Index; 
CINAHL; MEDLINE; PsycINFO; SPORTDiscus; AgeLine and 
Google SCHOLAR search - 401 Papers 
After removing duplicate papers and irrelevant papers – 70  
Full text papers - 34 
Medication switching – 9 
Schizophrenia – 3, MSK conditions – 2, Cancer – 1, Epilepsy – 1 
Depression – 1, Hypertension - 1 
Clinical trials and systematic 
reviews removed - 25 
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Table 2.3.1: Summary of the papers used in the review 
Author Study Objective Data source (n=) Disease Risk factors assessed Statistical 
method 
1. Ascher-Svanum 
et al. (2006) 
To determine time to all-
cause discontinuation of 
medication and 
associated factors 
Observational 
study  
(n=2327) 
Schizophrenia Age, gender, ethnicity, 
comorbidity, prior hospitalisation, 
enrolment site, insurance type, 
substance use, scores in the 
Positive and Negative Syndrome 
Scale 
Cox proportional 
hazards model/  
Kaplan-Meier 
2. Bartch et al. 
(2009) 
To determine factors 
predicting activity of 
second line therapy 
Retrospective 
study of females  
(n=97) 
Cancer Age, hormone receptor status, 
brain metastases, more than one 
metastatic site, first-line therapy 
Cox proportional 
hazards model/  
Kaplan-Meier 
logistic model 
3. Bennett et al. 
(2003) 
To determine the degree 
of switching from 
NSAIDS to COX2 and 
factors associated with 
switching 
Cohort study from 
General Medical 
Services 
(n=480573) 
Musculoskeletal 
Pain 
Age, gender, dose, co-
prescribing of anti-peptic ulcer 
drugs, drug type 
 
logistic model 
4. Chou et al. (2 
005) 
To explore factors 
influencing the switch in 
the use of anti-
hypertensive 
medications 
Cohort study on 
Taiwan National 
Health Insurance 
database 
(n=565048) 
Hypertension Age, gender, Initial practitioner, 
last practitioner, practitioner’s 
age, clinic change, Medication 
type, last physician age, 
logistic model 
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Author Study Objective Data source (n=) Disease Risk factors assessed Statistical 
method 
5. Essock  et al. 
(2006) 
To explore whether it is 
more advantageous to 
continue taking the 
medication being 
received at baseline or to 
switch to different 
antipsychotic 
Case-control study 
(n=1432) 
Schizophrenia Age, Drug type, Positive  and 
Negative Syndrome Scale score 
Cox proportional 
hazards model/  
Kaplan-Meier 
6. Hansen et al. 
(2009) 
Investigating the 
association between A-
rated antiepileptic drugs 
(AEDs) and epilepsy-
related events 
Case-control study 
(n=44217) 
Epilepsy Age, gender , region, type of 
seizure, number of prescriptions 
in 6 months 
logistic model, 
chi-squared test 
7. Marcus et al  
(2009) 
Examining the 
pharmacologic, clinical 
and demographic factors 
associated with switching 
antidepressants 
Cohort study on 
patients and 
PharMetrics 
administrative data 
(n=56521) 
Depression Age, gender, depressive 
disorder, co-morbid metal 
condition, general medical illness, 
anti-depressant class, initial dose 
 
logistic model 
8. Marshall et al. 
(2009) 
Comparison of time to all 
cause discontinuation 
across antipsychotic 
drug therapies 
Retrospective 
database analyses 
(n=1191) 
Schizophrenia Age, gender, ethnicity, drug type, 
type of episode 
Cox proportional 
hazards model/ 
Ordinary least 
squares model 
9. Rahme et al. 
(2005) 
To evaluate drug 
switching and associated 
costs among elderly 
chronic NSAIDS users 
Retrospective 
cohort study on 
claims database 
(n=953656) 
Musculoskeletal 
Pain 
Age, gender, prior health check, 
previous diagnosis, prior 
medication, previous switch, drug 
type, staff consulted 
Cox proportional 
hazards model 
Kaplan-Meier 
 
Italics –Non-significant factors in the models
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2.4 Evaluation of the studies 
The studies were evaluated for quality using the quality assessment criteria and the 
results are summarised in Table 2.4.1 below. All studies passed the 50% criteria 
mentioned in section 2.2.2.  In four of the papers, the authors justified the choice of the 
statistical method used in the modelling while five did not. They all however stated the 
need to adjust for other variables in the use of either the Cox model or the logistic model. 
Rahme et al. (2005) stated that the Cox model was used in order to determine hazard 
ratios for first switch while adjusting for baseline characteristics, and for multiple switches 
whilst further adjusting for the number of previous switches as well as treatment duration.  
Essock et al. (2006) stated the use of the Cox model was to compare the discontinuation 
and future switching rates between patients who switched at study entry and those who 
stayed on entry medication, while adjusting for other variables and assessing interactions.  
Bartch et al. (2009) used both the Cox model and the logistic models. The Cox model was 
used to evaluate the factors associated with switch to first line and second line treatments 
and the multinomial logistic model to evaluate variables associated with treatment 
response to second line treatments. Chou et al. (2005) used the logistic model to identify 
predictors of patient drop out from treatment regime or switching after 30 days under 
medication, in which switching was considered to have occurred or not in a fixed time 
interval. 
All the studies had a detailed description of study design, the study size, baseline 
characteristics and outcome variables. The study objectives and the modelling procedures 
to be followed were well spelt out with model development detailed step-by-step. The 
coefficients of the models were stated appropriately as hazard ratios (Cox model), odds 
ratios (Logistic model). Only two of the nine studies, (Essock et al. (2006) and Chou et al. 
(2005)) did not state the statistical packages used to fit the models. Three of the four 
papers that used the Cox regression model (Bartch et al., 2009; Rahme et al., 2005; 
Ascher-Svanum et al., 2006) stated testing the proportional hazards assumptions of the 
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models and also evaluated the discrimination and calibration of the models using Kaplan-
Meier curves.  Only 1 study (Ascher-Svanum et al., 2006) went on to use bootstrap re-
sampling to validate the models.  
Eight studies had sample sizes over 1000 with the largest having over 900,000 eligible 
participants. The study with the smallest sample size was by Bartch et al. (2009) which 
had 97 patients. It was intended to predict the response to second line therapy in the 
treatment of breast cancer in women. However despite the small sample size of the 
Bartch study, the study design, baseline characteristics, drug exposure and switching, 
significant variables and model coefficients together with significance levels were well 
detailed. The Bartch study used Kaplan-Meier plots to highlight the differences between 
the risk groups. Model development was detailed step-by-step and the creation of risk 
groups within the explanatory variables was given medical justification, for example age 
was categorised as less than 35, 35-64 and 65+ because response to therapy was similar 
within each age-group and presumably expected to be different between age groups. It is 
however not reported if the goodness-of-fit tests, model performance and validation with 
external data or same data through bootstrap methods were done.  
Although the studies in this review did not satisfactorily address all the items in the quality 
assessment criteria (for example in eight studies, models were not validated with different 
datasets and model goodness-of-fit measures were not given), it can be generally 
accepted that the quality of the studies with regards to statistical methodology can be 
taken as satisfactory as they adequately satisfied the 50% criteria on the quality 
assessment scale and the models can be considered credible. The models identified a 
wide range of factors associated with medication switching, varying according to the 
medical conditions and variables in the dataset. Variables associated with switching 
included age, gender, ethnicity, previous episodes of the condition, type of drug, 
underlying medical conditions, initial physician consulted, co-morbid conditions treated for, 
prior use of medication, side effects, initial dosage and the price of the medication. 
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Table 2.4.1: Satisfaction of the quality assessment criteria by studies 
Assessment criteria Study 
A. Validity of study design Ascher-
Svanum et al. 
(2006) 
Bartch 
et al. 
(2009) 
Bennett 
et al. 
(2003) 
Chou et 
al. 
(2005) 
Essock 
et al. 
(2006) 
Hansen 
et al. 
(2009) 
Marcus 
et al  
(2009) 
Marshall 
et al. 
(2009) 
Rahme 
et al. 
(2005) 
1. Were study objectives stated/ described? Y Y Y Y Y Y Y Y Y 
2. Were sampling methods clearly described? Y Y Y Y Y Y Y Y Y 
3. Was sample size stated and adequate? Y Y Y Y Y Y Y Y Y 
4. Were inclusion/exclusion criteria clearly stated? Y Y Y Y Y Y Y Y Y 
B. Statistical Methods          
1. Were the statistical methods used adequately 
stated or referenced? 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
2. Were the statistical methods used appropriate? Y Y Y Y Y Y Y Y Y 
3. Were the statistical methods applied correctly in 
data analysis? 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
4. Were model assumptions reported/ tested (e.g. 
Cox Proportional Hazards) 
 
Y 
 
Y 
 
N/A 
 
N/A 
 
N 
 
N/A 
 
N/A 
 
N 
 
Y 
5. Were additional analysis and tests used (e.g. K-M 
plots, bootstrap, log rank)? 
 
Y 
 
Y 
 
N 
 
N 
 
Y 
 
Y 
 
N 
 
Y 
 
Y 
6. Were models validated with different datasets? Y N N N N N N N N 
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Assessment criteria Study 
A. Validity of study design Ascher-
Svanum et 
al. (2006) 
Bartch 
et al. 
(2009) 
Bennett 
et al. 
(2003) 
Chou 
et al. 
(200
5) 
Essock 
et al. 
(2006) 
Hansen 
et al. 
(2009) 
Marcus 
et al  
(2009) 
Marshall 
et al. 
(2009) 
Rahme 
et al. 
(2005) 
C. Data description and Model presentation          
1. Were outcomes and relevant characteristics of the 
participants adequately summarised? 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
2. Were graphical illustrations used (e.g. Kaplan-
Meier plots)? 
 
Y 
 
Y 
 
N/A 
 
N/A 
 
Y 
 
N/A 
 
N/A 
 
Y 
 
Y 
3. Were model development steps/final models 
stated? 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
4. Were model parameters given with confidence 
intervals? 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
5. Were missing data accounted for?  Y Y Y Y Y Y Y Y 
6. Were model goodness-of-fit measures given (e.g. -
2logL)? 
 
Y 
 
N 
 
N 
 
N 
 
N 
 
N 
 
N 
 
N 
 
N 
7. Were conclusions drawn from the statistical 
analyses justified? 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
8. Were statistical packages used stated? Y Y Y Y Y Y Y Y Y 
Y = Yes, N = No, N/A = not applicable 
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Although the effects of variables vary from condition to condition in increasing or reducing 
the risk of switching, age, gender, underlying medical conditions and co-morbid conditions 
are common important variables linked to switching. In the studies looking at MSK 
conditions (Bennett et al., 2003, Rahme et al., 2009), for example, older, female patients 
and those with a history of taking anti-peptic drugs were found to be more likely to be 
switched from NSAIDs to COX-2 inhibitors.  
2.4.1 Justification of statistical model choice 
Some authors did not specifically state the reasons for their model choice but from their 
work it can be assumed that the objectives of the study, the type and quality of the data 
including the variables available influenced the choice of the statistical model to be used. 
The statistical packages used which include SAS, SPSS and Stata are all compatible with 
both statistical models used which rules out the possibility that the model choice was 
influenced by the statistical package at the disposal of the authors.  
The Cox and the logistic models have some similarities but the fundamental differences lie 
with the precision of event time, the proportional hazards assumption and that the logistic 
model is parametric. The Cox model is a semi-parametric or distribution-free approach 
that is; it does not assume that the data has a particular underlying distribution. The 
proportional hazards assumption; the hazards of the different groups are proportional, 
(Lawless 1982), which means that the unique effect of a unit increase in a covariate is 
multiplicative with respect to the hazard rate. For example, starting a long term 
pharmacological management of MSK with drug type A may halve one’s hazard rate for a 
need to switch to more potent drug, compared to type D over time.  
To appreciate the differences, Table 2.4.2 briefly describes the similarities and difference 
between the Cox and Logistic models.  
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Table 2.4.2: Characteristics of the Cox and the logistic models 
Cox Proportional Hazards Model Logistic Model 
Basic model,  (    )     ( )         
  ( )  is the baseline hazard and a function 
of time and   is a vector of regression 
coefficients (Section 6.2.3.1) 
Basic model,   ( )   
          
            
 
      is a linear function:  = intercept,   = 
regression coefficient,    =predictor variable 
Models instantaneous event probability at a 
given time point 
Models event probability in an observation 
time window 
Outcome - time to event Binary response “event occurred: yes 
Proportional hazards assumption No proportional hazards assumption 
Applicable to medical research Applicable to medical research 
Analyse the relation of time dependent 
events to other variables 
Analyse the relation of time dependent 
events to other variables  
Uses partial likelihood for parameter 
estimation  
Uses maximum likelihood for parameter 
estimation  
Semi-parametric  Fully parametric  
Parameter estimates nearly identical to 
logistic in case of rare events and short 
time intervals 
Parameter estimates nearly identical to Cox 
in case of rare events and short time 
intervals 
Sample size has no effect on difference in 
Cox and logistic parameters (D'Agostino et 
al., 1990) 
Sample size has no effect on difference in 
logistic and Cox parameters (D'Agostino et 
al., 1990) 
The objectives stated in the studies all suggest that the switching of medication and the 
factors that can be associated with the process were of importance, meaning that both the 
Cox and logistic models are applicable in all the studies. However, the definition of time as 
discrete (fixed time period in which events are evaluated to have occurred or not) or 
continuous (precise time to each event is measured) separates the studies. The objective 
of two studies (Ascher-Svanum et al., 2006; Marshall et al., 2009), which were to 
determine time to all-cause discontinuation of medication and associated factors rule out 
the logistic model as the objectives suggest the effect of time to each event is essential.  
If there is a need to evaluate the time until an individual event occurs or the instantaneous 
event probability at a given time, then the Cox is more appropriate. Hence it can be 
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postulated that the objectives of the studies did influence the choice of the statistical 
methods in some of the studies. 
2.5 Discussion 
The studies show that the Cox proportional hazards model and logistic regression are the 
commonly used methods to model switching of medications and they allow for 
multivariable modelling of the explanatory variables. Detail on the choice of categorisation 
in variables, model development and model evaluation depends on the researchers but 
can be used to validate the model choice as it suggests the researcher understands the 
appropriateness of the chosen method. The studies give no special justification as to the 
choice of the method, but it can generally be inferred from the studies and their objectives. 
The objectives of a study and the definition of the outcome variable can be assumed to 
significantly influence the statistical model choice among other factors.  
Given data that allow for both models, and similar objectives, the Cox proportional 
hazards model is a better approach than logistic regression as it considers switching also 
as a function of time to each switching event. The choice of the Cox model over the 
parametric forms of the time to event analysis modelling techniques such as the Weibull 
can be justified by the desire to avoid making assumptions about the underlying 
distributions of the data (Marubini, 1994).  
The selected studies highlight lack of efficacy and tolerability as some of the reasons that 
medication switching becomes a necessity. The lack of efficacy can be considered to be 
failure in achieving a desirable response to medication within an expected time frame. 
This makes the use of the logistic model appropriate for modelling factors associated with 
switching in which time to each switching event is not considered of importance (Berkhof, 
2009). 
Tolerance is a state of reduced sensitivity of drug to the body resulting in lower threshold 
pharmacological effect of the drug at normal dose (Joseph et al., 2009; Fitzcharles et al., 
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2010; Reid et al., 2010). It can be assumed to be associated with the time elapsed on that 
medication although the medical history of the patient and other factors can be associated 
too. This means that the switching under such circumstances is a function of time; hence 
the time to event models, in this case the proportional hazards model will be most 
appropriate. It therefore remains for individuals, in light of the available data, to select 
either the semi-parametric or fully parametric form of the model (Marubini, 1994). The 
choice should not be made without due consideration of the data and analysis objectives.  
The logistic model is suitable for discrete survival data or where the times to each event 
are not available (Berkhof et al., 2009). Both methods can handle continuous and 
categorical explanatory variables and allow multiple risk factors to be used systematically 
and reproducibly. They can be used as prognostic models (Mallet, 2010). In general, the 
outcomes in the Cox model are usually presented as hazard ratios while in logistic 
regression the outcomes are usually presented as odds ratios. For both the logistic 
regression and Cox model, the lack of model fit may be expressed by the deviance and 
evaluation of residuals (Dobson and Barnett, 2008).  
The limitations of this analysis are that the design of the systematic review, the conduct of 
literature search, the evaluation of the quality of the studies were all done by one person 
which leave room for errors and a person-specific interpretation of the findings. However 
this review was initially submitted in fulfilment of a module assessment for the training 
module Literature Synthesis and Systematic review. The feedback from the module 
lecturer and the feedback from my supervisors identified most of the weaknesses that 
lead to an improvement in the review process, which was developing study quality 
assessment criteria. The other limitation could be that a quality assessment criterion of the 
studies was derived from the assessment criterion by Mallet (2010) which was meant to 
assess the quality of studies in the development of prognostic models for cancer research. 
This makes the assessment subjective in that it is not a universally accepted criterion. 
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The review only considered published papers with full text. There is therefore likelihood 
that not all relevant studies were identified, therefore excluding other modelling 
approaches in the analysis. The review considered a range of medical conditions to 
enable a larger population of the studies to be used in the review. Treatment regimens 
vary according to each medical condition so that the choice of the statistical modelling 
approaches is determined by the type of data and the research questions being 
answered. No similar reviews were found in available literature to enable comparison of 
this review to what is already known. 
2.6 Conclusion 
The choice of statistical methods used in modelling medication switching seems to be 
influenced by among other factors: the objectives of the study, the type and quality of the 
data, but most importantly the perception or definition of time as discrete or continuous.  
The Cox model seems to be more informative of switching and associated factors as it 
incorporates the effect of time to each event. Notwithstanding other possible statistical 
modelling techniques that can be used, the Weibull model (section 6.2.2.2) may also be 
relevant and applicable for the main analysis in this thesis as it can be used in a similar 
way to the Cox model. Age, gender and prior medication use are commonly associated 
with medication switching. The data, variables, outcomes and the necessary analytic tools 
used in this thesis are introduced in the next chapter. 
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Chapter 3 
3 The hierarchical analgesia categorisation and data sources for 
the thesis 
The aims and objectives of the thesis stated in chapter 1 will be achieved using a 
previously derived categorisation of analgesia, the hierarchical analgesia categorisation 
(HAC) developed by Bedson et al. (2009).  
The thesis concerns the analysis of two distinct datasets. The first dataset of routinely 
recorded primary care data (the Consultations in Primary Care Archive (CiPCA)) will be 
used to study patients presenting with new episode (incident) MSK conditions. The 
second dataset, a linked medical record and survey dataset in a cohort of the general 
population aged 50 and over (the North Staffordshire Osteoarthritis Project (NorStOP)), 
will be used to study older patients with new or on-going consultations for MSK conditions.  
Both databases are held at the Keele University Arthritis Research UK Primary Care 
Centre.  
Chapter 3 aims to describe in more detail the HAC, the use of different potency levels of 
analgesia, the quality of the data used, use of Read codes in identifying MSK conditions 
and the rationale of the socio-demographic and clinical factors selected for investigation 
for their association with switching throughout the thesis. 
The objectives of the chapter are to: 
1. Introduce the HAC as a viable interpretation of the WHO guidelines on analgesia 
use in the management of MSK conditions 
2. Briefly describe the use of analgesia  in primary care and their associated adverse 
effects 
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3. Introduce and highlight the quality of the data to be used in the thesis and the use 
of Read codes in identifying MSK conditions 
4. Give a brief rationale of the factors selected for investigation in the thesis  
3.1 The HAC model of drug groups 
In the United Kingdom (UK) there are over 300 analgesia formulations available to general 
practitioners (GPs) to prescribe from (BNF 65 2013). Bedson and colleagues, using GPs 
in a consensus exercise, derived a hierarchical analgesia categorisation (HAC) where all 
analgesia formulations were categorised into six groups according to equipotency when 
treating varying levels of perceived pain (Bedson et al., 2012). Figure 3.1.1 shows the 
categorisation. Group 1 comprises basic analgesia e.g. paracetamol or topical NSAIDs, 
whilst groups 2-5 are made up of increasingly potent opioids either alone or in 
combination with other medications such as paracetamol, e.g. co-codamol. Group 6 
comprises non-steroidal anti-inflammatory drugs (NSAIDs) which the consensus exercise 
did not rank in the potency ladder but were considered as an adjunct to analgesia 
prescribing.  
The HAC is essentially a research tool which simplifies the examination of large numbers 
of analgesia. Additionally it provides ordered groups of increasingly potent analgesia 
which reflects the way in which the WHO prescription ladders present a framework of 
increasingly potent analgesia for use in the management of MSK pain. Consequently, the 
HAC’s analgesia groupings can now be used as reference points in understanding and 
evaluating the current prescription patterns of GPs when managing MSK pain, instead of 
attempting to compare the 300 or more individual analgesia formulations found in the BNF 
(BNF 65 2013) (Figure 3.1.1).  The HAC has been used successfully to evaluate factors 
associated with the prescription of opioids for joint pain (Green et al., 2012) and 
association of opioid use with disability among low back pain consulters in primary care 
(Muller et al., 2012). 
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Figure 3.1.1: Hierarchical Analgesia Categorisation model for prescribing analgesia and 
NSAIDs in primary care 
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Figure 3.1.2: Flexible Hierarchical Analgesia Categorisation model for prescribing 
analgesia and NSAIDs in primary care 
 
              Basic Analgesia        Weak-Moderate Analgesia                 Strong Analgesia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       
 
    
 
 
                                           
                                                                                                            
 
 
 
 
                                                   
                                                          NSAIDs Including Ibuprofen (600mg) 
Solid boxes – The initial categorisations in the HAC model, Dotted boxes – Categorisations used in the analysis 
For this thesis, due to the low prevalence of prescriptions from, in particular, the very 
strong analgesia category of the HAC and to aid interpretation, the HAC groupings are 
simplified  by combining closely similar categories of analgesia equipotency. In the 
  
 
Weak combination 
Analgesia 
Codeine (8mg) 
+Paracetamol 
Dihydrocodeine (10mg) 
+Paracetamol 
Tramadol (37.5mg) 
+ Paracetamol 
 
Moderate 
combination 
Analgesia 
+/- Paracetamol  
Codeine (15mg) 
Dihydrocodeine (20mg) 
Buprenorphine (5-
10mcg/hr + 200mcg) 
Co-proxamol  
Codeine (20mg)
+ Ibuprofen (300mg) 
Nefopam 
 
Strong combination 
Analgesia 
+/- Paracetamol  
Codeine (30mg) 
Dihydrocodeine 
(30mg) 
Buprenorphine  
(>20 mcg/hr + 
400mcg) 
Tramadol (50mg) 
Pentazocine  
Pethidine  
Meptazinol 
 
Very strong single 
Analgesia 
Morphine 
 
Oxycodone 
 
 
 
NSAIDs including Ibuprofen (600mg)  
+ COX 2     
 
Basic Analgesia 
Paracetamol 
 
Ibuprofen (200-
400mg) 
 
Aspirin (600mg) 
 
Capsaicin 
 
Topical NSAIDs 
 
38 
 
analysis of initially prescribed analgesia in new MSK consulters (Chapter 4), the 
categories are reduced into four main groups of basic analgesia, weak-moderate 
analgesia, strong analgesia and NSAIDs, by combining weak and moderate analgesia 
(weak-moderate analgesia), and strong analgesia with very strong analgesia (strong 
analgesia). In chapter 5-9, five main categories of basic analgesia, weak analgesia, 
moderate analgesia, strong analgesia and NSAIDs are used (Figure 3.1.2).  
While it was intended to use the HAC in its original form, the low prevalence of prescribing 
from some categories as outlined above prompted the reduction to four groups in Chapter 
4. However due to the longer follow-up period used from Chapter 5 onwards, and hence 
increasing number of patients’ prescribed weak and moderate analgesia, these were 
considered separately in these Chapters. 
3.1.1 Basic analgesia 
Basic analgesia are non-opioids; their possible side effects are toxicity when excessive 
dosages are consumed or in patients with impaired liver function, malnutrition or 
dehydration (Ehrlich, 2003; Fitzcharles et al., 2010). The majority of basic analgesia can 
be bought over the counter without a prescription (paracetamol, lower strength ibuprofen, 
topical NSAIDs, and aspirin) whilst all of them, including capsaicin, are available on 
prescription.  
According to the WHO analgesia ladder, basic analgesia, for example, paracetamol and 
ibuprofen are the first-line therapy for mild to moderate pain. They should be considered 
as the initial and on-going pharmacotherapy for the treatment of persistent pain, 
particularly MSK pain (Ehrlich, 2003; Fitzcharles et al., 2010).  
3.1.2 Opioids 
Within this thesis, opioid potency is determined through the use of the HAC. As seen in 
this categorisation, opioids can be considered in four categories depending on potency 
(Bedson et al., 2013). The first category of weak opioids (weak analgesia) (e.g. codeine 
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8mg and tramadol 37.5mg) is stronger than basic analgesia, moderate opioids (moderate 
analgesia) (e.g. codeine 15mg and nefopam) are stronger than weak opioids, and strong 
combination plus strong single opioids (strong analgesia) are stronger than moderate 
opioids.  
Nefopam, for example, is a painkiller which reduces moderate pain. Exactly how it does 
this is not fully understood although it is thought to interrupt the way pain messages are 
sent to your brain from your body (Moulin, 2001). The use of Co-proxamol, a moderate 
analgesia, is now less prevalent in the UK due to the associated adverse effects 
recognized by national guidelines for GPs (Bedson et al., 2012).  
Opioids are considered for moderate to severe pain, pain related functional impairment 
and diminished quality of life due to pain (Fitzcharles et al., 2010). They can be used 
independently or in combination with basic analgesia (Ehrlich, 2003; Moulin, 2001). It is 
recommended that patients using on-going opioid medications should be assessed 
regularly for attainment of therapeutic goals, adverse effects and safe and responsible use 
(Fitzcharles et al., 2010).  
The use of opioids has been associated with higher frequency of constipation, nausea, 
dizziness, cognitive impairment, respiratory problems, depression and urinary retention, 
overdose, self-poisoning and fractures (Dunn et al., 2010; Saunders et al., 2001; 
Benyamin et al., 2008; Fitzcharles et al., 2010). For example, constipation is reported 
among 40 to 95% of patients using opioids and 80% of patients using opioids report at 
least one of the adverse effects (Benyamin et al., 2008; Saunders et al., 2001). 
3.1.3 NSAIDs 
The NSAIDs category in the HAC consists of non-steroidal anti-inflammatory drugs 
including Cyclooxygenase 2 (COX-2) which are non-opioids. Within the consensus 
exercise used to develop the HAC, GPs felt that they could not exactly position NSAIDs 
and COX-2 within the potency ladder, but they were considered stronger than basic 
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analgesia. They are deemed as second-line therapy (treatment that is given when initial 
treatment doesn’t work, or stops working), either alone or as an adjunct to basic analgesia 
in the WHO ladder for management of moderate to severe MSK pain (Ehrlich, 2003; 
Fitzcharles et al., 2010).  
NSAIDs are rarely used, and with much caution, in older patients who do not obtain 
desired relief from other therapies, but are commonly used in younger patients 
(Fitzcharles et al., 2010, Oshima et al., 1996). Their potential adverse effects include 
gastrointestinal complications, acute renal failure, and bleeding disorder, cardiovascular 
complications (hypertension, congestive heart failure and increased cardiac mortality) 
(Fitzcharles et al., 2010; Oshima et al., 1996). The prescription of COX-2s has been less 
prevalent in the UK in the recent past (Bedson et al., 2012), due to warnings in national 
guidelines and directives to clinicians about adverse effects. 
3.2 Databases 
The Consultations in Primary Care Archive (CiPCA) database, used to examine analgesia 
prescribed in a group of new MSK consulters in Chapters 4 - 7 is described in section 
3.2.1. The NorStOP dataset used in chapters 8 and 9 is described briefly in section 3.2.2 
and in more detail in chapter 8. The derivation of the socio-demographic and clinical 
factors to be investigated for association with prescription of analgesia, prescription 
patterns and switching of analgesia and outcomes is also described in this section.  
3.2.1 Consultations in Primary Care Archive (CiPCA) 
In the UK, over 95% of the population are registered with a general practice, and this is 
normally the first point of access to the National Health Service (Lis and Mann, 1995). 
Primary care prescription and consultation data for the period 2004-2010 from the 
Consultations in Primary Care Archive (CiPCA) is used in Chapters 4-7. Approval for 
establishing CiPCA for research purposes was granted by the North Staffordshire 
Research Ethics Committee (Jordan et al., 2007; Jordan et al., 2010).  
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CiPCA is a high quality database of consultation information from 13 general practices in 
North Staffordshire. It is similar to other national databases such as the National Survey of 
Morbidity in General Practice (MSGP4) in terms of percentage composition of registered 
patients by age group and sex, and the annual prevalence of persons consulting for MSK 
conditions (Jordan et al., 2007). The  practices contributing to CiPCA cover a range of 
areas in terms of deprivation although generally North Staffordshire is more deprived than 
England as a whole (Jordan et al., 2010). 
The high quality of the database is ensured through an annual cycle of assessment, 
feedback and training in morbidity coding of the general practices conducted by the Keele 
Research Centre (Porcheret 2004; Jordan et al., 2007). The database contains 
consultation and prescription records for over 100,000 patients from 13 general practices 
in North Staffordshire from 1998 onwards. 12 practices contributed continuously in the 
time frame of the study reported here. The information contained in the database includes 
a unique patient identifier, date of birth, gender, member of staff consulted, consultation 
text (up to the first 250 text characters), their registered practice and Read codes. Read 
codes (NHS Clinical Terminology Service (2005)) are a hierarchy of morbidity, disease 
symptoms and process codes. They become more specific or precise to a condition 
consulted for further down the hierarchy (Jordan et al., 2007; Jordan et al., 2010).  
The prescription data is contained in a sister dataset (Prescriptions in Primary Care 
Archive (PiPCA)) to the consultation data and linkage is made using the unique patient 
identifiers. Data includes the BNF chapter, the drug item, issue date, quantity prescribed 
and price. Prescription data should be complete as clinicians must record the details 
electronically in order to prescribe medication (Porcheret 2004; Jordan et al., 2007; 
Jordan et al., 2010).   
CiPCA / PiPCA has been used in primary care research studies that has led to, as of 9th 
October 2013, 16 peer-reviewed publications. A previous study in PiPCA utilised the HAC 
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categorisation of analgesia and found that significant changes to prescribing occur at 
times when national advice and guidelines are issued to GPs (Bedson et al., 2012).  
CiPCA has also been used to examine prevalence of regional (knee, back, foot, etc) MSK 
problems in primary care (Jordan et al., 2010; Menz et al., 2010), compare MSK 
prevalence cross-nationally (Jordan et al., 2013), determine current management of 
morbidity (for example, gout, Roddy et al., 2010) and the associations between pairs of 
morbidities (Roddy et al., 2013; Burton et al., 2010). The potential limitations of CiPCA are 
that it is based on a regional dataset, is limited to patients from general practices in 
Staffordshire. However, the quality of CiPCA as a primary care database and 
comparability to national and international databases means that the findings of this thesis 
should be generalizable to a broader population than North Staffordshire. 
3.2.2 North Staffordshire Osteoarthritis Project (NorStOP)  
The North Staffordshire Osteoarthritis Project (NorStOP) was a longitudinal general 
population survey between 2001 and 2011, of those aged 50 and over in the general 
practice registered population (Thomas et al., 2004). There are three study cohorts, 
NorStOP1, NorStOP2 and NorStOP3. This thesis uses the first two cohorts for which six 
year data had been collected at the time of analysis. The survey consisted of health 
questionnaires that collected information on several areas of life including socio-
demographics, general health, bodily pain and interference of pain in their daily lives 
(Thomas et al., 2004). Similar questionnaires at baseline, three and six year follow-up 
were used in collecting the data and consent to view medical records was requested 
(Thomas et al., 2004).  
NorStOP was designed to describe the prevalence of pain and pain interference with 
activities, determine the course of joint (hand, knee, hip and foot) pain and related 
disability over 6 years, and determine the factors associated with their onset and 
persistence. It has also been used to describe the prevalence of participation restriction. 
The baseline population mailed the health survey in NorStOP1 and NorStOP2 combined 
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was 20214 and 13986 (69%) responded to the survey. This thesis used those who 
consented to medical record review and responded to baseline and 3 year surveys. The 
medical record data contains the same information as for CiPCA.  
More than 25 publications in peer reviewed journals have used the NorStOP data, for 
example, a study by Wilkie et al. (2008) found that both the onset and persistence of 
person-perceived participation restriction are more common in the older age-groups. 
Factors associated with future primary care prescription of opioids in those self-reporting 
joint pain have been evaluated using NorStOP based on the hierarchical analgesia 
categorisation (HAC), in which it was found that those most likely to receive a high-
strength analgesia were younger aged, males, and those overweight or obese (Green et 
al., 2012). NorStOP has also been used to investigate the association between hand 
arthritis and disability (Myers et al., 2007), the effect of age on the onset of pain 
interference in older adults (Thomas et al., 2007) and factors associated with persistently 
reporting pain that does not interfere with life (Jordan et al., 2012).  
Ethical approval for the NorStOP study was obtained from the North Staffordshire Local 
Research Ethics Committee (Thomas et al., 2004). A further description of the database 
and relevant variables is available in chapter 8. 
3.3 Data management 
The CiPCA database is a collection of routinely recorded medical information, and the 
data was not initially collected for statistical analysis, as such the data had to be cleaned 
and variables formulated for analysis as described below. 
The inclusion criterion for the MSK consulters in the final dataset is described in detail in 
Chapter 4. Year on year prescription and consultation records from 2004 to 2010 were 
merged to create the complete dataset. All analgesia that can be prescribed for MSK pain 
then had to be categorised according to the HAC categories such that the 300+ analgesia 
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and combinations could be identified as basic analgesia, weak analgesia, moderate 
analgesia, strong analgesia, very strong analgesia and NSAIDs.  
The identification of MSK conditions from consultation data to identify patients fitting the 
inclusion criteria is described below. Socio-demographic and clinical factors to be 
investigated for association with prescription of analgesia, prescription patterns and 
switching of analgesia were derived from the information available in the database. 
3.3.1 Sample size 
The sample sizes were dictated largely by the databases from which the study is based; 
hence the exact sample size required for the study was not calculated. However to ensure 
that the results derived from the study are credible, the minimum number of patients 
required was determined by reference to available literature from studies determining 
minimum sample sizes needed for Cox regression analysis in order to determine 
associated variables with outcomes in cohort studies within medical research.  
Mallet et al. (2010) in a systematic review study evaluating the development of prognostic 
models in cancer research observed that a sample size of 500 patients or above was less 
likely to produce asymptotically biased parameter estimates. Hsieh and Philip (2000) in a 
simulation study to derive an appropriate sample size for a Cox proportional hazards 
regression model within medical research established that a sample size of 717 patients 
was adequate to fit a model with 90% power at 5% significance level with covariates’ 
parameter estimates of 0.2 or a hazard ratio (HR) of 1.22, if the number of events was 
215. Alternatively, a sample of 510 patients was adequate to fit a model with 80% power 
at 5% significance level with covariates’ parameter estimate of 0.35 or a HR of 1.42, if the 
number of events was 51. It was therefore assumed that a cohort consisting of at least 
720 patients will be adequate for this study, considering that switching analgesia is a 
common event in the management of MSK pain, implying a potentially large number of 
events. In main analyses of this study, the minimum sample size used is 1309. 
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 3.3.2 Identification of conditions from consultation data through Read Codes 
The first task was to identify patients who had consulted for MSK conditions through the 
Read codes and Read terms entered by their GPs at their consultations. Read codes are 
a hierarchical classification commonly used in UK general practice to record medical 
conditions (NHS Clinical Terminology Service: Clinical Terms Version 3 (Read Codes); 
(Jordan et al., 2010; Bedson et al., 2007; Benson 2011), while Read terms are a brief 
description of the condition and location.  
The Read Code classification has five digit alpha-numeric codes using the numerals 0–9 
(indicating process of care), and the letters A–Z (indicating diagnostic Chapter), The first 
character relates to level 1 (for letters A-Z, the Read Chapter, broadly categorised 
morbidity, for example, N = musculoskeletal), the second to level 2 (Type of condition) and 
so on (Jordan et al., 2010; Benson, 2011). This makes the Read codes more disease and 
location specific as one moves down the levels, (for example, Read Code N05z6 has the 
Read Terms "osteoarthritis of the lower leg" and "osteoarthritis of the knee") (Jordan et al., 
2010). The Read code together with the Read Terms therefore identifies the precise MSK 
condition and location.  
The Read codes were also used to categorise MSK consultations by body region (back, 
hip, knee, shoulder, arm, neck, ankle and foot and other/unspecified) using a previously 
derived classification (Jordan et al., 2010). "Unspecified" problems tended to be codes 
where either no region was described in the associated Read Term (e.g. the term simply 
specified "arthralgia") or the problem covered more than one region (Jordan et al., 2010). 
The existence of co-morbidity and previous MSK consultations were also identified 
through the Read Codes. 
For this thesis, all codes under Chapter N “MSK and connective tissue diseases”, Chapter 
R, “Symptoms, signs and ill-defined conditions” and Chapter 1 "History/Symptoms" were 
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selected as they include codes  deemed to be predominantly MSK and have been used in 
previous research by Jordan et al. (2010). Chapter S, “Injury and Poisoning” can be 
classified as including MSK conditions (injuries) but was excluded for reasons described 
in Chapter 4. Jordan et al. (2010) derived all morbidity Read codes potentially relating to 
pain or MSK conditions within the database CiPCA. Snapshots of the first 45 Read Codes 
for each of chapter 1, N and R, together with the Read Terms and region of pain are 
included in Appendix A. 
3.3.3 Socio-demographic and clinical factors assessed for association with 
analgesia prescribing 
Medical record databases contain a wide range of patient information which may or may 
not be related to the progression and management of MSK conditions. The socio-
demographic, clinical factors routinely recorded in primary care being evaluated in the 
thesis are age, gender, deprivation, registered practice, staff consulted, region of pain, 
previous MSK consultation, previous prescribed analgesia, and co-morbidity. These 
factors, selected for investigation in this study for their association with medication 
management, are those that have been found in the literature or are assumed to be 
related to pain, MSK conditions and specifically the prescription of specific analgesia. 
For instance increasing age and female gender are associated with higher prevalence of 
MSK conditions, while the prescription of NSAIDs is more prevalent in younger patients 
and not recommended among the elderly (Wood 1999; Fitzcharles et al., 2010). Exposure 
to low social support and low social participation which are a common feature among 
deprived localities are also associated with higher levels of MSK pain (Jordan et al., 
2008). In the UK, low income families do not pay for their prescriptions, hence it can be 
hypothesised that the prescription patterns and utilisation of health services will vary with 
varying levels of deprivation. It can also be assumed that variables that can be closely 
linked to individuals’ life-style can have an impact on the prescription patterns too. 
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General practices have different staffing levels in terms of numbers and in diversity 
(experience, prescribing habits) of health practitioners, it is therefore logical to assume 
that even though clinicians are guided by national guidelines, there are aspects of 
prescribing that are open to individual interpretation depending on the clinician’s interest in 
the MSK condition. For example different general practitioners may manage MSK 
conditions differently (Richette et al., 2011). The prevalence of pain and pain interference 
vary by location of pain (Thomas et al., 2004), while stronger analgesia is recommended 
for moderate to severe pain that restricts movement and reduce the quality of life 
(Fitzcharles et al., 2010). It can therefore be assumed that the pain location may be an 
important determinant of the prescription patterns in MSK conditions. 
The previous MSK consultation and previous prescribed analgesia give a brief medical 
and analgesia history of the patient which GPs may consider in deciding whether to give 
medication or not, and which medication to prescribe (Schneider, 2010). GPs are also 
known to consider the existence of co-morbidities when they decide which analgesia to 
prescribe (Richette et al., 2011, Fitzcharles et al., 2010).The prescription of NSAIDs is not 
recommended among patients known to have diabetic related complications such as 
vascular disease, chronic obstructive pulmonary disease (COPD), cardiovascular, chronic 
kidney and gastro-intestinal complications (Fitzcharles et al., 2010).  
The detailed definition and description of all the socio-demographic and clinical 
characteristics evaluated for association with initial analgesia, prescription patterns and 
analgesia switching is given in the next chapter. 
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Chapter 4 
4 Pain medication prescriptions issued at first musculoskeletal 
consultation 
4.1 Introduction 
WHO guidelines on the management of MSK pain recommend clinicians administer basic 
analgesia like paracetamol or topical NSAIDS for pain relief prior to considering other 
alternatives (Ehrlich, 2003). Chapter 3 outlined the close relationship between the WHO 
guidelines and the categorisations by Bedson et al. (2009) of analgesia available for 
prescription. The adverse effects associated with analgesia use were highlighted as well 
as the factors which may be associated with analgesia use. It also described the CiPCA 
general practice database, the proposed use of Read codes in identifying MSK conditions 
and the rationale for the factors selected as potentially associated with the initiation and 
prescription of analgesia. 
Chapter 4 aims to evaluate the current practices in the pharmacological management of 
MSK conditions at the onset of seeking or accessing medical care and evaluate whether 
patients are prescribed medication on their first consultation, what medication is 
prescribed, and the factors associated with being prescribed pain medication and the 
medications used. The chapter sets the reference point for the future analyses assessing 
switching from one group of analgesia to another. 
The specific objectives of this chapter are to: 
1. Establish if patients are prescribed pain medication at the onset of consulting for a 
MSK condition. 
2. Establish which groups of analgesia are prescribed at the initial consultation. 
3. Determine characteristics associated with being prescribed any analgesia. 
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4. Determine factors associated with being prescribed higher potency analgesia 
rather than basic analgesia. 
4.2 Methods 
4.2.1 Data management and study population 
The Consultations in Primary Care Archive (CiPCA) for the period 2004-2006 served as 
the source of the data. Data from the 12 general practices with complete information for 
that period was used. The information contained in the database includes unique 
anonymised patient identifier, date of birth, gender, deprivation of the patient’s local 
neighbourhood, member of staff consulted, their registered practice and Read morbidity 
codes. The prescription data includes the BNF chapter, the drug item, and issue date. A 
full description of CiPCA is given in Chapter 3. 
The patients included in the analysis consisted of those who; 
 Had a record of  any MSK condition (MSK) in 2006,  
 Had no prior MSK consultation and no prescribed analgesia medication within 12 
months preceding their first MSK consultation in 2006, 
 Were aged 15 and above at time of consultation in 2006. 
Injuries were excluded from the definition of a MSK consultation based on the objectives 
of the main study (Chapter 1), to follow MSK conditions over time, as in the majority of 
cases injuries tend to be self-limiting and of relatively short duration. 
The inclusion criteria are defined in this way since it is reasonable to assume that any 
patient who does not consult for, and does not receive prescribed analgesia medication 
for 12 months, does not have a chronic or persistent MSK condition that is currently 
considered by the patient as a troublesome (Moulin, 2001).  
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4.2.2 Outcome measures 
The two dependent variables were i) receiving prescribed analgesia within 14 days of first 
MSK consultation in 2006 and  ii) the analgesia group (1-6) of the medication prescribed 
at this time. However due to the small numbers of patients prescribed moderate analgesia 
and strong single analgesia, weak analgesia were combined with moderate analgesia, 
and strong combination analgesia were combined with very strong single analgesia. This 
meant that the analgesia groups were reduced to: 1- basic analgesia, 2 - weak-moderate 
analgesia, 3 - strong analgesia and 4 - NSAIDs. 
4.2.3 Socio-demographic and clinical characteristics 
The factors being evaluated for their association with pain medication prescription on first 
consultation were age, gender, deprivation, co-morbidity, registered practice, staff 
consulted, region of pain, previous consultation and medication history. Age is considered 
both as a continuous and categorical variable while all other variables are categorical. The 
age of the patients was calculated as of the 1st of July 2006 and grouped into the 
following categories: 15-29, 30-44, 45-59, 60-74, and 75+.  The age group 30-44 is used 
as the reference category as the prevalence of MSK conditions increases with age as 
observed in the study by Jordan et al. (2007); a recognisable upward trend starts from this 
age group. Using the age group 15-29 where the prevalence is very low will mean a very 
high disparity with the older age groups leading to overinflated parameter estimates.  
Neighbourhood deprivation was based on the Index of Multiple Deprivation 2007. This is 
linked to the postcodes of patient addresses (Department for Communities and Local 
Government, 2007). The deprivation ranks range from 1 to 32,482, with 1 being the most 
deprived neighbourhood and 32,482 least deprived in England. This variable was 
categorised into 3 levels with patients in the lower third based on deprivation rank being 
the most deprived, the middle third moderately deprived and the top third least deprived.  
The staff member consulted was categorised into GPs and all other medical staff (such as 
practice nurses and nurse practitioners). 
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The region of pain was categorised as back, knee, hip, neck, foot and ankle, arm (hand, 
wrist, arm, elbow and upper limb), shoulder, and other or unspecified. The specified areas 
are the most common locations of MSK pain (Littlejohn, 2005). Identification of pain region 
used a previously derived classification by Jordan et al. (2010) which is described in 
Chapter 3. Previous consultation for a MSK problem was defined as having a recorded 
MSK consultation in the period 12 to 24 months before the baseline MSK consultation. 
Similarly, previous prescribed analgesia was defined as receiving any prescribed 
analgesia 12 to 24 months before the baseline MSK consultation. These variables give a 
brief medical history of the patient which clinicians may consider in deciding whether to 
give medication or not and which medication to prescribe (Sullivan et al., 2005). 
Co-morbidity was defined as the presence in the primary care records of one or more 
specified disorders or diseases in the period 0-24 months before the baseline MSK 
consultation. The specific comorbidities were diabetes, chronic obstructive pulmonary 
disease (COPD), depression, cardiovascular disease, chronic kidney disease, gastro-
intestinal, and neoplasm. These are long term comorbidities which clinicians take into 
consideration when deciding which type of analgesia to prescribe (Sullivan et al., 2005), 
and some have been discussed in section 3.3.2.  
The Read Codes were selected after discussion with a clinician (John Bedson) who is 
also my supervisor. The Read Codes of the selected comorbidities are C10… for 
diabetes, H3… for COPD, E2… for depression, G2…, G6… and G8… for cardiovascular 
diseases, 1Z1… for chronic kidney, J… for gastro-intestinal and B… for neoplasms. The 
registered general practices are anonymously coded as 1 – 12; hence this variable has 12 
levels. 
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4.2.4 Statistical Methods 
The analyses were designed to evaluate which factors are associated with being 
prescribed pain medication on first consultation and, if prescribed medication, which 
factors are associated with the potency level of medication prescribed. For the first 
analysis, multilevel logistic regression was used to evaluate the association of being 
prescribed any pain medication on first consultation with the patient and practice 
characteristics listed above.  
A second analysis was performed on only those receiving a pain medication. A multilevel 
multinomial logistic regression model with the analgesia group as the outcome variable 
was used to assess associations of patient characteristics with receiving analgesia from 
each of the analgesia groups. The reference category was group 1 (basic analgesia). 
The general practice (level 2) variable was included as a random variable (a variable 
accounting for between practice variations), while patient characteristics (level 1) were 
fixed effects in both analyses. 
Both adjusted and unadjusted multilevel logistic and multilevel multinomial models were 
fitted with statistical significance evaluated at the 5% level using the statistical package 
Stata. The adjusted model is the model in which all clinical and socio-demographic 
variables are included in the model, while the unadjusted model is the model in which only 
one variable is included at a time. 
It was not necessary to incorporate methods to address missing data in the analyses. The 
outcome variables had no missing values. Of the independent variables, only pain location 
had potentially missing data. Within the dataset, the Read Terms (described in Chapter 3) 
were sometimes ambiguous in the location of pain, such as “sports injury”, making it 
impossible to identify the exact region. The category of the pain location variable labelled 
“other/unspecified” accounts for these non-specific regions (about 2% of patients). 
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4.3 Results 
The results show the number of patients who consulted for MSK conditions, the number 
fitting the inclusion criteria and the number prescribed analgesia on first consultation. The 
proportions of the patients prescribed each analgesia category according to the socio-
demographic and clinical characteristics are given, together with the characteristics 
associated with being prescribed analgesia and the potency category. 
4.3.1 New consulters for musculoskeletal conditions 
In 2006, there were 83,875 patients aged 15 and over registered at the 12 practices. 3236 
(386 per 10,000) patients were identified as fitting the study inclusion criteria (section 
4.2.1), that is having a new consultation for a MSK problem in 2006 and aged 15+. 
Figure 4.3.1: Flowchart of patients consulting for MSK problem 
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4.3.2 Patients consulting for a new MSK conditions 
The mean age of these 3236 patients was 43 years (SD 15.8), and 1916 were males with 
mean age 44 years (SD 17.3), while 1320 were females with mean age 42 years (SD 
14.8). The mean age of the 1344 prescribed analgesia on first consultation was 45 years 
(SD 15.8). Age is summarised in Table 4.3.1. 
Table 4.3.1: Mean (SD) age of patients with new consulting episode of musculoskeletal 
pain in 2006 
Overall Prescribed analgesia 
Variable N Mean SD n Mean SD 
       
All 3236 43 15.8 1344 45 15.8 
Females 1320 42 14.8 551 46 17.3 
Males 1916 44 17.3 793 44 14.7 
The age group 30-44 made up 33% of the patients consulting for a new MSK problem in 
2006; while the age group 75+ made up the least, 3%. 59% were males while 41% were 
females. The back was the most common site of the MSK problem (26%), followed by the 
knee (11%). Least commonly affected was the hip (6%), with other or unspecified regions 
accounting for 26% (Table 4.3.2).  
13% had a recent history of consulting for a MSK problem, albeit not within the previous 
12 months, and 16% had received pain medication 12-24 months before their 2006 
consultation. Eighty-one per cent were seen by General Practitioners, 19% by other staff 
members including nurse practitioners and practice nurses. A detailed description of 
patients by each characteristic is given in Table 4.3.2. 
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Table 4.3.2: Socio-demographic and clinical characteristics of patients with new consulting 
episode of musculoskeletal pain in 2006  
Variable     Prescribed analgesia 
 N Column % n Row % 
Total 3236 - 1344 42 
Age (years)     
15-29 710 22 224 32 
30-44 1081 33 448 41 
45-59 963 30 428 44 
60-74 374 12 181 48 
75+ 108 3 63 58 
Gender     
Females 1320 41 551 42 
Males 1916 59 793 41 
Previous musculoskeletal 
consultation  
    
Yes 413 13 163 39 
No 2823 87 1181 42 
Previous analgesia 
prescription 
    
Yes 512 16 244 48 
No 2724 84 1100 40 
Region of Pain     
Back 838 26 465 55 
Knee 341 11 144 42 
Hip 203 6 68 33 
Foot and Ankle 223 7 94 42 
Arm 314 10 105 33 
Shoulder 245 8 129 53 
Neck 218 7 93 43 
Other/unspecified 854 26 246 29 
Co-morbidity     
Selected 119 4 63 53 
None 3117 96 1281 41 
Deprivation     
Most 1430 44 624 44 
Moderate 1263 39 508 40 
Least 543 17 212 39 
Staff category     
GPs 2616 81 1117 43 
Other 620 19 227 37 
Practice     
1 254 8 79 31 
2 224 7 78 35 
3 219 7 77 35 
4 253 8 76 30 
5 161 5 59 37 
6 283 9 115 41 
7 420 13 241 57 
8 324 10 143 44 
9 288 9 130 45 
10 327 10 166 51 
11 143 4 57 40 
12 340 11 123 36 
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4.3.3 Analgesia prescriptions 
Table 4.3.3: Socio-demographic and clinical characteristics of patients prescribed each 
group of analgesia 
Pain medication prescribed 
Variable                                    Basic 
Analgesia 
Moderate 
Analgesia 
NSAIDs Strong 
Analgesia 
 Total n  % c n % c n % c n % c 
 321 24 239 18 637 47 147 11 
Age (years)         
15-29 85 26 28 12 96 15 15 10 
30-44 73 23 66 28 250 39 59 40 
45-59 79 24 77 32 221 35 51 35 
60-74 53 17 44 18 65 10 19 13 
75+ 31 10 24 10 5 1 3 2 
Gender         
Females 137 43 118 49 230 36 66 45 
Males 184 57 121 51 407 64 81 55 
Previous 
musculoskeletal 
consultation  
        
Yes 33 10 28 12 83 13 19 13 
No 288 90 211 88 554 87 128 87 
Previous analgesia 
prescription 
        
Yes 40 12 49 21 127 20 28 19 
No 281 88 190 79 510 80 119 81 
Region of Pain         
Back 64 20 114 48 203 32 84 57 
Knee 44 14 11 5 84 13 5 3 
Hip 10 3 13 5 38 6 7 5 
Foot and Ankle 26 8 10 4 54 9 4 3 
Arm 31 10 8 3 47 7 1 1 
Shoulder 34 10 14 6 71 11 10 7 
Neck 17 5 15 6 44 7 17 12 
Other/unspecified 95 30 54 23 96 15 19 13 
Co-morbidity         
Selected 20 6 13 5 22 3 8 5 
None 301 94 226 95 615 97 139 95 
Deprivation         
Most 146 46 123 52 277 43 78 53 
Moderate 120 37 82 34 254 40 52 35 
Least 55 17 34 14 106 17 17 12 
Staff category         
GPs 273 85 210 88 523 82 111 76 
Other 48 15 29 12 114 18 36 24 
c = Column % 
57 
 
1344 (42%) patients received prescribed analgesia within 14 days of their new MSK 
consultation (Table 4.3.2). Of those who received prescribed pain medication, 24% 
received basic analgesia, 18% weak or moderate analgesia, 11% strong analgesia and 
47% NSAIDs (Table 4.3.3). Socio-demographic and clinical characteristics of those 
prescribed the different types of analgesia are detailed in Table 4.3.3. 
4.3.4 Factors associated with prescription of analgesia 
The associations of prescribing any analgesia with socio-demographic and clinical factors 
are shown in Table 4.3.4. Both adjusted and unadjusted odds ratios (OR) are included in 
the Table but only adjusted odds ratios are interpreted below. There was significant 
practice variation in the decision to prescribe (range across practices of 30% to 57% of 
patients receiving analgesia) with variation between practices accounting for 9% of 
unexplained variation in patients being prescribed analgesia in the multivariable model 
with all patient characteristics included. 
Compared to the 30-44 year old age group, the odds of being prescribed an analgesia on 
first consultation were significantly less in those aged 15 to 29 (OR 0.69 95% CI [0.56, 
0.85]) but higher in those aged 45 to 59 (1.23 [1.02, 1.49]),  60 to 74 (1.51 [1.17, 1.95]),  
and those aged over 75 (2.28 [1.49, 3.49]). Those in the least deprived areas were least 
likely to receive an analgesia prescription (0.69 [0.55, 0.86]). Analgesia were most likely to 
be prescribed for those with pain in the back; however, no difference was apparent 
between those with shoulder and back problems. Those who had received prescribed 
analgesia in the past were more likely to be prescribed analgesia at this new consultation 
(1.24 [1.01, 1.54]).   
There were no significant relationships of being prescribed analgesia with comorbidity, 
gender or whether the patient saw a GP or other medical staff. 
58 
 
Table 4.3.4: Associations with prescription of any analgesia at new consultation for 
musculoskeletal pain 
 OR [95% CI]  
Model Unadjusted Adjusted Adjusted P-value 
Fixed effects    
Age Group     
30-44                                                    1.00 1.00 - 
15-29 0.65 [0.53, 0.80] 0.69 [0.56, 0.85] < 0.001 
45-59 1.12 [0.94, 1.34] 1.23 [1.02, 1.49] 0.025 
60-74 1.28 [1.01, 1.64] 1.51 [1.17, 1.95] 0.002 
75+ 1.85 [1.23, 2.78] 2.28 [1.49, 3.49] < 0.001 
Gender     
Male 1.00 1.00 - 
Female 1.00 [0.87, 1.15] 1.02 [0.88, 1.19] 0.780 
Previous musculoskeletal 
consultation 
   
No 1.00 1.00 - 
Yes 0.89 [0.72, 1.09] 0.83 [0.66, 1.05] 0.119 
Previous analgesia 
prescription 
   
No 1.00 1.00 - 
Yes 1.24 [1.03, 1.49] 1.24 [1.01, 1.54] 0.045 
Pain Region    
Back 1.00 1.00 - 
Knee 0.59 [0.46, 0.77] 0.56 [0.43, 0.72] < 0.001 
Hip 0.38 [0.27, 0.52] 0.35 [0.25, 0.49] < 0.001 
Foot and Ankle 0.55 [0.40, 0.74] 0.52 [0.38, 0.71] < 0.001 
Arm 0.40 [0.30, 0.54] 0.39 [0.29, 0.53] < 0.001 
Shoulder 0.90 [0.67, 1.20] 0.81 [0.60, 1.08] 0.155 
Neck 0.58 [0.43, 0.79] 0.57 [0.42, 0.78] < 0.001 
Other/unspecified 0.32 [0.26, 0.39] 0.29 [0.24, 0.37] < 0.001 
Comorbidity    
Selected 1.00 1.00 - 
None 0.64 [0.44, 0.92] 0.77 [0.52, 1.13] 0.217 
Deprivation    
Most 1.00 1.00 - 
medium 0.85 [0.73, 1.01] 0.80 [0.67, 0.95] 0.012 
least 0.77 [0.63, 0.95] 0.69 [0.55, 0.86] 0.001 
Staff category    
Other 1.00 1.00 - 
GP 0.85 [0.70, 1.02] 0.85 [0.69, 1.04] 0.108 
Random effect                                                                                VARIANCE  
Practice                 0.08 [0.03, 0.21] 0.09[0.03, 0.23] < 0.001 
Unadjusted model = Individual variable  in the model, Adjusted model = All variables included simultaneously 
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4.3.5 Factors associated with type of analgesia prescribed  
In the 1344 patients prescribed analgesia, there was wide variation between practices in 
type of analgesia prescribed. Variation between practices accounted for 27% of all 
remaining variation in type of medication prescribed in the multivariable model including 
all patient and practice characteristics. 
Table 4.3.5 shows the associations of socio-demographic and clinical factors with type of 
analgesia in those prescribed analgesia.  Compared to those aged 30-44, patients aged 
15-29 were more likely to receive basic analgesia than weak-moderate analgesia, strong 
analgesia or NSAIDs. In the case of NSAIDs for example, for patients aged 15-29 the 
adjusted relative risk ratio (RRR) was (0.30 95% CI [0.20, 0.46]) compared to the 30-44 
age group. Also a decreased chance of NSAID prescription was also evident in those 
aged over 60 (for example, aged 75 and above, RRR 0.05 [0.02, 0.13]). Females were 
more likely than males to be prescribed weak-moderate analgesia compared to basic 
analgesia (RRR 1.45 [1.02, 2.09]). A previous history of analgesia prescription was 
associated with the prescribing of stronger analgesia compared to basic analgesia (for 
example, weak-moderate analgesia, RRR 1.88 [1.11, 3.10]). Strong analgesia were less 
likely to be prescribed than basic analgesia to those living in the least deprived areas 
(RRR 0.45 [0.23, 0.88]). There was a non-significant increased likelihood of being 
prescribed NSAIDs if the patient did not have comorbidity (RRR 1.89 [0.96, 3.73]) 
Those with back pain were more likely to be prescribed weak-moderate analgesia, strong 
analgesia and NSAIDs than basic analgesia compared to those presenting with MSK 
problems in other regions. Those who were seen by GPs were more likely to be 
prescribed strong analgesia than basic analgesia (RRR 1.74 [1.01, 3.02]). 
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Table 4.3.5: Associations with type of analgesia prescribed at new consultation for musculoskeletal pain in those prescribed an analgesia 
MODEL RRR [95% CI] 
Fixed effects Weak-moderate Analgesia Strong Analgesia NSAIDs 
 Unadjusted        Adjusted Unadjusted          Adjusted Unadjusted        Adjusted 
Age Group 
30-44 
 
1.00                          1.00 
 
1.00                         1.00 
 
1.00                      1.00 
15-29 0.33 [0.19, 0.57]   0.32 [0.18, 0.57] 0.20 [0.10, 0.38]   0.20 [0.10, 0.40] 0.30 [0.20, 0.45]    0.30 [0.20, 0.46] 
45-59 1.07 [0.67, 1.17]    1.32 [0.81, 2.15] 0.79 [0.48, 1.30]   1.04 [0.62, 1.78] 0.81 [0.56, 1.18]    0.83 [0.54, 1.22] 
60-74 0.87 [0.51, 1.46]    1.19 [0.67, 2.13] 0.42 [0.22, 0.78]   0.71 [0.35, 1.42] 0.34 [0.21, 0.53]    0.35 [0.22, 0.57] 
75+ 0.76 [0.40, 1.47]    1.01 [0.50, 2.05] 0.11 [0.03, 0.37]   0.18 [0.05, 0.64] 0.04 [0.02, 0.11]    0.05 [0.02, 0.13] 
Gender 
Male 
 
1.00                          1.00 
 
1.00                         1.00 
 
1.00                      1.00 
Female 1.32 [0.94, 1.86]     1.45[1.02, 2.09] 1.10 [0.74, 1.62]   1.31 [0.85, 2.01] 0.77 [0.58, 1.01]    0.95 [0.70, 1.28] 
Previous 
musculoskeletal 
consultation 
No 
 
 
 
1.00                          1.00 
 
 
 
1.00                         1.00 
 
 
 
1.00                      1.00 
Yes 1.10[0.64, 1.90]     0.86 [0.47, 1.58] 1.23[0.67, 2.27]    0.98[0.49, 1.95] 1.24 [0.80, 1.93]     0.93 [0.57, 1.54] 
Previous analgesia 
prescription 
No 
 
 
1.00                          1.00 
 
 
1.00                         1.00 
 
 
1.00                      1.00 
Yes 1.64 [1.03, 2.61]    1.88 [1.11, 3.10] 1.49 [0.88, 2.56]    1.72 [0.94, 3.16] 1.58 [1.07, 2.35]    1.74 [1.11, 2.71] 
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MODEL RRR [95% CI] MODEL RRR [95% CI] 
 
 
   
Fixed effects Weak-moderate Analgesia Strong Analgesia NSAIDs 
 Unadjusted        Adjusted Unadjusted        Adjusted Unadjusted        Adjusted 
Pain Region 
Back 
 
1.00                          1.00 
 
1.00                         1.00 
 
1.00                      1.00 
Knee 0.13 [0.06, 0.26]    0.11 [0.05, 0.23] 0.08 [0.03, 0.21]    0.08 [0.03, 0.23] 0.54 [0.34, 0.87]    0.65 [0.40, 1.08] 
Hip 0.72 [0.29, 1.77]    0.61 [0.24, 1.55] 0.53 [0.19, 1.48]    0.62 [0.21, 1.81] 1.18 [0.55, 2.56]    1.59 [0.71, 3.55] 
Foot and Ankle 0.21 [0.09, 0.47]    0.17 [0.07, 0.39] 0.11 [0.04, 0.35]    0.10 [0.03, 0.32] 0.63 [0.37, 1.12]    0.61 [0.34, 1.10] 
Arm 0.12 [0.05, 0.26]    0.10 [0.05, 0.23] 0.02 [0.00, 0.14]    0.02 [0.00, 0.13] 0.40 [0.24, 0.67]    0.40 [0.24, 0.69] 
Shoulder 0.22 [0.11, 0.45]    0.18 [0.09, 0.37] 0.21 [0.10, 0.47]    0.18 [0.08, 0.40] 0.62 [0.38, 1.05]    0.56 [0.33, 0.96] 
Neck 0.49 [0.23, 1.06]    0.50 [0.23, 1.12] 0.76 [0.35, 1.61]    0.83 [0.37, 1.84] 0.81 [0.43, 1.54]    0.82 [0.42, 1.62] 
Other/unspecified 0.36 [0.22, 0.57]    0.32 [0.20, 0.53] 0.17 [0.10, 0.32]    0.18 [0.10, 0.34] 0.34 [0.22, 0.51]    0.38 [0.25, 0.59] 
Comorbidity 
Selected 
 
1.00                          1.00 
 
1.00                         1.00 
 
1.00                      1.00 
None 1.18 [0.57, 2.44]  1.49[0.68, 3.26] 1.18 [0.50, 2.76]     1.40 [0.56, 3.53] 1.89 [1.30, 3..57]  1.89 [0.96, 3.73] 
Deprivation  
Most 
 
1.00                          1.00 
 
1.00                         1.00 
 
1.00                      1.00 
Medium 0.85 [0.58, 1.26]    0.75 [0.49, 1.13] 0.85 [0.58, 1.33]    0.76 [0.47, 1.22] 1.17 [0.86, 1.61]    1.19 [0.85, 1.67] 
least 0.74 [0.44, 1.23]    0.58 [0.33, 1.01] 0.58 [0.31, 1.09]    0.45 [0.23, 0.88] 1.02 [0.68, 1.54]    1.00 [0.64, 1.56] 
Staff category  
Other 
 
1.00                          1.00 
 
1.00                         1.00 
 
1.00                      1.00 
GP 0.79[0.47, 1.04]      0.81[0.47, 1.39] 1.86 [1.12, 3.09]      1.74 [1.01, 3.02] 1.25 [0.84, 1.86]     1.17 [0.77, 1.79] 
Random effect                                                                                
Practice                                                     0.27 [0.13] 
Unadjusted model = Individual variable in the model, Adjusted model = All variables included simultaneously
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4.4 Discussion 
On first consultation for MSK conditions, 42% of the patients were prescribed analgesia. 
NSAIDs were most frequently prescribed followed by basic analgesia while opioids alone 
or in combination with other analgesia were the least prescribed. The higher potency 
opioids were less commonly prescribed. There was variation in prescription rates by 
different factors. Being prescribed any analgesia on first consultation was associated with 
the age of the patient, their level of neighbourhood deprivation, the body region in which 
they experienced pain and their registered general practice.   
The chances of being prescribed weak-moderate analgesia over basic analgesia were 
associated with patient age, whether they are female, having received any analgesia in 
the past, the location of pain and the registered practice. The prescription of strong 
analgesia over basic analgesia is associated with patient age, level of deprivation, region 
of pain and registered practice. The chances of prescribing NSAIDs over basic analgesia 
are associated with patient age, region of pain, having received analgesia in the past, and 
registered practice. 
Table 4.4.1 below gives a summary of the significant socio-demographic and clinical 
variables associated with being prescribed weak-moderate analgesia, strong analgesia 
and NSAIDs instead of basic analgesia, after adjusting for all possible variables. 
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Table 4.4.1: Summary of the factors associated with type of prescribed analgesia 
Variable Weak - moderate 
Analgesia 
Strong 
Analgesia 
NSAIDS 
Age 
15-29 
30-44 
45-59 
60-74 
75+ 
 
<Yes 
- 
No 
No 
No 
 
<Yes 
- 
No 
No 
<Yes 
 
<Yes 
- 
No 
<Yes 
<Yes 
Gender 
Female 
 
>Yes 
 
No 
 
No 
Previous musculoskeletal 
consultation  
Yes 
 
 
             No 
 
 
          No 
 
 
       No 
Previous Analgesia 
prescription 
Yes  
 
 
           >Yes 
 
 
          No 
 
 
   > Yes 
Pain region 
Back 
Knee 
Hip 
Foot and ankle 
Hand and wrist 
Shoulder 
Neck 
Other/Unspecified 
 
- 
<Yes 
No 
<Yes 
<Yes 
<Yes 
No 
<Yes 
 
- 
<Yes 
No 
<Yes 
<Yes 
<Yes 
No 
<Yes 
 
- 
No 
No 
No 
<Yes 
<Yes 
No 
<Yes 
Deprivation 
Least  
Medium 
Least 
 
- 
No 
No 
 
- 
No 
<Yes 
 
- 
No 
No 
Co-morbidity 
Selected conditions 
None 
 
- 
No 
 
- 
No 
 
- 
No 
Staff category 
 GPs 
Other staff 
 
- 
No 
 
- 
>Yes 
 
- 
No 
Reference group = -, Significant increased likelihood of having analgesia = >Yes, Significant decreased likelihood of having analgesia = <Yes 
Non-significant = No 
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The adherence to the WHO guidelines in starting pharmacological management of MSK 
pain is to some extent evident in that 58% of the patients consulting for the first time were 
not prescribed any pain medication while medications at the higher end of potency were 
less commonly prescribed (Bope et al., 2004). A previous study of those aged over 50 
consulting in primary care for MSK pain, and who had not consulted in the previous 30 
days, also reported that less than half were prescribed analgesia  (Muller et al., 2012). 
The strongest opioid analgesia was prescribed less than basic analgesia on first 
consultation. Higher potency drugs are more likely to have adverse side effects while 
starting at low potency minimises exposure to side effects (Dunn et al., 2010; Saunders et 
al., 2001; Benyamin et al., 2008; Fitzcharles et al., 2010; Schneider, 2010). Hence it can 
be assumed that in addition to following the guidelines, clinicians do consider the risk of 
adverse effects. 
Doctors consider whether a patient is young or elderly (Garbez and Puntillo, 2005; 
Benyamin et al., 2008) when deciding whether to prescribe analgesia or not and the level 
of potency to prescribe.  Older age groups appear more likely to be prescribed analgesia 
which mirrors the consultation prevalence for MSK pain increasing with age (Jordan et al., 
2007; Fitzcharles et al., 2010) such that for example, despite fewer patients being aged 
75+, they are the most likely to be prescribed pain medication. It is  likely that older 
patients had consulted previously for MSK pain and are able to communicate their pain 
and hence may be perceived by providers as experiencing more pain (Garbez and 
Puntillo, 2005; Saunders et al., 2001). The patient’s communication of pain is regarded as 
the strongest predictor of the amount and strength of medication given (Eder et al., 2003) 
and a patient’s experience gives meaning to their pain (Manias et al., 2002). 
Patients aged over 75 were twice as likely to receive analgesia as younger age groups, 
but were less likely to be prescribed NSAIDs. This finding is in keeping with current advice 
on NSAID use in older patients who might be considered more likely to experience 
adverse effects such as renal toxicity (Sullivan et al., 2005; Wood, 1999)  and 
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gastrointestinal haemorrhage (Akarca, 2005; Schneider, 2010; Fitzcharles et al., 2010)  
with NSAIDs. Stronger analgesia were less likely to be used in those aged over 75, a 
finding that has also been described previously (Benyamin et al., 2008; Edlund et al., 
2007;  Green et al., 2012; Walker-Bone et al., 2000). This would make clinical sense since 
using more potent opioid type drugs in the elderly has been associated with increased 
rates of falls and bone fractures (Dunn et al., 2010; Saunders et al., 2001; Benyamin et 
al., 2008; Fitzcharles et al., 2010; Schneider, 2010). Comorbidity was linked to a lower 
likelihood of being prescribed NSAIDs which also reflects the possibility that clinicians are 
avoiding using these drugs in patients more vulnerable to side effects (Schaffer et al., 
2006). However, this finding was non-significant and the prevalence of our selected 
comorbidities in this group with new MSK problems was low.  
Younger adults (15-29) were more likely to be prescribed basic analgesia, perhaps 
reflecting the less severe nature of pain in younger people with MSK problems (and are a 
possible reflection of adherence to analgesia guidelines). Due to their age, this group is 
less likely to have previous exposure to prescribed analgesia medication. Therefore where 
it is used, the first level of analgesia as suggested in these guidelines is most commonly 
prescribed (Sarzi-Puttini et al., 2005).  Female patients were more likely to be prescribed 
weak- moderate analgesia over basic analgesia compared to male patients. Females are 
often perceived by GPs as experiencing more pain than males and females are better 
than males at communicating their pain (Garbez and Puntillo, 2005; Curatolo and Bogduk, 
2001), which may influence the decision to prescribe more potent medication than basic 
analgesia.  
GPs’ knowledge of previous medication affects their prescribing; a patient with a record of 
previous medication is more likely to be given weak-moderate analgesia. GPs will 
generally inquire from the patient about their medication use prior to consultation (Garbez 
and Puntillo, 2005; Fitzcharles et al., 2010) which makes a potential case for the use of 
weak-moderate analgesia over previously used basic analgesia. Basic analgesia are 
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available over the counter without prescription, and patients first seen in primary care may 
already be using these medications.  
Patients from the most deprived areas were more likely to be prescribed pain medication 
than patients from medium and least deprived areas. Patients from least deprived areas 
were less likely to be prescribed strong analgesia compared to most and medium 
deprivation patients. The association of level of deprivation with prescription of analgesia 
is closely related to findings by (Jordan et al., 2008; Berkman, 2004) that social 
characteristics such as neighbourhood level of unemployment have an additional 
detrimental effect on health.  
The level of pain is associated with emotional distress, low social support and low social 
participation (Katz, 2002; Garbez and Puntillo, 2005). This high level of emotional distress 
may inflate the GP’s perceived level of pain (Katz, 2002). People who live in socially 
deprived areas have more MSK symptoms (Urwin et al., 1998) which probably leads to 
them being prescribed analgesia due to potentially higher perceived levels of pain.  
Patients in more deprived areas may rely on prescribed medication even for pain that can 
be eased with over the counter medications as prescriptions are free for low income 
patients in the UK.  Patients from least deprived areas may prefer to purchase over the 
counter medications as they pay for their prescriptions, which is similar to findings by 
(Bedson et al., 2001) on factors affecting over the counter use of aspirin in cardiovascular 
diseases. 
Patients with pain in the knee, hip, foot and ankle, hand and wrist, neck and other or 
unspecified parts were less likely to be prescribed pain medication than pain in the back. 
Pain in the knee, foot, ankle, hand, wrist, shoulder and other or unspecified parts was less 
likely to be prescribed weak or moderate analgesia and strong single or combination 
analgesia. Doctors use NSAIDs less for pain in the hand, wrist and shoulder and use 
strong analgesia less for pain in the knee, foot, ankle, hand, wrist, neck and shoulder. 
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Back pain limits the functional reach of limbs and the ability to rotate the trunk repetitively 
which is essential for mobility, and results in restrictions on individuals’ social and physical 
activities and have a substantial impact on their life style (Rudy et al., 2007; Fitzcharles et 
al., 2010). Back pain also constitutes about 10% of all MSK conditions consulted for and is 
a leading cause of disability (Main 2002; Brooks, 2006). Therefore, the GPs may be more 
likely to perceive back pain as limiting in the day to day activities that a person has to 
perform hence the need to prescribe stronger pain medication for back pain. GPs may 
perceive pain differently in varying regions, in terms of the handicap it causes, back, knee 
and hip pain being debilitating in terms of mobility and shoulder, wrist and hand pain 
limiting daily activities such as washing, cooking, cleaning (Littlejohn, 2005).  
The potential limitations of the study include that it is based on a regional dataset, is 
limited to patients selected over a 12 month consultation period, and the inclusion criteria 
may include patients with MSK pain episodes with a periodicity of more than 12 months 
and those who have been taking over the counter medications. Their initial consultation of 
2006 and subsequent medication prescribed may not be a true reflection of the starting 
point of their pharmacological management for MSK pain. However the inclusion criteria 
ensures that it is reasonable to consider the patients as having no chronic pain prior to 
consulting as chronic pain is often defined as pain lasting more than three months, 
(Kraoenke et al., 2008). The inclusion criteria may eliminate patients who may have been 
treated for non-MSK conditions which are treatable with analgesia, leading to potential 
loss of co-morbidity or multi-morbidity patients.  
GPs consider multiple factors including co-morbidity in deciding the medication and 
appropriate potency level (Bope et al., 2004); Garbez and Puntillo, 2005; Schneider, 
2010). There may be other unmeasured variables like other contraindications for whether 
one may or may not be prescribed a certain drug although relevant comorbidities were 
examined. Pain severity, weight, alcohol misuse and ethnicity might also impact on 
68 
 
prescription of analgesia (Breckenridge and Clark, 2004) and these are not evaluated in 
the analysis.  
Despite the limitations of the study, the important associations found have previously been 
observed in other related but different studies such as Muller et al. (2012).  A study 
sample greater than 500 can adequately give reliable parameter estimates in logistic 
regression (Mallett, 2010) hence a sample of 3236 and 1344 can be assumed to be 
adequate in the multilevel logistic and multilevel multinomial logistic model respectively.  
The data used in the study is drawn from a high quality data set, CiPCA, which gives 
comparable consultation prevalence Figures for MSK problems as the larger national 
datasets (Jordan et al., 2007). The study provides a good starting point for further 
research into the pharmacological management of MSK pain over time as it identifies 
baseline factors associated with prescription of analgesia. 
4.5 Conclusion 
The study is an evaluation of initial pain management strategies in the treatment of MSK 
pain and suggests that the HAC model of prescribing in general practice is a valuable tool 
in describing prescription dynamics. Not all patients consulting for a new episode of a 
MSK condition are prescribed analgesia. A variety of factors appear to be taken into 
account which also appear to influence, which category of analgesia is deemed suitable. 
The prescription profiles or pathways followed by different patients over time are 
investigated in the next chapter. 
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Chapter 5 
5 Prescription patterns of analgesia in musculoskeletal 
conditions in primary care over five years: A latent class analysis 
5.1 Introduction 
Chapter 4 identified socio-demographic and clinical characteristics associated with 
analgesia prescribing at the time of a new MSK consultation. The chapter demonstrated 
that the hierarchical analgesia categorisation (HAC) model has potential as a tool in 
describing prescribed analgesia issued at first consultation for MSK pain. That chapter 
highlighted that while some patients consulting for the first time are not prescribed pain 
medication, factors such as age of the patient, gender and previous prescribed analgesia 
seem to be taken into consideration when deciding to prescribe and the initial potency 
level given.  
Changing analgesia is an essential feature of long term treatment of MSK pain in primary 
care (Ehrlich, 2003). There are several factors that may influence the need to change 
analgesia ranging from the pain intensity which may seriously limit mobility, side effects, 
effectiveness of the analgesia, co-morbidity and patient preference (Chou et al., 2005; 
Rahme et al., 2006). The use of stronger medication over time may be a marker for the 
severity of the pain and its effect on everyday activities (Hunt et al., 2007).   
Changing or switching analgesia leads to patients having different prescribed medication 
profiles or pathways over time. A patient’s medication profile over time can be a proxy for 
the severity of their MSK condition. The starting point for measuring management success 
or failure may be identifying the changes in prescribed analgesia based on the 
interpretation of the HAC analgesia ladder (Chapter 3), which reflects the World Health 
Organisation (WHO) (Ehrlich, 2003) guidelines for the treatment of MSK conditions.  
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As seen in Chapter 3, the WHO ladder suggests starting with non-opioid analgesia before 
moving up the potency ladder. The potency levels of the HAC prescribed over time can 
therefore define a medication pathway, enabling evaluation of what medication pathways 
or profiles that the patients are consigned to, based on their baseline characteristics. One 
hypothesis is that patient characteristics at the onset of pharmacological treatment are 
predictive of their eventual pathway. Additionally the predictive characteristics, if any, 
might help clinicians identify patients at risk of switching to more potent analgesia and 
accordingly ‘flag’ these patients for special monitoring. 
The aim of the analysis set out in this chapter, therefore, is to use latent class analysis to 
identify common medication profiles defined by varying degrees of analgesia potency 
levels prescribed to MSK consulters over time and examine the socio-demographic and 
clinical variables associated with membership of each medication profile.  
The specific objectives of the chapter are: 
1. To determine if patients newly consulting with MSK problems can be grouped into 
a small number of distinct clusters based on the potency levels of their analgesia 
prescribed in primary care over 5 years  
2. To assess the association of patient socio-demographic and clinical characteristics 
with the identified prescribing patterns 
3. To determine whether latent class analysis is a feasible method for grouping 
patients based on analgesia prescriptions 
Classifying patients using their prescribed analgesia potency levels over time and 
identifying the associations with clinical and socio-demographic factors have the potential 
to give a valuable insight into the current analgesia prescribing patterns in MSK 
conditions.  
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5.2 Methods 
The pain analgesia profiles among MSK patients were identified through latent class 
analysis. The underlying principle of latent class analysis (Vermunt and Magidson, 2000) 
is that the pain medication profiles for the MSK consulters are assumed to be finite in 
number, are mutually exclusive combinations of the six potency levels within the HAC that 
are prescribed to the patients over time, and the patients within each cluster profile are 
homogenous with respect to medication potency levels received. The resulting medication 
profiles are then characterised by socio-demographic and clinical characteristics of 
patients using descriptive statistics and multilevel multinomial logistic regression.  
5.2.1 Data management and study population 
All the patients identified and included in the analysis in chapter 4, were considered in this 
analysis. A further addition to the inclusion criteria was that the patients remained 
registered throughout the five year period under consideration. Patients were excluded 
from the analysis if their registration records showed them as not registered in any of the 
years after 2006 up to the end of 2010. This was designed to ensure the patients were 
comparable in terms of exposure time or follow-up period, so that a comparison of those 
lost to follow-up and those followed to the end could be avoided as it is hypothesised that 
the prescription patterns are dependent on time. Pain medication profiles were therefore 
based on primary care prescription records from the first MSK consultation of 2006 up to 
the end of 2010.  
5.2.2 Outcome measures 
The outcome measures (the “indicator” variables) were the potency levels defined by the 
HAC model, which means there were six possible potency levels that patients can be 
prescribed under the HAC model over time. These were basic analgesia (BA), weak 
combination analgesia (WCA), moderate combination analgesia (MCA), strong 
combination analgesia (SCA) and very strong single analgesia (VSSA) and NSAIDs. The 
indicator variables were defined as binary variables, “prescribed” or “not prescribed”.  
72 
 
5.2.3 Socio-demographic and clinical characteristics 
The baseline variables investigated for association with medication profiles over the 5 
years were age, gender, deprivation, co-morbidity, registered practice, staff consulted (GP 
or other), region of pain at first MSK consultation (e.g. knee, back), previous MSK 
consultation and previous prescribed analgesia. All variables were used as categorical 
variables with age having five categories, deprivation with three categories of most, 
medium and least deprivation (Chapter 4). As in Chapter 4, comorbidity was also used as 
a binary variable: having at least one of the selected co-morbidities (diabetes, chronic 
obstructive pulmonary disease (COPD), depression, cardiovascular, chronic kidney, 
gastro-intestinal and neoplasm) or none.  
5.2.4 Latent class analysis 
The fundamental principle of latent class analysis (LCA) is that the responses to observed 
variables in a population can be grouped into finite distinct mutually exclusive and 
exhaustive unobserved sub-populations called latent classes (Henry and Muthen, 2010; 
Vermunt and Magidson, 2008). LCA assumes that that each patient belongs to one and 
only one latent class (or cluster) and that the response variables are mutually independent 
of each other within each latent class. 
LCA has the potential to find clinically homogenous groups which can then be compared 
on baseline socio-demographic and clinical variables (Ahn et al 2008; Nylund et al., 2007). 
For example, a group prescribed only NSAIDs may be found to have common 
characteristics such as initial body region of pain and age group, which may confirm the 
known association of NSAID prescription and age, but highlight the importance of the 
region of pain in the decision making after age has been taken into consideration.  
In this study LCA was used to determine groups of patients with similar analgesia 
potencies prescribed over five years. The potency levels are defined according to the 
HAC model, and they are as described above (section 5.2.2).  
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Let     denote whether individual   was prescribed category   of the hierarchical analgesic 
categorisation (HAC), the response variable, where            .   is the total 
number of individuals,   is the total number of response variables. In this case there are 
six observed binary response variables (the potency levels) (1=basic analgesics, 2=weak 
analgesics, 3=moderate analgesics, 4=strong combination analgesics, 5=strong single 
analgesics and 6=NSAIDs).     = 1 represents being prescribed the potency level j at least 
once during follow-up and 0 otherwise. Each patient is characterised by the vector 
Yi=(                           ) which represents their prescribing pattern across the six 
potency levels  
Let   represent a single nominal variable consisting of   distinct latent classes or 
clusters               , which cannot be observed directly from the data. The basic 
idea underlying the latent class model is that the probability of an individual to have a 
prescription pattern  ,  (    )  is an average of the   cluster-specific probabilities of 
having a prescription pattern given membership of cluster  . The assumption of local 
independence (the   response variables are assumed to be independent within clusters) 
leads to the general form of LCA (based on notation of Vermunt and Magidson, 2008): 
 (    )  ∑  (   )
 
   
∏ (   
 
   
       ) 
 (    ) is the probability of an individual   having a prescription pattern     (   ) is 
the probability that a randomly selected individual belongs to cluster   and specifies the 
estimated size of the cluster.  (          ) is the probability of receiving category   
given cluster membership of   . The multiplication of the six HAC category conditional 
probabilities, ∏  (   
 
          ) is a result of the underlying assumption of LCA that 
within a cluster  , the observed variables are mutually independent.  
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After estimating the conditional prescription probabilities  (          ), the comparison 
of the cluster-specific probabilities of prescribing each potency level shows how the 
clusters differ from each other in prescription patterns. The clusters may then be named 
according to the dominant potency levels (HAC) in the cluster, for example a cluster of 
patients with a high probability of receiving basic analgesics and low probability of 
receiving analgesics from the other categories could be labelled as “Basic analgesics”.  
The assumption of local independence cannot be investigated a priori but can be 
evaluated through examining the bivariate residuals after model fitting. Bivariate residuals 
less than 1 suggest the assumption is not likely to be violated while values greater than 1 
suggest a violation of the independence assumption (Vermunt and Magidson, 2008). The 
violation of the assumption suggests the model has difficulty in discriminating between the 
corresponding variable pairs of indicator variables (i.e. the pair of analgesia categories 
with bivariate residual greater than 1) in the model. There is no specific single way of 
dealing with the violation of the assumption (Nylund et al., 2007); hence the statistician 
has to make a subjective choice among the possible ways which include fitting a multilevel 
model or joint modelling of the variables for which the bivariate residual is greater than 1. 
 In this study any violation was addressed by merging adjacent categories of analgesia 
(joint modelling of the analgesia categories where necessary, for example strong 
combination analgesia  are clinically similar to very strong single analgesia, hence a single 
variable of strong analgesia  could be considered if the bivariate residual for these two 
categories was greater than 1). Weak and moderate combination analgesia can be 
combined as weak/moderate analgesia.  
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5.2.4.1 Posterior probability 
In latent class analysis it is assumed that each individual belongs to only one cluster and 
the appropriate cluster membership is defined by their posterior membership probabilities 
for each cluster. The posterior membership probabilities for any individual are obtained 
using Bayes theorem as follows:  
 (        )  
 (   ) (        )
 (    )
 
The higher the conditional probability of cluster membership given their prescription 
pattern,  (        )  the more likely the individual belongs to that cluster. Individuals 
are allocated to the cluster for which their posterior probability is highest. 
5.2.4.2 Model goodness-of-fit analysis 
The difficulty in latent class analysis is identifying the optimal number of clusters as there 
is no dominant criterion for choosing the best model. Models are fitted successively 
starting from a 1-cluster model and adding a further cluster each time. The most 
statistically significant model, in latent class analysis also known as the parsimonious 
model, can be determined through a variety of goodness-of-fit statistics (Ahn et al., 2008; 
Nylund et al., 2007) and for this study, the Akaike’s Information Criterion (AIC), Bayes 
Information Criterion (BIC) and the Constant Akaike’s Information Criterion (CAIC) and the 
likelihood ratio test were used.  
The Akaike Information Criterion (AIC) 
The AIC is based on the log-likelihood of the model; hence for a k-cluster model it is 
defined as:                   where   is the number of parameters to be estimated 
(Vermunt and Magidson, 2008; Nylund et al., 2007). The AIC is used to compare across 
several plausible models reflecting different numbers of clusters and the lowest value 
indicates the optimal number of clusters. 
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 Bayes Information Criterion (BIC)  
The BIC is also based on the log likelihood of the model and takes into account the 
sample size  ; hence for a k-cluster model it is defined as:                 (  ( )) 
where   is the number of parameters to be estimated and   is the sample size (Nylund et 
al 2007; Bozdogan, 2000). The BIC is used to compare across several plausible models 
and the lowest value indicates the optimal number of clusters.  
 Constant Akaike Information Criterion (CAIC) 
The CAIC is a derivative of the AIC which penalises models that have a large number of 
parameters like the BIC, by incorporating the natural logarithm of the sample size plus 1. It 
is defined as:                  (  ( )   ) where   is the number of free model 
parameters or parameters to be estimated and   is the sample size (Nylund et al., 2007; 
Bozdogan 2000). The CAIC is used to compare across several plausible models and the 
lowest value indicates the optimal number of clusters.  
Likelihood ratio test 
The likelihood ratio test compares the improvement in the fit between neighbouring class 
models through their log likelihoods and provides a p-value that can be used to determine 
if there is a statistically significant improvement in fit by inclusion of one more cluster 
(Nylund et al., 2007). The likelihood ratio test follows a chi-squared distribution. Consider 
a k-cluster model, then the neighbouring class model is (k-1)-class, the difference 
between log likelihoods of the models can be expressed as      (      (   )) 
(Nylund et al., 2007; Bozdogan, 2000). A p-value less than 0.05 indicates that the model 
is not a good fit hence adding another cluster improves model fit.  
5.2.5 Model validation 
The best model in this study is that which is both clinically and statistically justifiable. 
While it is essential to establish a model choice through statistical evaluation techniques, 
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the clinical interpretation of the model is equally important. The goodness-of-fit statistics 
discussed above are not always conclusive especially when clinical importance is factored 
into model selection. The posterior probabilities also complement and validate model 
choice.  
While there is no specific probability cut off point, the higher the posterior probability the 
better, as low posterior probabilities indicate that the model has difficulty in distinguishing 
between combinations of analgesia and allocating cluster membership (Henry and Muthen 
2010; Nylund et al., 2007; Bozdogan, 2000; Vermunt and Magidson, 2008). In this study 
the minimum, maximum and mean posterior probabilities for patients within each cluster 
were considered as a means to evaluate and choose the final model in addition to the 
goodness-of-fit statistics.  
There is no agreed specific cut-off point to indicate satisfactory posterior probabilities. 
Here, the proportions of the posterior probabilities above 0.7 and below 0.55 were 
compared. The 0.7 mark was used to indicate patients with a very high likelihood of being 
in their allocated cluster while probabilities below 0.55 indicate the patients have almost 
equal probabilities of being in another cluster. The goal of latent class analysis is to 
determine the smallest number of latent clusters that is sufficient to explain or account for 
associations among the observed variables (Henry and Muthen 2010; Vermunt and 
Magidson, 2008). Models with fewer clusters will take priority over models with more 
clusters in deciding the final model in the event of inconclusive goodness-of-fit measures.  
The final model should be clinically meaningful and interpretable in line with knowledge of 
prescription patterns of pain analgesia from published studies. There are known 
prescription trends by age, gender, pain location, medication history and co-morbidity for 
different potency levels of analgesia. For example NSAIDs are the mainstay of drug 
treatment of acute and chronic pain, but their side effects make them less suitable for the 
elderly and they should be less used for patients with comorbidity (for example, bowel or 
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gastrointestinal problems) (Main, 2002; Brooks, 2006) Garbez and Puntillo, 2005), and 
Curatolo and Bogduk, 2001).  
Factoring in clinical knowledge ensures that the final model is not only statistically valid 
but clinically useful and informative too. The model should help describe prescription 
patterns of analgesia in primary care treatment of MSK conditions over time and help 
establish factors associated with the prescription patterns. 
5.2.6 Model evaluation and final model selection 
The full clinical meaning and interpretation of the final model can be appreciated by 
establishing links to the clinical and socio-demographic patient variables available at 
baseline (onset of seeking medical care). The clinical importance of the model was 
evaluated by considering the prescription profiles of the clusters and comparing socio-
demographic and clinical characteristics associated with the clusters to those related to 
analgesia prescribing identified from published papers and with discussion with a clinician 
(Dr John Bedson) and a biostatistician (Dr Kelvin Jordan) who have thorough knowledge 
through extensive research in MSK conditions. Two models were evaluated before the 
final model was chosen.  
Descriptive comparison of the clusters by the analgesia categories and baseline variables 
were used to assess the magnitude of homogeneity of patients in each cluster and extent 
of heterogeneity between clusters. A multilevel (patient (level 1) and practice (level 2)) 
multinomial logistic model with cluster membership as the dependent variable was used to 
determine associations with socio-demographic and clinical characteristics. The model 
uses relative risk ratios (RRR) to compare and evaluate how different from the reference 
cluster are the other clusters. The reference cluster in the regression models was the 
cluster thought to have the least potent drugs prescribed. RRRs were reported with their 
95% confidence interval (95%CI).  
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Only the adjusted models were discussed in detail to illustrate the heterogeneity between 
the clusters.  The probability of being in a given cluster may vary from one individual to the 
other, and hence the multilevel multinomial logistic model was fitted with the probability of 
being in a cluster for each individual used as weighting in the model. Weighting accounts 
for the level of uncertainty in cluster membership. It also ensures the contribution of 
characteristics of an individual to the estimation of the model parameters is related to the 
probability of them being in the cluster. The latent class model was fitted using Latent 
Gold 4.0 while the multilevel multinomial logistic model was fitted using STATA. 
Conclusions and discussion points were drawn from the detailed analysis and comparison 
of the best two models fitted. The two models were examined closely to consolidate the 
conclusions to be drawn about the suitability of latent class analysis in analysing 
prescribed pain medication profiles among primary care MSK consulters. The final 
preferred model from the two was selected after consideration of their goodness-of-fit 
statistics, posterior probabilities, clinical interpretability and validity, homogeneity of 
individuals within each cluster and heterogeneity across clusters.  
5.3 Results 
5.3.1 Data description 
Of the 3236 patients who were identified in Chapter 4 as having consulted for a new MSK 
condition, 370 (11%) were lost to follow-up. Since the specific reason for loss to follow-up 
could not be ascertained, and the aim of the analysis was to characterise long-term 
prescription patterns over time, these 370 were excluded from the analysis. A total of 
2866 patients were registered throughout the five year period under consideration which is 
89% of the cohort that consulted for new MSK pain in 2006.  
The excluded patients were similar to the overall cohort by age and gender composition. 
There were 214 (58%) males in the excluded group with a mean age of 42 years with a 
standard deviation of 21.2. The mean age of the 2866 patients included in the study in 
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years was 40.7 with a standard deviation of 17.2 and a median age of 40. The ages of the 
patients ranged from 15 to 92 years. 60% of the participants were male. Not all the 
patients received prescribed pain medication during the 5 years.  
A total of 1992 (70%) received at least one category of the HAC in terms of pain 
medication prescribed over the five years. The mean follow up period was 4.5 years (as 
first consultation could be anytime during 2006). NSAIDs were the most commonly 
prescribed (to 62% of the patients over the 5 years) followed by basic analgesia (31%) 
and weak analgesia (21%). Very strong single analgesia was rarely prescribed (<1%), 
Table 5.3.1.  
As in Chapter 4, the outcome variables were complete with no missing values and the 
only independent variable with missing data (categorised as “other/unspecified”) was pain 
location.  
Indicator variables  
Table 5.3.1: Number (%) of patients prescribed analgesia from each category 
Indicator                                  Number of patients     % of total patients 
Basic Analgesia                                             892                              31                                
Weak combination analgesia                        602                              21 
Moderate combination analgesia                  198                                7 
NSAIDs                                                         1771                              62 
Strong combination analgesia                      544                               19 
Very strong single analgesia                          16                           <0.01   
5.3.2 Six indicator variable models 
Models based on all 6 indicator variables were fitted. The chi-squared p-values for the log-
likelihood ratio test which were not statistically significant at 5% level, the Akaike’s 
Information Criterion (AIC), the Bayes Information Criterion (BIC) and the Constant 
Akaike’s Information Criterion (CAIC) suggested a choice between the 3-cluster and the 4-
cluster models seemed reasonable, see Table 5.3.2. The p-values of 0.10 for the 3-cluster 
model and 0.38 for the 4-cluster model indicate good fit for both models. The CAIC 
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(14512.76) and the BIC (14492.76) were at their lowest in the 3-cluster model. The AIC 
(14370.27) was lowest in the 4-cluster model. Therefore both the 3-cluster and the 4-
cluster model are justifiable choices; hence both were evaluated for the assumption of 
local independence. 
Table 5.3.2: Goodness of fit statistics for the cluster models with 6 indicators  
                   LL       BIC (LL)          AIC (LL)        CAIC (LL)         L² p-value 
1-Cluster        -7401.89       14851.54        14815.78     14857.54          525.38 5.5e-7    
2-Cluster        -7206.56       14516.62        14439.13     14529.62          134.74 1.0e-9    
3-Cluster        -7166.77       14492.76        14373.54      14512.76           55.15 0.10     
4-Cluster        -7158.13       14531.21        14370.27      14558.21           37.88 0.38     
5-Cluster        -7156.69       14584.06        14381.39      14618.06           35.00 0.20    
6-Cluster        -7149.88       14626.15        14381.77      14667.15           21.37 0.50 
 Evaluation of the local independence assumption 
The bivariate residuals (BVR) for the 4-cluster model and the 3-cluster model in Table 
5.3.3 suggest that for both models, the assumption of local independence is violated as 
some of the residuals are greater than 1. The BVR of (1.3176) in the 3-cluster model for 
the pair of very strong single analgesia and NSAIDs indicate the 3-cluster model has 
difficulty in discriminating between these two potency levels. The BVRs of (2.0489), 
(2.2661) and (6.9140) in the 4-cluster model indicate that the model has difficulty in 
discriminating very strong single analgesia from basic analgesia, NSAIDs and strong 
combination analgesia respectively. The best models using 6-indicator variables were 
therefore in violation of the local independence assumption.  
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Table 5.3.3: Bivariate residual output for the 4-cluster and 3-cluster models 
Indicators Basic analgesia Weak 
combination 
analgesia 
Moderate 
combination 
analgesia 
NSAIDs Strong 
combination 
analgesia 
Very strong 
single 
analgesia 
4-cluster model       
Basic analgesia    -      
Weak combination analgesia    0.1740 -     
Moderate combination analgesia 0.1055 0.0646 -    
NSAIDs  0.0015 0.0745 0.2712 -   
Strong combination analgesia  0.0246 0.0089 0.0003 0.1329 -  
Very strong single analgesia 0.0002 0.1266 0.6675 1.3176 0.1339 - 
3-cluster model       
Basic analgesia    -      
Weak combination analgesia  0.5868 -     
Moderate combination analgesia 0.0591 0.0102 -    
NSAIDs  0.0285 0.0222 0.3599 -   
Strong combination analgesia  0.0027 0.0210 0.0660 0.0189 -  
Very strong single analgesia 2.0489 0.0904 0.0945 2.2661 6.9140 - 
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5.3.3 Five indicator variable models 
The strong combination and very strong single analgesia categories were merged into a 
single indicator variable named strong analgesia. The five indicators were therefore basic 
analgesia, weak analgesia, moderate analgesia, strong analgesia and NSAIDs. The 5-
indicator variable model was fitted and the 3-cluster and 4-cluster models were selected 
based on the goodness-of-fit statistics. 
The BIC (14316.46), AIC (14215.13) and the CAIC (14333.46) are at their lowest in the 3-
cluster model but the differences in these measures for the 3 cluster and the 4 cluster 
models are marginal. The p-values for both models, 0.11 for the 3-cluster and 0.054 for 
the 4-cluster model are greater than 0.05. The change in the log likelihood from the 3-
cluster to the 4-cluster model is very small as shown in the graph in Figure 5.3.1 which 
shows why the likelihood ratio test identifies the two models as likely candidates. Further 
evaluation of the 5 indicator model is explored with the evaluation of the local 
independence assumption. 
Figure 5.3.1: Illustration of change in log likelihood with increasing number of clusters 
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Table 5.3.4: Goodness of fit statistics for the 5-indicator model 
          LL BIC (LL) AIC (LL) CAIC (LL) L²     p-value 
1-Cluster   -7305.82 14651.45 14621.64 14656.45       451.15        4.1e-79 
2-Cluster   -7127.17 14341.91 14276.34 14352.91         93.85         1.6e-11 
3-Cluster   -7090.56 14316.46 14215.13 14333.46         20.64         0.11 
4-Cluster   -7087.87 14358.85 14221.75 14381.85         15.26           0.054 
5-Cluster   -7083.11 14397.08 14224.22 14426.08           5.73           0.057 
Evaluation of local independence assumption in the 5 indicator models 
The bivariate residuals for all the pairs of indicator variables are substantially less than 
one in both the 3-cluster and 4-cluster models (Table 5.3.5). This suggests that the 
models do not have difficulty in discriminating between any of the variable pairs. The 
assumption of local independence is not violated for both the 3-cluster and the 4-cluster 
models. 
 Table 5.3.5: Bivariate residuals between variable pairs for the 3 and 4-cluster models 
Indicators Basic 
analgesia 
Weak 
analgesia 
Moderate 
analgesia 
NSAIDs Strong 
analgesia 
4-cluster model 
     
Basic analgesia    -     
Weak analgesia    0.3604 -    
Moderate analgesia 0.0019 0.0163 -   
NSAIDs  0.0619 0.0044 0.3055 -  
Strong analgesia    0.0162 0.0025 0.1305 0.1458 - 
3-cluster model 
     
Basic analgesia    -     
Weak analgesia    0.0000 -    
Moderate analgesia 0.0018 0.0799 -   
NSAIDs  0.0064 0.0237 0.1914 -  
Strong analgesia    0.0137 0.0009 0.0000 0.0369 - 
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5.3.4 Cluster properties 
The 3-cluster model 
The clusters are labelled according to the evidently dominant analgesia within each 
cluster as follows; Cluster 1 – Basic analgesia, Cluster 2 – NSAIDs and Cluster 3 – 
Multiple-potency. The cluster properties are illustrated in Table 5.3.6 and Table 5.3.7. 
Basic Analgesia cluster: The cluster contains 40% of all the patients in this analysis and 
consists of patients who received mainly no pain medication or basic analgesia. The 
patients have a 0.34 probability of being prescribed basic analgesia and a 0.11 probability 
of being prescribed weak analgesia. The cluster has minimum, maximum and mean 
posterior probabilities of 0.52, 0.86 and 0.70 respectively. 86% of the patients are 
classified in this cluster as belonging to the cluster with probability 0.70 or above while 
less than 1% was classified with probability less than 0.55.  
NSAIDs cluster: The cluster contains 37% of all the patients in the analysis and consists 
of patients who received predominantly NSAIDs only within the five year period. The 
patients have a 0.61 probability of being prescribed NSAIDs, 0.14 probability of being 
prescribed weak analgesia and 0.19 probability of being prescribed strong analgesia. The 
cluster has minimum, maximum and mean posterior probabilities of 0.44, 0.82 and 0.76 
respectively. 84% of the patients in this cluster are classified with probability 0.70 or above 
while less than 1% was classified with probability less than 0.55.  
Multiple-potency cluster: The cluster contains 23% of all the patients in the analysis and 
they received combinations of the five potency levels without any potency level clearly 
dominating the cluster. The patients have probabilities 0.65 of being prescribed basic 
analgesia, 0.50 of being prescribed weak analgesia, 0.20 of being prescribed moderate 
analgesia, 0.62 of being prescribed NSAIDs and 0.51 of being prescribed strong 
analgesia. The minimum, maximum and mean posterior probabilities are 0.45, 0.99 and 
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0.77 respectively. 61% of the patients in this cluster were classified with probability 0.70 or 
above while 22% were classified with probability less than 0.55. 
The 4-cluster model 
The 4-cluster model is an extension of the 3-cluster model described above. It splits the 
Basic analgesia cluster into two clusters: no medication cluster and a basic analgesia 
cluster. The clusters are labelled according to the evidently dominant analgesia within 
each cluster as follows; Cluster 1 – NSAIDs, Cluster 2 – No Medication, Cluster 3 – Basic 
analgesia and Cluster 4 – Multiple-potency. The cluster properties are illustrated in Table 
5.3.6 and Table 5.3.7. 
Basic Analgesia cluster: The cluster contains 23% of the patients in the analysis and 
consists of patients who were predominantly prescribed basic analgesia throughout the 
follow-up period. The patients have a probability 0.16 of receiving weak analgesia. The 
minimum, maximum and mean posterior probabilities are 0.36, 0.82 and 0.69 respectively. 
63% of the patients in this cluster are classified with probability 0.70 or above while 21% 
were classified with probability less than 0.55. 
NSAIDs cluster: The cluster contains 32% of the patients in this analysis and consists of 
patients predominantly prescribed NSAIDs throughout the follow-up period. The patients 
have probabilities 0.65 of receiving NSAIDs, 0.22 of receiving weak analgesia and 0.27 of 
receiving strong analgesia. The minimum, maximum and mean posterior probabilities are 
0.43, 0.80 and 0.59 respectively. 21% of the patients in this cluster are classified with 
probability 0.70 or above while 16% were classified with probability less than 0.55. 
Multiple-potency cluster: The cluster contains 17% of the patients in this analysis who 
received combinations of the five potency levels without any potency level clearly 
dominating the cluster. The patients have probabilities 0.72 of being prescribed basic 
analgesia, 0.52 of being prescribed weak analgesia, 0.23 of being prescribed moderate 
analgesia, 0.63 of being prescribed NSAIDs and 0.56 of being prescribed strong 
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analgesia.  The minimum, maximum and mean posterior probabilities are 0.40, 0.98 and 
0.78 respectively. 78% of the patients in this cluster are classified with probability 0.70 or 
above while 21% was classified with probability less than 0.55. 
No medication cluster: The cluster contains 28% of the patients in the analysis who 
received no prescribed medication throughout the follow-up period. The minimum, 
maximum and mean posterior probabilities are 0.46, 0.57 and 0.57 respectively. None of 
the patients were classified with probability 0.70 or above while 3% was classified with 
probability less than 0.55.  
The mean posterior cluster probabilities were higher in the three-cluster than the four-
cluster model for the basic analgesia and NSAIDs clusters, but similar for the Multiple-
potency clusters.
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Table 5.3.6: Within cluster probability of receiving analgesia medication 
                                     3-Cluster model                                                        4-Cluster model 
 Basic 
Analgesia 
NSAIDs Multiple-
Potency 
 Basic 
Analgesia 
 
NSAIDs 
Multiple-
Potency 
No 
Medication 
Cluster Size       0.3971 0.3717 0.2313  0.2332 0.3208 0.1674 0.2786 
Indicators         
Basic analgesia         
No                0.6589 0.9309 0.3509  0.4379 0.8440 0.2804 0.9654 
Yes                0.3411 0.069 0.6491  0.5621 0.1560 0.7196 0.0346 
Weak analgesia         
No           0.8890 0.8642 0.4990  0.8374 0.7799 0.4761 0.9492 
Yes                0.1110 0.1358 0.5010  0.1626 0.2201 0.5239 0.0508 
Moderate analgesia         
No              0.9816 0.9566 0.8026  0.9839 0.9395 0.7688 0.9741 
Yes                0.0184 0.0434 0.1974  0.0161 0.0605 0.2312 0.0259 
NSAIDs         
No               0.9006 0.3927 0.3801  0.9165 0.3523 0.3740 0.7252 
Yes               0.0994 0.6073 0.6199  0.0835 0.6477 0.6260 0.2748 
Strong analgesia         
No                 0.9969 0.8080 0.4902  0.9963 0.7325 0.4379 0.9650 
Yes                 0.0031 0.1920 0.5098  0.0037 0.2675 0.5621 0.0350 
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Table 5.3.7: Summary of posterior probabilities by cluster  
3-Cluster model 4-Cluster model 
Cluster Basic                          
Analgesia NSAIDs 
Multiple-
Potency 
Basic                          
Analgesia NSAIDs 
Multiple-
Potency 
No 
medication 
Summary statistic  
Size (n)                                                          1428 858 580 554 1049 360 903 
Minimum                0.52 0.44 0.45 0.36 0.43 0.40 0.46 
Mean                     0.70 0.76 0.77 0.69 0.59 0.78 0.57 
Maximum              0.86 0.82 0.99 0.82 0.80 0.98 0.57 
% > 0.70                                                                                           86 84 61 63 21 78 0 
% < 0.55                                                                        <0.1 <0.1 22 21 16 21 3 
5.3.5 Cluster description by baseline characteristics 
In the 3-cluster model, of the 2866 patients, 1428 were in the basic analgesia, 858 in the 
NSAIDs and 580 in the multiple-potency clusters while in the 4-cluster model 554 were in 
the basic analgesia, 1049 in the NSAIDs, 360 in the multiple-potency and 903 in the no 
medication clusters. These cluster compositions are as observed from the data and not 
model estimated.  
Table 5.3.8 describes the prevalence of the patients in each cluster according to the 
categories of the baseline characteristics. For example in the 3-cluster model, 56% of the 
15-29 age group were in the basic analgesia cluster, 29% in the NSAIDs cluster and 15% 
in the multiple-potency cluster, while 18%, 34%, 10% and 38% of this age group were in 
the basic analgesia cluster, NSAIDs cluster, multiple-potency cluster and no medication 
cluster respectively, in the 4-cluster model. 
In the 3-cluster model, the age groups with the highest prevalence in the basic analgesia 
cluster were the 15-29 (56%) and 75+ (60%), while in the NSAIDs cluster it was the 30-44  
group (41%), and 60-74 (35%) and the 75+ (34%)in the multiple-potency cluster. In the 4-
cluster model, the age group with the highest prevalence in the basic analgesia cluster 
was the 75+ (54%), while in the NSAIDs cluster it was the 30-44 (48%), the 75+ (34%) in 
the multiple-potency and the 15-29 (38%) in the no medication cluster. 
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Table 5.3.8: Cluster description by baseline variables 
         3-Cluster model                                                                4-Cluster model 
 
Variable 
Total (n) Basic 
Analgesia 
NSAIDs Multiple-
Potency 
Basic 
Analgesia 
NSAIDs Multiple-
Potency 
No 
medication 
Age group 
15-29 
30-44 
45-59 
60-74 
75+ 
 
539 
933 
908 
386 
100 
% Col  
56 
42 
44 
47 
60 
% Col 
29 
41 
33 
18 
6 
% Col 
15 
17 
23 
35 
34 
% Col 
18 
12 
15 
25 
54 
% Col 
34 
48 
42 
25 
4 
% Col 
10 
9 
14 
26 
34 
% Col 
38 
31 
29 
24 
10 
Gender 
Female 
Male 
 
1154 
1712 
 
50 
50 
 
25 
33 
 
25 
17 
 
22 
18 
 
33 
39 
 
15 
11 
 
30 
32 
Previous musculoskeletal 
consultation 
Yes 
No 
 
 
407 
2459 
 
 
49 
50 
 
 
31 
30 
 
 
20 
20 
 
 
19 
19 
 
 
38 
36 
 
 
13 
13 
 
 
30 
32 
Previous Analgesia 
prescription 
Yes 
No 
 
 
475 
2391 
 
 
38 
52 
 
 
32 
30 
 
 
30 
18 
 
 
18 
20 
 
 
41 
36 
 
 
19 
11 
 
 
22 
33 
Pain location 
Back 
Knee 
Hip 
Foot and ankle 
Hand and wrist 
Shoulder 
Neck 
Other/Unspecified 
 
690 
311 
188 
226 
219 
216 
203 
813 
 
38 
53 
49 
53 
54 
40 
51 
59 
 
39 
31 
28 
29 
28 
36 
29 
22 
 
23 
16 
23 
18 
18 
24 
20 
19 
 
16 
21 
19 
21 
17 
15 
29 
23 
 
45 
37 
35 
35 
35 
45 
40 
27 
 
15 
9 
16 
12 
9 
15 
9 
13 
 
23 
33 
30 
32 
39 
25 
31 
37 
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  3-Cluster model 4-Cluster model 
 
Variable 
Total (n) Basic 
Analgesia 
NSAIDs Multiple-
Potency 
Basic 
Analgesia 
NSAIDs Multiple-
Potency 
No 
medication 
Deprivation 
Most 
Medium 
Least 
 
1212 
1141 
513 
 
48 
51 
52 
 
31 
30 
29 
 
21 
19 
19 
 
21 
18 
19 
 
38 
36 
36 
 
14 
12 
12 
 
28 
35 
34 
Comorbidity 
Selected 
None 
 
107 
2749 
 
47 
38 
 
28 
36 
 
25 
26 
 
22 
24 
 
36 
35 
 
16 
16 
 
26 
25 
Staff category 
GP 
Other 
 
2296 
570 
 
50 
51 
 
29 
33 
 
21 
17 
 
20 
17 
 
36 
38 
 
13 
10 
 
31 
35 
General practice 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
 
215 
210 
175 
230 
145 
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290 
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152 
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65 
55 
62 
53 
43 
60 
31 
49 
48 
47 
53 
48 
 
18 
29 
20 
30 
34 
17 
45 
33 
28 
29 
34 
32 
 
17 
16 
18 
16 
23 
23 
24 
18 
24 
24 
14 
20 
 
19 
17 
30 
16 
12 
31 
13 
18 
20 
21 
21 
18 
 
24 
37 
25 
37 
43 
20 
56 
41 
35 
38 
37 
34 
 
11 
8 
13 
9 
13 
18 
12 
10 
14 
16 
11 
15 
 
46 
38 
32 
38 
32 
31 
18 
32 
31 
26 
32 
33 
% 
Col
 = Column %
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5.3.6 Cluster comparison by baseline variables: Multinomial logistic models 
The unadjusted and adjusted multilevel-multinomial logistic models were fitted to compare 
clusters in: i) the 3-cluster model and ii) 4-cluster model and the relative risk ratios (RRR) 
show which baseline factors were significantly associated with cluster membership in 
each model. 
Multinomial logistic model on the 3-cluster model 
The unadjusted model showed that NSAIDs cluster and the Multiple-potency cluster were 
significantly different from the Basic analgesia cluster by age, gender, previous prescribed 
analgesia and pain location and not by deprivation, consultation history, co-morbidity and 
staff category. The adjusted model showed significant difference by age, gender, 
medication history, deprivation, comorbidity and pain location. There was variation by 
practice as shown in Table 5.3.9. General practice accounted for 12% of the unexplained 
variation. 
Compared to those aged 30-44, the youngest age group (15-29) and oldest age groups 
(60-74 and over 75) were less likely to be classified in the NSAIDs cluster than in the 
basic analgesia cluster. For example, for patients aged 15-29 the adjusted relative risk 
ratio (RRR 0.55 95% CI [0.41, 0.74]) compared to the 30-44 age group. Those aged 60-
74, (RRR 0.42 [0.28, 0.63]) and those aged 75+ (RRR 0.08 [0.02, 0.40]) were also less 
likely to be in the NSAIDs cluster. The patients who previously received prescribed 
analgesia in the past, (RRR 1.47 [1.10, 1.97]) were more likely to be in the NSAIDs cluster 
than in the basic analgesics cluster. Patients presenting at the initial consultation with a 
MSK problem in the knee, (RRR 0.61 [0.42, 0.89]), hand and wrist, (RRR 0.48 [0.31, 
0.73]), neck (RRR 0.57 [0.37, 0.89]) or unspecified locations (RRR 0.41 [0.30, 0.55]) were 
less likely to be in the NSAIDs cluster when compared to those presenting with a back 
problem.    
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Table 5.3.9: Unadjusted and adjusted multinomial logistic models that examines the association of baseline variables with cluster membership 
in the 3-cluster model 
Model                                                                                                          RRR Estimates [95% CI] 
Reference cluster- Basic analgesia                                           NSAIDs Cluster                                      Multiple-potency Cluster                                                                      
                                                                                           Unadjusted                 Adjusted                   Unadjusted                        Adjusted 
Age Group  
 30-44                                                     
 
1.00 
 
1.00 
 
1.00 
 
1.00 
15-29                                                  0.51 [0.38, 0.69] 0.55 [0.41, 0.74] 0.69 [0.48, 0.99] 0.69 [0.48, 1.01] 
45-59                                                     0.77 [0.60, 0.99] 0.83 [0.65, 1.08] 1.34 [0.99, 1.81] 1.44 [1.05, 1.95] 
60-74                                                 0.38 [0.26, 0.56] 0.42 [0.28, 0.63] 2.01 [1.41, 2.86] 2.20 [1.52, 3.18] 
75+                                                     0.07 [0.01, 0.36] 0.08 [0.02, 0.40] 1.64 [0.81, 3.31] 1.54 [0.74, 3.19] 
Gender  
Male 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Female                                         0.74 [0.60, 0.90] 0.82 [0.67, 1.03] 1.40 [1.11, 1.75] 1.45 [1.15, 1.85] 
Previous musculoskeletal consultation 
No 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Yes                                                1.10 [0.81, 1.42] 1.08 [0.81, 1.44] 1.04 [0.81, 1.53] 0.82 [0.59, 1.14] 
Previous Analgesia prescription 
 No 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Yes                                              1.47 [1.12, 1.94] 1.47 [1.10, 1.97] 2.37 [1.79, 3.15] 2.27 [1.68, 3.06] 
Region of Pain 
 Back 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Knee                                              0.55 [0.39, 0.79] 0.61 [0.42, 0.89] 0.46 [0.30, 0.72] 0.46 [0.29, 0.72] 
Hip                                                 0.55 [0.35, 0.85] 0.70 [0.44, 1.12] 0.74 [0.47, 1.20] 0.76 [0.46, 1.25] 
Foot and Ankle                              0.54 [0.36, 0.81] 0.73 [0.47, 1.13] 0.55 [0.34, 0.88] 0.66 [0.40, 1.09] 
Hand and Wrist                              0.49 [0.33, 0.74] 0.48 [0.31, 0.73] 0.49 [0.30, 0.79] 0.45 [0.27, 0.74] 
Shoulder                                        0.88 [0.58, 1.32] 0.84 [0.55, 1.28] 0.92 [0.58, 1.46] 0.78 [0.48, 1.26] 
Neck                                              0.54 [0.35, 0.82] 0.57 [0.37, 0.89] 0.59 [0.36, 0.95] 0.60 [0.36, 1.00] 
Other/unspecified                          0.35 [0.26, 0.47] 0.41 [0.30, 0.55] 0.52 [0.38, 0.71] 0.51 [0.37, 0.71] 
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Model                                                                                                          RRR Estimates [95% CI] 
Reference cluster- Basic analgesia                                           NSAIDs Cluster                                      Multiple-potency Cluster    
 Unadjusted    Adjusted Unadjusted Adjusted 
Deprivation 
Most 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Medium                                         0.91 [0.73, 1.13] 0.83 [0.66, 1.03] 0.83 [0.65, 1.06] 0.68 [0.52, 0.88] 
Least                                             0.87 [0.66, 1.15] 0.82 [0.61, 1.11] 0.81 [0.59, 1.11] 0.62 [0.45, 0.88] 
Co-morbidity 
Selected 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Other                                                      1.03 [0.44, 1.61] 1.38 [1.02, 1.88] 0.69 [0.39, 1.32] 0.60 [0.44, 0.83] 
Staff category  
GP 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Other                                               1.10 [0.89, 1.42] 1.13 [0.89, 1.43] 0.72 [0.64, 1.03] 0.84 [0.63, 1.11] 
Random effect                                                                         Variance [SD] 
General Practice                                   0.12 [0.06]   
Unadjusted model = Individual variable in the model, Adjusted model = All variables included simultaneously
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The age groups 45-59 and 60-74 with (RRR 1.44 [1.05, 1.95]) and (RRR 2.20 [1.52, 3.18]) 
respectively were more likely to be in the Multiple-potency cluster. Females (RRR 1.45 
[1.15, 1.85]) and patients who previously received prescribed analgesia in the past (RRR 
2.27 [1.68, 3.06]) were more likely to be in the Multiple-potency cluster. Patients from 
medium and least deprived areas (RRR 0.68 [0.52, 0.88] and 0.62 [0.45, 0.88]) 
respectively are less likely to be in the Multiple-potency cluster when compared to those 
living in the most deprived areas. Patients presenting at the initial consultation with a MSK 
problem in the knee (RRR 0.46 [0.29, 0.72]), hand and wrist (RRR 0.45 [0.27, 0.74]), and 
unspecified locations (RRR 0.51 [0.37, 0.71]) are less likely to be in the Multiple-potency 
cluster compared to those experiencing back problems.  
Multinomial logistic model on the 4-cluster model 
The unadjusted model showed that the NSAIDs cluster, the Basic analgesia cluster and 
the Multiple-potency clusters were significantly different from the No pain medication 
cluster by age, gender, medication history, pain location and by deprivation but not by 
previous MSK consultation, co-morbidity and staff category. The adjusted model showed 
significant differences by age, gender, medication history, comorbidity, deprivation and 
pain location (Table 5.3.10).  
With the No pain medication cluster as the reference cluster, the age group 15-29 with 
(RRR 0.60 95% CI [0.42, 0.85]) was less likely to be in the NSAIDs cluster when 
compared to those aged 30-44. Patients who received prescribed analgesia in the past 
(RRR 1.77 [1.25, 2.51]) were more likely to be in the NSAIDs cluster. Patients 
experiencing pain in the knee (RRR 0.57 [0.37, 0.87]), hand and wrist (RRR 0.41 [0.26, 
0.67]) and unspecified locations (RRR 0.38 [0.27, 0.53]) were less likely to be in the 
NSAIDs cluster when compared to those consulting initially for pain in the back. Those 
from medium deprivation (RRR 0.69 [0.53, 0.91]) were also less likely to in the NSAIDs 
cluster. 
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Also, age groups 60-74 and over 75 with (RRR 3.11 [1.89, 5.10]) and (RRR 16.2 [4.28, 
61.4]) respectively are more likely to be in the Basic analgesia cluster than no medication 
cluster compared to those aged 30-44. Patients from medium deprivation (RRR 0.69 
[0.51, 0.94]) are less likely to be in the Basic analgesia cluster. The age groups 45-59, 60-
74 and over 75 with (RRR 1.71 [1.14, 2.57], 4.27 [2.60, 7.01] and 11.8 [2.97, 46.9]) 
respectively are more likely to be in the Multiple-potency cluster. Females (RRR 1.54 
[1.13, 2.10]) and patients who previously received prescribed analgesia in the past (RRR 
2.48 [1.66, 3.69]) are more likely to be prescribed multiple potency levels.  
Patients from medium and least deprivation neighbourhoods (RRR 0.55 [0.39, 0.77] and 
0.52 [0.33, 0.80]) respectively are less likely to be in the Multiple-potency cluster when 
compared to the most deprived. Patients experiencing pain in the knee (RRR 0.36 [0.19, 
0.65]), hand and wrist (RRR 0.33 [0.17, 0.63]), neck (RRR 0.42 [0.21, 0.85]) and 
unspecified locations (RRR 0.46 [0.30, 0.70]) are less likely to be in the Multiple-potency 
cluster compared to those experiencing back pain. With practice considered as a random 
effect in the multilevel model, a statistically significant variance of 0.093 [SD 0.047] shows 
that there is practice variation in cluster membership. Practice accounts for 9% of the 
unexplained variation. 
97 
 
Table 5.3.10: Unadjusted and adjusted multinomial logistic models that examine the association of baseline variables with cluster membership 
in the 4-cluster model  
Model                                                                                                          RRR Estimates [95% CI 
(Reference cluster - No 
medication) 
 
(Basic analgesia) 
 
(NSAIDs) 
 
(Multiple-potency)                            
 Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted 
Age Group  
 30-44                                                     
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
15-29                                                  1.42 [0.87, 2.11] 1.32 [0.86, 2.03] 0.57 [0.40, 0.81] 0.60 [0.42, 0.85] 0.86 [0.60, 1.42] 0.88 [0.54, 1.41] 
45-59                                                     1.39 [0.88, 2.01] 1.42 [0.96, 2.12] 0.91 [0.72, 1.22] 0.99 [0.74, 1.34] 1.54 [1.04, 2.32] 1.71 [1.14, 2.57] 
60-74                                                 2.87 [1.83, 4.80] 3.11 [1.89, 5.10] 0.72 [0.42, 1.14]  0.77 [0.49, 1.23] 3.70 [2.33, 6.01] 4.27 [2.60, 7.01] 
75+                                                     16.0 [4.33, 60.0] 16.2 [4.28, 61.4] 0.33 [0.03, 2.41] 0.31 [0.04, 2.66] 12.2 [3.09, 46.0] 11.8 [2.97, 46.9] 
Gender  
Male 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Female                                         1.32 [1.01, 1.74] 1.17 [0.88, 1.55] 1.02 [0.70, 1.22] 1.03 [0.80, 1.32] 1.60 [1.21, 2.14] 1.54 [1.13, 2.10] 
Previous musculoskeletal 
consultation 
No 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
Yes                                                1.12 [0.74, 1.54] 1.05 [0.72, 1.54] 1.11 [0.82, 1.53] 1.04 [0.77, 1.41] 1.00 [0.66., 3.91] 0.92 [0.61, 1.39] 
Previous analgesia 
prescription 
 No 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
Yes                                              1.34 [0.89, 2.00] 1.28 [0.85, 1.97] 1.78 [1.33, 2.51] 1.77 [1.25, 2.51] 2.68 [1.77, 3.85] 2.48 [1.66, 3.69] 
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Model                                                                                                          RRR Estimates [95% CI 
(Reference cluster - No 
medication) 
 
(Basic analgesia) 
 
(NSAIDs) 
 
(Multiple-potency)                            
 Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted 
Region of Pain 
Back 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Knee                                              1.02 [0.57, 1.56] 0.84 [0.50, 1.41] 0.52 [0.43, 0.81] 0.57 [0.37, 0.87] 0.38 [0.22, 0.72] 0.36 [0.19, 0.65] 
Hip                                                 1.09 [0.58, 1.90] 0.79 [0.42, 1.47] 0.64 [0.32, 0.90] 0.63 [0.37, 1.09] 0.80 [0.44, 1.41] 0.67 [0.35, 1.28] 
Foot and Ankle                              1.12 [0.61, 1.93] 0.79 [0.44, 1.42] 0.54 [0.32, 0.84] 0.61 [0.37, 1.02] 0.64 [.033, 1.00] 0.59 [0.31, 1.11] 
Hand and Wrist                              0.69 [0.44, 1.22] 0.68 [0.38, 1.22] 0.41 [0.34, 0.70] 0.41 [0.26, 0.67] 0.41 [0.21, 0.74] 0.33 [0.17, 0.63] 
Shoulder                                        1.01 [0.48, 1.86] 0.96 [0.51, 1.82] 0.88 [0.54, 1.53] 0.83 [0.50, 1.39] 0.90 [0.54, 1.56] 0.71 [0.37, 1.33] 
Neck                                              1.04 [0.62, 1.77] 0.88 [0.48, 1.62] 0.63 [0.43, 1.02] 0.63 [0.39, 1.01] 0.39 [0.23, 0.94] 0.42 [0.21, 0.85] 
Other/unspecified                          1.00 [0.66, 1.45] 0.83 [0.56, 1.24] 0.43 [0.34, 0.53] 0.38 [0.27, 0.53] 0.54 [0.44, 0.77] 0.46 [0.30, 0.70] 
Deprivation 
Most 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Medium                                         0.72 [0.53, 0.88] 0.69 [0.51, 0.94] 0.76 [0.64, 0.92] 0.69 [0.53, 0.91] 0.70 [0.49, 0.85] 0.55 [0.39, 0.77] 
Least                                             0.82 [0.51, 1.14] 0.71 [0.48, 1.05] 0.80 [0.63, 1.14] 0.71 [0.51, 1.01] 0.66 [0.54, 1.13] 0.52 [0.33, 0.80] 
Co-morbidity 
Selected 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
None                                                      0.82 [0.43, 1.64] 0.64 [0.45, 0.90] 0.78 [0.42, 1.64] 2.27 [1.67, 3.07] 0.67 [0.34, 1.06] 0.70 [0.49, 1.00] 
Staff category  
GP 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Other                                               0.83 [0.64, 1.13] 0.83 [0.60, 1.15] 0.89 [0.70, 1.24] 1.10 [0.86, 1.41] 0.68 [0.45, 0.70] 0.80 [0.56, 1.14] 
Random effect                                                                          Variance [SD] 
General Practice 0.093 [0.047] 
Unadjusted model = Individual variable in the model, Adjusted model = All variables included simultaneously
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5.3.7 Final model choice  
The goodness-of-fit statistics BIC (14316.46), AIC (14215.13) and CAIC (14333.46) in the 
3-cluster model are lower than in the 4-cluster model, BIC (14358.85), AIC (14221.75) and 
CAIC (14381.85). The cluster mean posterior probabilities in the 3-cluster model of 0.70 
(basic analgesia cluster), 0.76 (NSAIDs), and 0.77 (multiple-potency) compared to 0.69 
(basic analgesia cluster), 0.59 (NSAIDs), 0.78 (multiple-potency), and 0.57 (no 
medication) in the 4-cluster model indicate that there is more uncertainty in discriminating 
between cluster memberships between the no medication and the basic analgesia 
clusters in the 4-cluster model. Only 41% of the subjects in the 4-cluster model compared 
to 86% in the 3-cluster model are classified with probability of 0.70 or above. If the mean 
cluster posterior probabilities are considered as a measure of homogeneity within the 
clusters and heterogeneity across clusters, then clusters in the 3-cluster model are more 
heterogeneous and members in each cluster are more homogeneous.  
The current WHO guidelines on how general practitioners should prescribe in the 
pharmacological management of MSK problems suggest a stepped approach (Ehrlich, 
2003). The guidelines suggest that clinicians start with a basic analgesia such as 
paracetamol and then consider NSAIDs before prescribing strong analgesia if pain 
persists. Hence it can be said that the 3 cluster model reflects what current advice 
advocates making it a suitable choice.  
The model shows that there are three categories of prescription profiles over time, namely 
basic analgesia only or no medication, NSAIDs, and mixture of analgesia including 
stronger analgesia. Based on the model it can be assumed that those prescribed NSAIDs 
generally needed something stronger than basic analgesia but less than stronger 
analgesia and those on a mixture of analgesia or stronger analgesia can no longer be 
treated adequately with NSAIDs or basic analgesia only. The opinions of the clinician Dr 
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John Bedson and the biostatistician Dr Kelvin Jordan concur that the 3-cluster model was 
more clinically interpretable in line with current guidelines. 
After universal consideration of the goodness-of-fit statistics, posterior probabilities, the 
cluster sizes, homogeneity of individuals within each cluster and heterogeneity across 
clusters, the 3-cluster model is statistically superior to the 4-cluster model.  
Three cluster model analgesia prevalence summary 
In the basic analgesia cluster, 61% received no medication, 25% received basic 
analgesics only and 14% basic analgesia and weak combination analgesia. In the NSAIDs 
cluster, 57% received NSAIDs only, 12% a combination of NSAIDs-WCA, 3% a 
combination of NSAIDs-MCA and 25% a combination of NSAIDs-SA. In the multiple-
potency cluster there were many combinations of the five potency levels, but prominently, 
4% received all five potency levels, 14% a combination of four potency levels, 54% a 
combination of three potency levels and 14% a combination of two potency levels 
including strong analgesia. 
Model Similarities: 3-cluster v 4-cluster model 
Cluster comparison by baseline characteristics suggest similar clinical conclusions can be 
drawn from both models. Both models highlight similar subgroups of patients, a group 
dominated by NSAIDs prescriptions and a group dominated by prescription of multiple 
potency levels. In the 3-cluster model, the Basic analgesia cluster is dominated by those 
receiving basic analgesia even though there were some patients with no medication; this 
is similar to a combination of the No medication and the Basic analgesia clusters in the 4-
cluster model. Similar conclusions can be drawn from both models on the association of 
the combinations of medication potency levels and age, gender, medication history, pain 
location and deprivation. 
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Over the course of five years following a new MSK consultation, the observations 
highlighted by both model classifications were that compared to only receiving basic 
analgesia or no analgesia: 
1. NSAIDs were less likely to be prescribed to the elderly, but were more likely to be 
prescribed to the working age groups. 
2. NSAIDs were more likely to be prescribed to males, people who have been 
prescribed pain medication in the past and people experiencing pain in the back. 
3. Multiple potency prescriptions were more likely in over 60 age groups. 
4. Multiple potency prescriptions were most common among females, people with 
prescribed medication in the past and those presenting initially with back pain 
The 4-cluster model adds some observations about the people who were not prescribed 
any pain medication in contrast to those prescribed any pain medication: 
1. The prevalence of people who were not prescribed any pain medication over 5 
years declines with increasing age from a peak amongst 15-29 to a low among the 
over 75.  
2. People with back pain and people with previously prescribed analgesia in the past 
were more likely to be prescribed pain medication than no medication at all. 
3. People from most deprived backgrounds were more likely to be prescribed pain 
medication than no medication at all. 
4. Adults over 60 years were more likely to be prescribed basic analgesia than no 
medication at all 
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5.4 Discussion  
The use of latent class analysis has uncovered distinct subpopulations characterised by 
prescribed analgesia potency levels within a cohort of new MSK consulters which are both 
clinically relevant and supported by findings from different research settings. The first 
cluster which comprises those prescribed no pain medication or basic analgesia and 
occasionally weak analgesia may reflect the initial steps in the hierarchical treatment of 
MSK pain where patient concerns can be addressed through non-pharmacological means 
or basic analgesia.  
The second cluster which comprises patients prescribed predominantly NSAIDs and to a 
lesser extent stronger analgesia, may reflect cases where stronger analgesia  are deemed 
necessary but non-steroidal anti-inflammatory drugs (NSAIDs) have precedence over 
opioids. However in some patients, stronger analgesia is also tried. The third cluster of 
patients with high probability of all potency levels reflect possibly patients returning with 
severe conditions and intolerable levels of pain leading to combinations of potency levels 
or quick ascendency up the potency levels due to lack of effectiveness of weaker 
analgesia .  
This analysis has not assessed the order of the analgesia prescribed as this will be the 
focus of Chapters 6-7. However, the clusters do not contradict the medication pathways 
related to the WHO analgesia ladder for the management of low back pain. This ladder 
suggests that pharmacological therapy starts with low potency non-opioid analgesia 
(hence the emergence here of a basic analgesia cluster) and a gradual addition of weak 
opioids before addition of stronger opioids (Ehrlich, 2003).  
There is a link between pain intensity and the analgesia potency level received as well as 
side effects (Muller et al., 2011). The variation of cluster membership may be attributed to 
pain intensity or side effects. The multiple potency prescriptions in the third cluster may be 
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reflective of higher pain intensity that varies over time leading to prescription of multiple 
potency levels.  
The association of living in less deprived areas being less likely to be prescribed multiple 
analgesia may reflect that patients from more deprived backgrounds are more likely to be 
prescribed analgesia free of charge whilst those in more affluent areas may prefer to 
purchase some medications over the counter. It can also be assumed that the less 
deprived are healthier and require less intervention. This analysis has concentrated on 
prescribed medications and the use of over the counter analgesia in this cohort is 
unknown, though 90% of prescriptions issued within the NHS are free of charge 
suggesting we are likely to have identified the majority of analgesia being used in primary 
care (House of Commons Committee of Public Accounts, 2008). 
Latent class analysis has never been used in this context before but the results suggest it 
can be a valuable method in understanding prescription patterns in the pharmacological 
management of MSK conditions. Latent class analysis has a distinct advantage over other 
clustering methodologies in that the statistical model is based on the underlying probability 
distributions that generate the data hence the choice of cluster criterion is probability 
based (Vermunt and Magidson, 2002). This enables maximum likelihood estimation, 
rigorous statistical tests and goodness-of-fit measures in determining the best model. For 
example, in the initial six indicator model, the bivariate residuals identified the violation of 
the local independence assumption. One of the potential causes of the violation is a large 
number of indicator variables resulting in data becoming sparse and the parameter 
estimation process lacking precision (Popper, 2004; Vermunt and Magidson, 2000). The 
final model in this study was supported by four goodness-of-fit measures, the likelihood 
ratio test, the BIC, AIC and the CAIC. The high average posterior probabilities suggest low 
misclassification rates and that statistically the model is good quality while the clinical 
interpretation of the model was substantiated by a clinician’s evaluation.  
104 
 
The highly statistically significant variables in the multilevel multinomial logistic model 
show that the established clusters do not contradict the known guidelines and trends in 
the management of MSK pain, for example NSAIDs are known to be less likely to be 
prescribed for the 75+ age group due to the associated adverse effects for this age group 
(Fitzcharles et al., 2010, Oshima et al., 1996). 
The prescription rate of NSAIDs in these patients is 62% over the period and they are 
prescribed mostly to age groups between 30 and 45 years reinforcing the view that 
NSAIDs are the mainstay of drug treatment of acute and chronic pain, but their side 
effects make them less suitable for the elderly (Main, 2002; Brooks, 2006; Garbez and 
Puntillo, 2005; Curatolo and Bogduk, 2001). The multiple-potency cluster suggests 
combination therapies which may be necessitated by the need to contain intolerable levels 
of pain while controlling the resultant side effects. Hunt et al. (2007) observed that 
combined use of NSAIDs and other analgesia is associated with fewer gastro-intestinal 
complications than treatment with NSAIDs alone, which might be the case in this cluster.  
The study highlights that there are three distinct treatment profiles, associated with patient 
baseline characteristics over 5 years in patients consulting with new MSK problems, which 
can be described as no or basic analgesia, mainly NSAIDs or multiple pain analgesia. The 
intriguing group is the multiple analgesia group, which is the smallest group of 23% and 
has a high exposure to medication side effects. It could be postulated that if in a period of 
five years they have received at least three out of five potency levels (over 70%) or 
potency combinations including strong analgesia, they may have limited further viable 
medication options in the long run. This group consists mostly of females and the age 
distribution is skewed towards the older age group which is of concern given MSK 
conditions and their severity increase with age (Jordan et al., 2007), and that this is the 
age group with highest levels of comorbidity. 
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Despite the findings the study has its limitations. Although the designs incorporates five 
years of follow-up, the analysis is essentially a cross-sectional analysis and the likelihood 
is that analgesia prescriptions and potency level decided upon by GPs has time 
dependence and this analysis does not observe the sequence of the prescriptions. We are 
associating baseline factors with prescription patterns over five years and it is possible 
some baseline factors (e.g. comorbidity) may change. However despite the limitations, the 
latent class models provide a valuable insight into the prescription patterns of analgesia 
by potency levels among MSK consulters which provides strong foundations for further 
research. The older age group with multiple medications might be one that GPs should 
carefully follow up or be aware of since they may need greater clinical input that might 
avoid multiple drug use.  
5.5 Conclusion 
There are distinct latent classes of pain analgesia prescribing profiles for patients over a 5 
year period. The existence of patient clusters that differ by demographic and clinical 
characteristics suggests that general practitioners may consider a number of factors 
including age and previous analgesia potency in deciding the potency level to prescribe 
next. Further research may be able to identify the group of patients at risk of high potency 
combinations.  
The HAC model provides a reasonably good understanding of prescription patterns in the 
pharmacological treatment of MSK conditions as observed from current practices. Some 
patients because of their characteristics at the onset of seeking medical care are more 
likely to progress through the medication potency levels over time than others. The next 
chapter will examine the factors associated with time to changes or progression through 
the potency levels.  
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Chapter 6 
6 Factors associated with time to any switch of analgesia potency 
level among new musculoskeletal consulters 
6.1 Introduction 
Chapters 4 and 5 suggested that the HAC can provide a practical tool for describing the 
pharmacological management of MSK conditions with respect to using analgesia. Chapter 
5 highlighted that there are three distinct prescription profiles within MSK consulters over 
time which consist of those prescribed Basic analgesia, NSAIDs and Multiple-potency 
(analgesia from across all potency levels). There are baseline factors associated with the 
prescription patterns which include age, gender, pain location, level of locality deprivation 
and previous prescribed analgesia. The potential group of interest is the 580 patients 
(23% of all new MSK consulters) who evidently use analgesia from several potency levels 
over time, despite the fact that the risk of adverse effects of analgesia becomes more 
likely. 
There are numerous reasons which might be related to changes in analgesia. These 
include full or temporary recovery, deterioration of their condition, lack of efficacy, or 
patient decision (or choice). As a consequence, some patients will continue with the 
analgesia they started with, some will stop using analgesia permanently or for a while, 
while some change to higher potency analgesia or alternate between potency levels. This 
suggests that the analgesia switching process should be considered as a function of time, 
hence statistical models incorporating time to event in determining the factors associated 
with switching analgesia can add further information to the understanding of the switching 
process.  
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The association of time when a particular type of switch occurs, and the factors 
associated with switching may help to evaluate how general practitioners use analgesia to 
manage MSK pain over time and the potential risk of exposure to adverse effects. The 
time between subsequent switches will vary across and within individuals over time, but 
evaluating socio-demographic and clinical factors associated with switching may help 
clinicians to make therapeutic choices that might limit switching because the drugs used 
will suit the patient better. 
As seen in the systematic review for statistical methods (Chapter 2), the Cox proportional 
hazards, a semi-parametric model, is suitable as it incorporates the effect of time, but 
parametric models (Weibull for example) could also be considered in any quest to obtain 
the best fit. The choice between semi-parametric or fully parametric form of the model is 
difficult, but consideration of the sample size, study objectives and potential benefits of 
each model can be a guiding principle (Marubini, 1994). The suitability of the statistical 
methods used should also be evaluated to ensure that the conclusions drawn from the 
study are applicable, informative and add to the existing knowledge of pharmacological 
management of MSK conditions.  
The aim of this chapter is therefore to use semi-parametric and parametric statistical 
methods to evaluate both socio-demographic and clinical factors associated with time to 
switching analgesia in the pharmacological management of MSK conditions. This will 
further highlight the patients at higher risk of switching analgesia and therefore potentially 
exposure to potential adverse effects.  
The specific objectives of the chapter are: 
1. To model factors associated with change from initial analgesia potency level 
2. To establish if factors associated with  switch from initial analgesia vary with the 
potency level of initial analgesia 
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3. To model factors associated with switching taking into account successive 
switches from the initial analgesia potency to different potency levels over time 
4. To model factors associated with the rate of switching  
5. To compare semi-parametric and parametric models in modelling factors 
associated with switching from initial analgesia to different potency levels 
The Cox model, the Weibull model and the Poisson model were employed to achieve the 
above objectives. The Cox model was identified through the literature review (Chapter 2) 
as the most commonly used approach in medication switch analysis. The first phase of 
analysis (Analysis 1) used both Cox and Weibull methods to model time to the first 
change from the initial potency level, (1st, 2nd and 5th objectives), while the second phase 
(Analysis 2) models all switches in potency levels (3rd and 5th objectives) using the 
multivariate versions of the same models. To account for unmeasured covariates, Weibull 
models with gamma frailty were also evaluated in both analyses 1 and 2. The third phase 
used Poisson and negative binomial regression to evaluate rates of switching over the 5 
year follow-up period and associations with the clinical and socio-demographic covariates 
(4th and 5th objectives, Analysis 3). 
6.2 Analysis 1 - Modelling time to the first change from initial 
medication potency 
6.2.1 Methods 
The analysis of time to the first switch (change) is considered in two steps to enable 
iterative model building and evaluation. Switching analgesia, as defined in chapter 1, is 
defined as either a record of a prescription of an analgesia of a potency different from that 
previously prescribed (this may be in place of, or in addition to the initial analgesia), or a 
record of prescribed analgesia without a previous analgesia prescription on first 
consultation (Gore et al., 2012, Rahme et al., 2006). Stopping medication is not 
considered as a switch as the precise time to stopping cannot be ascertained. The 
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statistical approaches are defined in brief, to highlight the differences between the models, 
and their detailed descriptions can be found in in a wide range of literature including 
Dobson and Barnett (2008). 
Step 1: The event of interest (outcome variable) was the first switch of analgesia potency 
level. Analysis of time to the first change will establish if there was any relationship 
between change in analgesia potency from the initially prescribed analgesia and baseline 
clinical, socio-demographic and time-varying covariates.  
Step 2: In the second step, the analysis was repeated but with the individual strata (HAC 
categories) of the initial analgesia potency level analysed separately.  Analysis of time to 
first change stratified on the initial medication potency assumed that each category (initial 
analgesia potency level) had a different likelihood of switching and associated factors 
which may not be identified when modelled jointly. The Weibull and the Cox models were 
fitted on each initial analgesia stratum separately to establish if the factors associated with 
a switch varied by initial medication potency.  
A descriptive analysis was conducted initially on the types of changes, that is, for patients 
in each potency category initially, to what potency level they changed to on first switch, if 
they switched.  
6.2.2 Data management and study population 
All the patients identified and included in the analysis in Chapter 4 were considered in this 
analysis but with a slight variation. Patients whose registration records showed them as 
not registered any time after their initial 2006 consultation were censored at their last 
registration date (date of leaving the practice). Those whose last registration date after the 
first consultation could not be established were excluded from the analysis. The time to 
first switch was derived from the initial consultation date and issue date of prescriptions. 
Those who did not switch medications had their times censored at the end of 2010 or end 
of registration.  
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Outcome variables: The outcome variable was time to the first switch from the initial 
analgesia potency level. The time, in days, is the time between the date of first 
consultation in 2006 to the date when an analgesia was prescribed of a potency level 
(based on the HAC) different from initially prescribed, as it is considered they are at risk of 
starting or changing analgesia from the onset of consultation. The switch from initial 
analgesia potency was defined as first prescription of analgesia on a different potency 
level (less or more potent) in the HAC than that prescribed at initial consultation, or first 
prescription for analgesia in those not prescribed analgesia at initial consultation. 
Censoring: Inevitably some patients left their practices before the end of follow-up. These 
individuals therefore have censored times, censored on the dates when they became 
unregistered (e.g. left or died) from their practices. Registration data for CiPCA though 
was only available at the mid and end dates of years, so censoring for those leaving their 
practice was at last date of recorded registration or last recorded prescription date, 
whichever was later.  
Baseline  covariates: The variables measured at time of initial consultation and 
considered in this analysis were age, gender, deprivation, co-morbidity, registered 
practice, staff consulted (GP or other), region of pain (e.g. knee, back) at onset of 
consultation, previous MSK consultation and previous prescribed analgesia as described 
in Chapter 4. The initial analgesia received within two weeks of first consultation was also 
included (basic analgesia, weak analgesia, moderate analgesia, strong analgesia, 
NSAIDs and no medication). As described in Chapter 5, strong combination analgesia and 
very strong single analgesia were combined to a single category of strong analgesia. 
General practice was considered as a clustering variable (section 6.1.2).  
Time-varying covariates: Time-varying covariates are variables that change during 
follow-up. The time-varying variables were based on information to the earliest of the first 
switch, end of follow-up (end of 2010) or date of censorship. They were the number of 
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analgesia prescriptions for the analgesia category prescribed at initial consultation, 
number of further MSK consultations after first consultation date, and consulting for pain in 
more than one location over time. The covariates are evaluated as products of the 
variables and the natural log of time (Maller and Zhou, 1996). Including the time-varying 
covariates in the model as the product of the log of time to the event and the measured 
variable minimises the risk of over or under inflated parameter estimates resulting from 
the influence of outlying observations. 
6.2.3 Statistical analyses 
Kaplan-Meier survival curves, the Cox model and Weibull model were used. The use of 
proportional hazards models was considered, but the statistical significance of the time-
varying covariates meant that the proportional hazards assumption was no longer valid 
(Dobson and Barnett, 2008); hence just the Cox and Weibull models assuming non-
proportional hazards were used. Kaplan-Meier curves were used as an exploratory 
analysis to decide if the times to first change are different between categories of the 
independent variables, with particular interest in the initial medication potency levels. 
Weibull models with a gamma frailty were used to model the dependence of time to first 
switch on the socio-demographic and clinical factors. Frailty modelling was used to deal 
with the possibility of unaccounted variation in switching due to unmeasured covariates. 
Comparison of the deviance (-2logL) values were further used to evaluate whether the 
inclusion of a cluster variable (practice) improved model efficiency, and whether the Cox 
model or the Weibull model is more suitable in the analysis of analgesia switching. The 
statistical package Stata was used.  
6.2.3.1 Cox proportional hazards model 
The basic model is defined by Cox (1972), Marubini (1994) and by Crowder et al. (1991) 
among several other authors as follows:  
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Consider a study with N individuals, each with the observed vector (        ), where    is a 
vector of covariates of   dimension,    (         )   for individual   and    is the switch 
or censoring indicator (1=switch, 0=censor) Consider in this case failure to be defined by 
switching from one medication potency level to another and time to failure to be the time 
to switching. Then the hazard function (the instantaneous rate of switching)  (    ) for the 
time to switch t for an individual   is defined as: 
 (    )    ( )          ,  
Where   ( ) is the baseline hazard and is an arbitrary function of time only,   ( ) is the 
same for all subjects and β is a vector of regression coefficients.  
The Cox model is a semi-parametric or distribution-free model; that is, it does not assume 
that the data has a particular underlying distribution, but its major assumption is that the 
hazards of the different groups are proportional (Lawless, 1982). Proportional hazards 
cannot be assumed in models with time-varying covariates, which is the case in this 
thesis. 
Cluster and strata variables can also be used in the Cox model. A cluster variable 
accounts for correlation of failure times within and between the clusters in which the data 
is partitioned in the estimation of the model parameters (Collet, 2003). The data can be 
partitioned into 12 general practices, and so including general practice as a cluster 
variable in the model enables the model to account for the variation or the correlation of 
switch times within practices in the final model and enables testing to see if practice has 
an influence on model parameters. By contrast, strata variables enable the modelling 
process to consider stratum-specific hazards in estimating model parameters, for example 
if initially prescribed analgesia was included as a strata variable, the model will consider 
baseline hazards for potency level different and account for that in model parameter 
estimation. 
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The hazard ratios associated with a covariate are estimated through the partial likelihood 
function (Cox (1972)) which is  
  ( )   ∏
    
∑        (  )
 
   
 
It works as an ordinary likelihood for making inferences about coefficients of the 
covariates in the model. 
6.2.3.2 The Weibull model 
The Weibull model is based on the assumption that the baseline survivor function follows 
a Weibull distribution. Consider the Weibull distribution as defined by Crowder et al. 
(1991) as a function of time as follows:  
 ( )     (  )        (  )               
Where   is the scale parameter and   is the shape parameter, the hazard function (the 
instantaneous rate of switching)  
 ( )    (  )    
The scale parameter   controls the spread of the Weibull distribution such that the larger 
the value of    , the more spread is the distribution. The shape parameter   controls the 
shape of the distribution, for example how skewed the distribution is. To illustrate the 
effect of the scale and shape parameters, a Weibull distribution with parameters       
  gives a constant hazard rate and an exponential distribution (Lee and Wang, 2003). For 
3 ≤   ≤ 4, it is close to the Normal distribution and when   is large, say   ≥ 10 it is close to 
the smallest extreme value distribution (Nelson, 1982). The hazard rate increases over 
time when     and decreases when     as time increases (Lee and Wang, 2003).  
For an individual with time to switching medication   and a covariate vector of   
variables,    (         ), the Weibull hazard may be expressed as; 
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 (    )    (  )
            
The log of the Weibull likelihood function  ( ) is 
 ( )               (   )∑  
 
 
      ∑(  )
 
 
 
 
   is the switch or censoring indicator. The parameter estimates obtained that maximise 
the log likelihood function can then be used to calculate estimated covariate coefficients, 
standard errors and confidence intervals (Marubini et al., 1995). 
The main difference between the Weibull and the Cox model is that the Cox model 
estimates the baseline survivor function without any reference to a theoretical distribution. 
They can yield similar results if the data indeed follows a Weibull distribution or if the 
proportional hazards assumption is true. The Weibull model may yield smaller standard 
errors due to the parametric form of the baseline hazard instead of estimating hazard 
rates at every event time (Marubini et al., 1995). The Weibull can also yield smaller 
standard errors than the Cox if the sample sizes are small, for example less than 30, but 
there is little difference with larger samples. If the distributional assumptions can be met, 
the Weibull model will fit the data better than the Cox (Lee and Wang, 2003).  
6.2.3.3 Assessing model fit and Goodness-of-fit tests 
The evaluation of the fitted model is achieved through residual analysis and the analysis 
of the survival or hazard functions. These are best illustrated through graphical plots. The 
residuals commonly used for assessing model fit are Cox-Snell, Martingale and 
Schoenfeld residuals (Marubini et al., 1995). The evaluation of the proportional hazards 
assumption is also an essential aspect of model evaluation. However time-varying 
covariates allow for changing hazard ratios over time, which means the proportional 
hazards assumption can be relaxed and is no longer a necessary condition in assessing 
model fit (Collet, 2003).  
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6.2.3.4 Gamma frailty model 
The concept of frailty is based on the heterogeneity amongst individuals (Collet, 2003), 
that is, not all individuals are the same. High risk or frail individuals will tend to have 
shorter times before switching medication and lower risk ones will take much longer. 
Frailty models therefore attempts to account for some of the possible unobserved or 
unmeasured covariates which may influence switching, and for within group correlations.  
If we consider a Weibull model as above, but include a random variable (the frailty 
element)    the hazard becomes;  
 (   )     (  )            
The frailty distribution in this analysis is assumed to be gamma but can take any form in 
general. The gamma distribution is responsive to non-monotonic hazard functions over 
time and best suited in models with time-varying covariates, (Marubini et al., 1995).  
6.2.4 Results 
Data description 
Of the original 3236 patients, 57 (2%) ceased to be registered with a last date known to be 
registered prior to their index consultation, hence time to event could not be determined 
nor was censoring possible. Most of the independent variables were complete except for 
pain location (see Chapter 4). The excluded patients were not very different from the main 
cohort by age and gender, 34 (60%) were males and their mean age was 44 years with a 
standard deviation of 19.6. 
There were 3179 people considered in the analysis with mean age 45 years, (SD 15.9), of 
which 59% were males. 1629 (51%) people switched from the analgesia prescribed in 
their first consultation in 2006 or started analgesia. Very high proportions of those initially 
prescribed weak (70%), moderate (62%) and strong analgesia (70%) switched from 
initially prescribed analgesia over the five years of follow-up. Over 50% of those aged over 
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45, females, those with prior MSK consultations, previous prescribed analgesia, pain in 
the back and hip and selected co-morbidities switched (Table 6.2.1). 
Table 6.2.1: Baseline socio-demographic and clinical characteristics of patients switching 
analgesia 
 Switch Analgesia 
Variable N No (Row %) Yes (Row %) 
Total 3179 1550(49) 1629(51) 
Age (years)    
15-29 688 392(57) 296(43) 
30-44 1068 556(52) 512(48) 
45-59 953 435(46) 518(54) 
60-74 369 132(36) 237(64) 
Over 75 101 35(35) 66(65) 
Gender    
Females 1293 580(45) 713(55) 
Males 1886 970(51) 916(49) 
Previous musculoskeletal 
consultation 
   
Yes 409 179(44) 230(56) 
No 2770 1371(49) 1399(51) 
Previous prescribed 
analgesia 
   
Yes 509 145(28) 364(72) 
No 2670 1405(53) 1265(47) 
Region of Pain    
Back 818 376(46) 442(54) 
Knee 388 177(52) 161(48) 
Hip 199 88(44) 111(56) 
Foot and Ankle 219 104(47) 115(53) 
Hand/upper limb 256 129(50) 127(50) 
Shoulder 244 114(47) 130(53) 
Neck 215 114(53) 101(47) 
Other/unspecified 890 448(50) 442(50) 
Co-morbidity    
Selected conditions 118 53(45) 65(55) 
Other conditions/none 3061 1497(49) 1564(51) 
Deprivation    
Most 1402 657(47) 745(53) 
Moderate 1239 624(50) 615(50) 
Least 538 269(50) 269(50) 
Staff category    
GPs 2575 1255(49) 1320(51) 
Other 604 295(49) 309(51) 
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 Switch Analgesia 
Variable N No (Row %) Yes (Row %) 
Number of pain locations    
One 2472 1053(43) 1419(57) 
More 707 497(70) 210(30) 
Analgesia  group (1st 
consultation) 
   
Basic analgesia 346 159(46) 187(54) 
Weak analgesia 223 66(30) 157(70) 
Moderate analgesia 47 18(38) 29(62) 
Strong analgesia 160 47(30) 113(70) 
NSAIDs 687 321(47) 366(53) 
No medication 1716 939(55) 777(45) 
Of those switching analgesia, at least 30% first switched to or added NSAIDs from all 
initial potency levels, the highest number being from strong analgesia (53%). More than 
30% also switched to or added basic analgesia from all potency levels, with 53% of those 
initially on NSAIDs and 48% on weak analgesia first switching to basic analgesia. Less 
than 20% from all initial potency levels switched to strong analgesia. Those with no 
medication prescribed at initial consultation were more likely to be prescribed NSAIDs 
(38%) or basic analgesia (35%) during follow-up (Table 6.2.2). 
Table 6.2.2: First switch from initial analgesia potency in those switching 
Analgesia 
prescribed on 
1st consultation 
Group Switched to 
 Basic 
analgesia 
Weak 
analgesia 
Moderate 
analgesia 
Strong 
analgesia 
NSAIDs 
 N n (row%) n (row%) n (row%) n (row%) n (row%) 
Basic analgesia 187 - 50(27) 64(34) 17(9) 56(30) 
Weak analgesia 157 76(48) - 7(5) 27(17) 47(30) 
Moderate 
analgesia 
 
29 
 
13(44) 
 
2(7) 
 
- 
 
5(17) 
 
9(31) 
Strong analgesia 113 35(31) 12(11) 6(5) - 60(53) 
NSAIDs 366 193(53) 80(22) 23(6) 70(19) - 
No medication 777 272(35) 106(13) 32(4) 75(10) 292(38) 
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Of those who switched analgesia, the mean time to switch was 606 days; the median 
switch time was 485 days and interquartile range (IQR) (118, 1002). 
Rates of analgesia switching 
The Kaplan-Meier survival curves suggested evidence of different rates of analgesia 
switching between some age groups, by gender and by medication history. Some 
covariates showed no evidence of difference, that is, co-morbidity, location of pain, 
consultation history and staff consulted. The Kaplan-Meier curves showed that, there are 
more people switching within the first 30 days of starting analgesia for all potency levels. 
There is evidence of variation in the rates of switching by the initially prescribed analgesia 
over time (Figure 6.1.1). 
Figure 6.2.1: Analgesia switching estimates by initial analgesia prescribed 
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6.2.4.1 Time to first analgesia switch models  
The time-varying covariates were statistically significant in the final models meaning that 
the proportional hazards assumption no longer holds for the model. The -2logL of the 
models also showed that the inclusion of practice as a cluster variable does not improve 
model fit; hence the practice variable was left out of the final models. Both the adjusted 
and the unadjusted models were fitted and the hazard ratios reported with 95% 
confidence intervals (HR [95%CI]) for both the statistically significant and non-significant 
variables (Table 6.2.3). The statistically significant variables from these two models are 
highlighted in bold.  
The models show that the baseline variables of age, gender, previous medication history, 
and analgesia potency at onset of consultation are all statistically significantly related to 
switching analgesia potency level. Number of MSK consultations and number of analgesia 
prescriptions of same potency as at initial consultation over follow-up are also associated 
with switching. Consulting for pain in more than one location over time also significantly 
increases the risk of switching analgesia. The hazard ratios are similar for Cox and 
Weibull models with minor variations in some cases. The hazard ratios can be interpreted 
as the average hazards associated with each variable over time. 
The Cox model 
Baseline variables: The model shows that when compared to the 30-44, the age groups 
60-74 (adjusted hazard ratio ((HR) 1.31; 95% CI [1.11, 1.53]), and 75 plus (HR 1.45 [1.11, 
1.90]) were more likely to experience an analgesia switch when all other factors are held 
constant. Females were more likely than males to experience analgesia switch (HR 1.14 
[1.03, 1.26]). Patients prescribed pain medication 12-24 months prior to their first 
consultation in 2006, with hazard ratio (HR 1.57 [1.38, 1.78]) also had an increased risk of 
experiencing a medication switch.  
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Those who started with no medication at initial consultation (HR 0.74 [0.63, 0.88]) were 
less likely to change medication status while those starting on weak analgesia (HR 1.34 
[1.08, 1.67]), and those starting on strong analgesia (HR 1.34 [1.04, 1.72]) were more 
likely to switch medication, compared to those starting on basic analgesia. Prior history of 
MSK consultations, level of deprivation, comorbidity, pain location at initial consultation 
and staff consulted were not significantly related to time to first analgesia switch. 
Time Varying Covariates: Patients who consulted for pain in more than one location over 
time (HR 1.03 [1.02, 1.06]) were more likely to switch analgesia. The hazard ratios of (HR 
0.90 [0.88, 0.91]) for number of consultations over time and (HR 1.01 [1.001, 1.02]) for 
number of analgesia prescribed over time shows that each consultation for MSK reduced 
the risk of switching analgesia by 10% but each extra prescription increases the risk of 
analgesia change by 1%, respectively (Table 6.2.3). 
The Weibull model 
The Weibull model identified significant covariates similar to those identified by the Cox 
model with slightly lower hazard ratios in some instances, for example (HR 1.28 [1.09, 
1.51] for the 60-74 and 1.43 [1.10, 1.88]) for the 75+ age groups (Table 6.1.3). The 
Weibull shape parameter of 0.85 [0.81, 0.88] suggests that the underlying hazard rate 
decreases as time increases. The -2logL of 7980 suggests the Weibull model is a better fit 
than the Cox model. 
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Table 6.2.3: Unadjusted and Adjusted Cox and Weibull models that examine factors associated with time to 1st medication switch   
 
Variable                                                             
 
Hazard Ratio [95% CI] 
Cox Model Weibull Model 
Unadjusted Adjusted Unadjusted Adjusted 
Age Group 
30-44 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
15-29 0.92[0.80, 1.07] 0.92[0.79, 1.06] 0.92[0.79, 1.06] 0.91[0.78,  1.06] 
45-59 1.11[0.98, 1.25] 1.03[0.91, 1.17] 1.11[0.98, 1.25] 1.03[0.91, 1.17] 
60-74 1.50[1.29, 1.75] 1.31[1.11, 1.53] 1.48[1.27, 1.72] 1.28[1.09, 1.51] 
75+ 2.19[1.70, 2.83] 1.45[1.11, 1.90] 2.17[1.68, 2.80] 1.43[1.10, 1.88] 
Gender 
Male 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Female 1.28[1.16, 1.41] 1.14[1.03, 1.26] 1.271.15, 1.40] 1.12[1.01, 1.24] 
Previous prescribed analgesia 
No 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Yes 1.69[1.51, 1.90] 1.57[1.38, 1.78] 1.68[1.49, 1.88] 1.54[1.36, 1.75] 
Previous musculoskeletal consultation 
No 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Yes 1.09[0.96, 1.25] 0.92[0.79, 1.07] 1.09[0.95, 1.26] 0.93[0.80, 1.08] 
Comorbidity  
Selected 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
None 0.91[0.71, 1.16 1.14[0.89, 1.47] 0.93[0.72, 1.19] 1.17[0.92, 1.52] 
Staff category 
GP 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Other 1.02[0.90, 1.15] 1.02[0.90, 1.15] 1.02[0.90, 1.15] 1.03[0.91, 1.17] 
Deprivation  
Most 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Medium 0.87[0.78, 0.96] 0.95[0.85, 1.06] 0.86[0.78, 0.96] 0.94[0.85, 1.06] 
Least 0.83[0.72, 0.96] 0.91[0.79, 1.05] 0.83[0.73, 0.96] 0.91[0.80, 1.06] 
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Variable                                                             
 
Hazard Ratio [95% CI] 
Cox Model Weibull Model 
Unadjusted Adjusted Unadjusted Adjusted 
Pain Region  
Back 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Knee 0.82[0.69, 0.99] 0.95[0.79, 1.15] 0.82[0.68, 0.98] 0.96[0.80, 1.15] 
Hip 1.05[0.85, 1.29] 1.05[0.84, 1.30] 1.06[0.86, 1.30] 1.08[0.87, 1.33] 
Foot and Ankle 0.92[0.75, 1.13] 1.02[0.83, 1.27] 0.91[0.74, 1.12] 1.02[0.83, 1.26] 
Hand/upper limb 0.82[0.68, 1.00] 0.97[0.79, 1.18] 0.83[0.68, 1.01] 0.97[0.79, 1.19] 
Shoulder 0.94[0.78, 1.15] 1.00[0.82, 1.22] 0.94[0.78, 1.15] 1.00[0.82, 1.22] 
Neck 0.77[0.62, 0.96] 0.86[0.69, 1.07] 0.76[0.61, 0.94] 0.84[0.68, 1.05] 
Other/unspecified 0.88[0.77, 1.01] 0.97[0.85, 1.12] 0.88[0.77, 0.99] 0.97[0.84, 1.11] 
Initial analgesia (1st consultation) 
Basic analgesia 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Weak analgesia 1.66[1.34, 2.04] 1.34[1.08, 1.67] 1.66[1.34, 2.05] 1.33[1.07, 1.66] 
Moderate analgesia 1.16[0.79. 1.72] 0.99[0.66, 1.46] 1.17[0.79, 1.73] 1.02[0.69, 1.52] 
NSAIDs 0.87[0.73, 1.04] 1.01[0.84, 1.21] 0.88[0.74, 1.05] 1.01[0.84, 1.21] 
Strong analgesia 1.63[1.29, 2.06] 1.34[1.04, 1.72] 1.63[1.29, 2.06] 1.34[1.05, 1.72] 
No medication 0.68[0.58,0.80] 0.74[0.63, 0.88] 0.68[0.58, 0.79] 0.73[0.62, 0.86] 
Time-varying     
Multiple location 
No 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Yes 0.86[0.84, 0.87] 1.03[1.02, 1.06] 0.86[0.84, 0.87] 1.03[1.02, 1.06] 
No. of consultations 0.91[0.90, 0.92] 0.90[0.88, 0.91] 0.91[0.90, 0.92] 0.89[0.88, 0.91] 
No. of Prescriptions 1.00[1.00, 1.01] 1.01[1.001, 1.02] 1.00[1.00,1.03] 1.01[1.001, 1.02] 
-2logL  23690  7980 
Weibull shape parameter - - - 0.85[0.81, 0.88] 
Unadjusted model = Individual variable in the model, Adjusted model = All variables included simultaneously
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6.2.4.2 Initial analgesia strata-specific models 
The Cox and Weibull models were fitted on each strata of the initial analgesia potency 
separately. The Cox and Weibull models identified similar variables associated with time 
to switching for each potency level. For those on basic analgesia initially, time to switch 
was associated with age, gender, pain location on first consultation, staff initially consulted 
(GP or other), number of MSK consultations and number of prescriptions received. For 
those on weak analgesia initially, medication history, pain location, pain in more than one 
location over time, number of MSK consultations and number of prescriptions were 
associated with time to switch, while for those on moderate analgesia age and number of 
MSK consultations were associated with switching. 
 For those initially on strong analgesia, only pain location on first consultation, pain in 
more than one location over time, and number of MSK consultations over time were 
associated with medication switching. For those initially on NSAIDs, gender (female), 
previous prescribed analgesia, pain in more than one location over time, number of MSK 
consultations and number of prescriptions were associated with time to switch. Those who 
were prescribed no pain analgesia initially had age, gender, previous prescribed 
analgesia, and pain in more than one location over time, and number of MSK 
consultations associated with time to starting medication (Table 6.2.4 and 6.2.5). 
Both the Cox and the Weibull stratified models are characterised by large hazard ratios 
accompanied by very wide confidence intervals. This is expected as fewer individuals 
contribute to the estimation process due to low numbers at risk in the individual categories 
of the initial analgesia potency. The adjusted Cox and Weibull models in Table 6.2.3 are 
therefore better fits to the data than the stratified models. 
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Table 6.2.4: Initial analgesia stratified Cox models that examine factors associated with time to 1st medication switch   
Variable Hazard Ratio [95% CI] - Cox 
 Basic 
Analgesia 
Weak 
Analgesia 
Moderate 
Analgesia 
Strong 
Analgesia 
NSAIDs No medication 
Age Group 
30-44 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
15-29 0.86[0.54,1.36] 1.20[0.69,2.07] 0.72[0.15,3.40] 0.84[0.40,1.76] 1.06[0.76,1.48] 0.90[0.74,1.10] 
45-59 1.04[0.66,1.65] 0.75[0.47,1.18] 0.08[0.01,0.62] 0.92[0.56,1.49] 1.13[0.88,1.45] 0.99[0.83,1.19] 
60-74 1.93[1.17,3.18] 0.88[0.51,1.52] 0.39[0.04,3.12] 0.77[0.39,1.53] 1.37[0.97,1.94] 1.43[1.12,1.82] 
75+ 1.46[0.83,2.57] 0.50[0.23,1.08] 0.58[0.04,8.03] 0.66[0.07,5.60] 2.23[0.89,5.59] 2.74[1.77,4.23] 
Gender 
Male 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Female 0.70[0.51,0.96] 1.17[0.81,1.68] 1.95[0.41,9.10] 0.93[0.60,1.45] 1.42[1.15,1.76] 1.21[1.05,1.40] 
Previous prescribed analgesia 
No 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Yes 1.49[0.95,2.34] 1.93[1.28,2.91] 0.07[0.01,0.60] 1.35[0.81,2.26] 1.40[1.08,1.82] 1.72[1.43,2.08] 
Previous musculoskeletal 
consultation 
No 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
Yes 0.63[0.37,1.06] 0.59[0.34,1.02] 2.58[0.20,32.9] 1.48[0.80,2.75] 0.75[0.53,1.05] 1.02[0.82,1.26] 
Comorbidity  
Selected 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
None 1.15[0.62,2.13] 2.02[0.95,4.28] 0.67[0.05,7.97] 0.98[0.40,2.38] 0.96[0.53,1.73] 0.95[0.63,1.42] 
Staff category 
GP 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Other 0.54[0.34,0.87] 1.43[0.88,2.34] 0.66[0.16,2.74] 1.40[0.86,2.27] 1.14[0.86,1.52] 0.99[0.83,1.18] 
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Variable Hazard Ratio [95% CI] - Cox 
 Basic 
Analgesia 
Weak 
Analgesia 
Moderate 
Analgesia 
Strong 
Analgesia 
NSAIDs No medication 
Deprivation  
Most 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Medium 1.13[0.79,1.62] 1.01[0.69,1.48] 0.41[0.12,1.38] 1.04[0.65,1.65] 0.93[0.74,1.18] 0.89[0.76,1.04] 
Least 1.41[0.93,2.15] 0.96[0.58,1.61] 0.51[0.05,4.94] 0.95[0.46,1.96] 0.92[0.67,1.25] 0.85[0.69,1.05] 
Pain Region  
Back 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Knee 0.45[0.25,0.79] 1.07[0.52,2.22] 2.16[0.05,80.0] 1.62[0.63,4.20] 0.98[0.69,1.38] 0.99[0.75,1.32] 
Hip 1.24[0.55,2.76] 1.79[0.90,3.55] 9.56[0.17,510] 3.34[1.57,7.10] 0.64[0.39,1.06] 0.99[0.73,1.34] 
Foot and Ankle 1.03[0.57,1.88] 1.82[0.77,4.29] - 0.91[0.21,4.00] 0.99[0.66,1.50] 1.00[0.75,1.32] 
Hand/upper limb 0.80[0.46,1.40] 2.82[1.25,6.40] - 12.5[1.28,122] 0.76[0.48,1.20] 0.92[0.67,1.25] 
Shoulder 0.69[0.39,1.21] 2.79[1.44,5.39] - 1.16[0.51,2.67] 0.98[0.69,1.40] 0.87[0.61,1.24] 
Neck 0.41[0.19,0.89] 0.70[0.28,1.73] - 0.90[0.48,1.68] 0.75[0.44,1.27] 0.72[0.52,1.01] 
Other/unspecified 0.60[0.38,0.94] 0.86[0.56,1.34] 4.88[0.57,41.3] 1.08[0.59,2.00] 1.01[0.74,1.38] 1.00[0.82,1.22] 
Time-varying       
Multiple location 
No 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Yes 1.11[0.58,2.14] 3.69[1.16,11.7] 8.68[0.51,146] 7.72[2.07,28.8] 1.58[1.00,2.49] 1.28[0.97,1.67] 
No. of Consultations 0.88[0.84,0.92] 0.75[0.67,0.83] 0.78[0.65,0.94] 0.77[0.68,0.87] 0.88[0.85,0.91] 0.93[0.92,0.95] 
No. of Prescriptions 1.00[1.00,1.01] 1.00[1.00,1.01] 0.99[0.96,1.01] 1.00[0.99,1.01] 1.00[1.00,1.01] - 
Unadjusted model = Individual variable in the model, Adjusted model = All variables included simultaneously
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Table 6.2.5: Initial analgesia stratified Weibull models that examine factors associated with time to 1st medication switch   
Variable Hazard Ratio [95% CI] - Weibull 
 Basic 
Analgesia 
Weak 
Analgesia 
Moderate 
Analgesia 
Strong 
Analgesia 
NSAIDs No medication 
Age Group 
30-44 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
15-29 0.84[0.53,1.33] 1.27[0.74,2.18] 0.42[0.09,1.88] 0.94[0.45,1.95] 1.06[0.76,1.47] 0.91[0.75,1.11] 
45-59 1.01[0.65,1.59] 0.76[0.48,1.20] 0.03[0.01,0.29] 0.94[0.58,1.53] 1.11[0.87,1.43] 1.01[0.84,1.21] 
60-74 2.07[1.25,3.40] 0.81[0.47,1.41] 0.12[0.01,1.02] 0.90[0.46,1.77] 1.31[0.92,1.85] 1.43[1.12,1.83] 
75+ 1.39[0.79,2.42] 0.52[0.24,1.12] 0.24[0.01,3.59] 0.95[0.11,8.15] 2.12[0.85,5.31] 2.69[1.74,4.15] 
Gender 
Male 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Female 0.68[0.49,0.94] 1.25[0.87,1.78] 2.68[0.58,12.4] 0.87[0.55,1.36] 1.37[1.11,1.70] 1.20[1.04,1.39] 
Previous prescribed 
analgesia 
No 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
Yes 1.47[0.94,2.15] 1.95[1.29,2.95] 0.03[0.01,0.30] 1.46[0.87,2.45] 1.35[1.03,1.75] 1.73[1.43,2.08] 
Previous musculoskeletal 
consultation 
No 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
Yes 0.65[0.38,1.08] 0.60[0.34,1.06] 4.97[0.41,59.6] 1.40[0.76,2.59] 0.75[0.53,1.06] 1.02[0.83,1.26] 
Comorbidity  
Selected 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
None 1.19[0.64,2.20] 2.22[1.04,4.71] 1.01[0.09,10.6] 0.98[0.40,2.39] 0.99[0.55,1.80] 0.96[0.64,1.44] 
Staff category 
GP 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Other 0.52[0.32,0.84] 1.42[0.87,2.32] 0.46[0.10,2.08] 1.57[0.96,2.57] 1.13[0.85,1.50] 0.98[0.82,1.17] 
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Variable Hazard Ratio [95% CI] - Weibull 
 Basic 
Analgesia 
Weak 
Analgesia 
Moderate 
Analgesia 
Strong 
Analgesia 
NSAIDs No medication 
Deprivation  
Most 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Medium 1.14[0.80,1.63] 1.02[0.70,1.49] 0.27[0.08,0.90] 1.08[0.68,1.72] 0.95[0.75,1.20] 0.88[0.75,1.03] 
Least 1.42[0.94,2.15] 1.02[0.61,1.70] 0.60[0.05,7.10] 0.99[0.48,2.04] 0.95[0.69,1.30] 0.84[0.68,1.03] 
Pain Region  
Back 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Knee 0.42[0.24,0.74] 1.04[0.51,2.14] 14.5[0.35,598] 1.64[0.63,4.28] 1.01[0.72,1.42] 0.99[0.75,1.32] 
Hip 1.23[0.55,2.74] 1.73[0.88,3.43] - 3.04[1.45,6.36] 0.66[0.40,1.09] 1.01[0.74,1.36] 
Foot and Ankle 1.04[0.57,1.89] 2.01[0.84,4.80] - 0.81[0.18,3.56] 0.94[0.62,1.43] 0.93[0.68,1.27] 
Hand/upper limb 0.79[0.45,1.36] 2.24[1.01,5.03] - 2.63[0.31,22.3] 0.74[0.47,1.17] 1.01[0.76,1.33] 
Shoulder 0.67[0.38,1.19] 3.12[1.61,6.06] - 1.13[0.49,2.63] 0.96[0.67,1.37] 0.86[0.61,1.22] 
Neck 0.37[0.17,0.81] 0.76[0.31,1.84] - 0.77[0.41,1.46] 0.74[0.44,1.25] 0.71[0.51,0.99] 
Other/unspecified 0.58[0.37,0.92] 0.80[0.52,1.24] 16.8[1.57,184] 1.01[0.54,1.84] 1.00[0.73,1.37] 1.00[0.81,1.22] 
Time-varying       
Multiple location 
No 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Yes 1.19[0.61,2.32] 8.15[2.24,29.6] 1.75[0.16,18.7] 11.4[3.10,42.5] 1.64[1.03,2.60] 1.27[0.96,1.66] 
No. of Consultations 0.87[0.83,0.91] 0.67[0.58,0.76] 0.82[0.70,0.97] 0.70[0.61,0.81] 0.87[0.85,0.90] 0.93[0.92,0.95] 
No. of Prescriptions 1.00[1.00,1.01] 1.00[0.99,1.01] 0.98[0.96,1.01] 1.00[0.99,1.01] 1.01[1.00,1.02] - 
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6.2.4.3 Gamma frailty Weibull model time to first-switch 
The Weibull model with gamma frailty shows that there was a statistically significant effect 
of frailty on the model. The frailty parameter with a value of (HR 0.57 [0.32, 0.99]) 
suggests that the effect of frailty is declining with time. The Weibull shape parameter (HR 
0.97 [0.89, 1.05]) is not statistically significantly different from 1 suggesting a constant 
hazard. The model identified similar associated covariates as the Weibull model without 
frailty (shown in Table 6.1.3) but with slightly higher hazard ratios, for example (HR 1.17 
[1.04, 1.33]) for females, for the frailty model and (HR 1.12 [1.01, 1.24]) for the Weibull 
without frailty model (Table 6.2.6). 
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Table 6.2.6: Gamma frailty Weibull and Weibull models that examine factors associated 
with time to 1st medication switch   
Variable Hazard Ratio [95% CI] 
Gamma frailty Weibull Weibull 
Age Group 
30-44 
 
1.00 
 
1.00 
15-29 0.91[0.76, 1.08] 0.91[0.78,  1.06] 
45-59 1.01[0.86, 1.18] 1.03[0.91, 1.17] 
60-74 1.34[1.09, 1.64] 1.28[1.09, 1.51] 
75+ 1.49[1.05, 2.12] 1.43[1.10, 1.88] 
Gender 
Male 
 
1.00 
 
1.00 
Female 1.17[1.04, 1.33] 1.12[1.01, 1.24] 
Previous prescribed analgesia 
No 
 
1.00 
 
1.00 
Yes 1.65[1.39, 1.94] 1.54[1.36, 1.75] 
Previous musculoskeletal 
consultation 
No 
 
1.00 
 
1.00 
Yes 0.93[0.77, 1.13] 0.93[0.80, 1.08] 
Comorbidity  
Selected 
 
1.00 
 
1.00 
None 1.22[0.88, 1.68] 1.17[0.92, 1.52] 
Staff category 
GP 
 
1.00 
 
1.00 
Other 1.04[0.89, 1.22] 1.03[0.91, 1.17] 
Deprivation  
Most 
 
1.00 
 
1.00 
Medium 0.94[0.82, 1.08] 0.94[0.85, 1.06] 
Least 0.91[0.76, 1.09] 0.91[0.80, 1.06] 
Pain Region  
Back 
 
1.00 
 
1.00 
Knee 0.94[0.74, 1.18] 0.96[0.80, 1.15] 
Hip 1.05[0.80, 1.36] 1.08[0.87, 1.33] 
Foot and Ankle 0.98[0.75, 1.26] 1.02[0.83, 1.26] 
Hand/upper limb 0.93[0.72, 1.19] 0.97[0.79, 1.19] 
Shoulder 0.99[0.76, 1.27] 1.00[0.82, 1.22] 
Neck 0.75[0.57, 0.99] 0.84[0.68, 1.05] 
Other/unspecified 0.93[0.78, 1.11] 0.97[0.84, 1.11] 
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Variable Hazard Ratio [95% CI] 
Gamma frailty Weibull Weibull 
Initial analgesia (1st consultation) 
Basic analgesia 
 
1.00 
 
1.00 
Weak analgesia 1.41[1.05, 1.89] 1.33[1.07, 1.66] 
Moderate analgesia 1.16[0.67, 1.99] 1.02[0.69, 1.52] 
NSAIDs 0.97[0.76, 1.22] 1.01[0.84, 1.21] 
Strong analgesia 1.53[1.09, 2.15] 1.34[1.05, 1.72] 
No medication 0.61[0.48, 0.77] 0.73[0.62, 0.86] 
Time-varying   
Multiple location 
No 
 
1.00 
 
1.00 
Yes 1.40[1.09, 1.78] 1.03[1.02, 1.06] 
No. of consultations 0.89[0.87, 0.91] 0.89[0.88, 0.91] 
No. of Prescriptions 1.01[1.00, 1.02] 1.01[1.001, 1.02] 
-2logL 7996 7980 
Weibull shape parameter 0.97[0.89, 1.05] 0.85[0.81, 0.88] 
Frailty parameter 0.57[0.32, 0.99] - 
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6.3 Analysis 2 - Modelling analgesia switching taking into account 
multiple-event switches over time 
6.3.1 Methods 
In the analysis of factors associated with time to first analgesia switch the Weibull and the 
Cox models show that the baseline variables of age, gender, previous prescribed 
analgesia, and analgesia potency at onset of consultation are all statistically associated 
with switching. Number of MSK consultations and number of analgesia prescriptions over 
follow-up are also associated with switching. Consulting for pain in more than one location 
over time also increases the risk of switching analgesia. The Cox and Weibull model 
parameters are similar with minor variations in some cases. 
In the long term management of MSK conditions it is inevitable that individuals will switch 
across analgesia potency levels on more than one occasion. As in section 6.2.1, switching 
analgesia is defined as either a record of a prescription of an analgesia of a potency 
different from that previously prescribed (this may be in place of, or in addition to the initial 
analgesia), or a record of prescribed analgesia without a previous analgesia prescription 
on first consultation (Gore et al., 2012, Rahme et al., 2006; Schneider, 2010). Stoppages 
between the multiple switches are not considered in the analysis as only precise 
prescription dates and not stopping dates can be ascertained.  
The analgesia potency categories as defined by the hierarchical analgesia categorisation 
(HAC) implies that individuals can switch up to five times without repetition of a category, 
for example, assuming they started with no medication the order could be: basic 
analgesia, weak analgesia, moderate analgesia, strong analgesia  and NSAIDs. However, 
there is a possibility the prescription pattern may follow fluctuating switches, for example, 
NSAIDs, weak analgesia , moderate analgesia , NSAIDs, basic analgesia, NSAIDs.  
Different analgesia or potency levels of analgesia have potential for different adverse 
effects, which implies that the multiple-event switches may be of clinical importance as a 
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risk of exposure to the adverse effects of analgesia changes as switches occur. Analysing 
time to individual switches or just adjusting for the number of switching events over time 
would neglect the correlation between the switch times for an individual. The switching 
event for each individual should be considered as correlated as switching between 
analgesia is informed by the preceding analgesia. For this reason, the presence of 
multiple-event switches in the analgesia switching process should be included in the 
analysis of switching. 
As a reminder, the objectives of this section were to; 
1. Determine clinical and socio-demographic factors associated with switching 
analgesia taking into account if an individual switches more than once 
2. Determine if the inclusion of frailty in the models improves model fit 
The factors associated with higher risks of switching analgesia taking into account the 
possibility of multiple switches can be modelled as in the previous section; however the 
Cox and Weibull models need to account for correlation and dependence among 
successive switch times for each individual. This can be achieved through the use of the 
multivariate Cox and Weibull models. 
6.3.2 Data management and study population 
All the patients identified and included in the analysis in the previous section were 
considered in this analysis. The socio-demographic and clinical variables are as defined in 
section 6.2.1, while the time-varying covariates are defined up to the first switch date. The 
number of analgesia changes will be determined for the entire period under review and 
the time between successive switches was determined through the issue dates of the 
successive potency levels. The counting process approach was used in defining time to 
the events as described below. 
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Outcome variables 
Due to the nature of pharmacological management of MSK pain it is logical to consider 
that from the onset of seeking medical care for a MSK condition, the individual is at risk of 
changing their medication status. The time when an individual is at risk of switching 
analgesia is the risk interval (Ezell et al., 2001). The risk interval can be considered as the 
time between events (time from last switch) or the entire time before the event (time from 
initial consultation), which leads to the definition of time by either the counting process or 
the total time process. The total time approach considers time from first consultation up to 
each switch while the counting process considers time from the previous switch (Ezell et 
al., 2001). The counting process was used in this analysis. 
The first switch is defined as the first change in potency level or point of addition of a 
different potency level to the initial analgesia potency level for the subject. The second 
switch is the second change or addition of a new analgesia, the third is the third change or 
addition of another potency level.  
Counting process approach  
The time of only the first switch is calculated from first consultation while subsequent 
switches are calculated from the point of the previous switch. For example, considering a 
patient prescribed NSAIDs at first consultation, who is later prescribed strong analgesia, 
and later weak analgesia. The time to the first switch is the time between the initial 
consultation date and the first prescription date of strong analgesia; the second switch 
time is calculated as the time from the first prescription date of strong analgesia to the first 
prescription date of weak analgesia. If a patient is not prescribed analgesia at first 
consultation, but later receives an NSAID, and later weak analgesia, the first switch time is 
the time between the initial consultation date and the first prescription date of NSAIDs, 
while the second switch time is the time between first date of NSAIDs prescription and the 
first weak analgesia prescription date.  
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As in section 6.2.1 censoring for those leaving their practice was at last date of recorded 
registration or last recorded prescription date, whichever was later.  
6.3.3 Statistical Analysis 
The multivariate Cox and Weibull models were used to model the factors associated with 
switching analgesia taking into account multiple switches. The proportional hazards will 
not be assumed in modelling switching taking into account multiple switch times as time-
varying covariates are included in the model. The multivariate Cox and Weibull models 
discussed below are minor variations of the univariate Cox proportional hazards models 
and univariate Weibull models. The multivariate Weibull model with a gamma frailty was 
also used and compared to the Weibull model.  
6.3.3.1 The multivariate Cox and Weibull models 
As in the univariate models, consider a study with   individuals, each with the observed 
vector (           ), (         ) where some or all individuals experience more than one 
event. In this case consider failure to be defined by switching between different analgesia 
potency levels, and time to failure to be the time to the switching events, then the 
observed vector represents the     switch, (       ). Then the hazard function 
 (     ) for the  
   time to switch     for an individual   with covariate vector 
    (            ) 
with     being the  
   switch or censoring indicator (1=switch, 0=censor) is defined for the 
Cox proportional hazards model as: 
 (     )     ( )            
Where    ( )  is the baseline hazard for the  
   failure or switch, and is an arbitrary 
function of time only.     ( ) is allowed to vary over each of the switch times as an 
arbitrary function of time and    is a vector of regression coefficients to be estimated after 
adjusting for the   failure events that each individual experienced (Ezell et al., 2001). 
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The Weibull proportional hazards model is as for the Cox model with the only variation 
being the hazard function, thus;  
 (     )    (  )
              
With    ( )     (  )
   , and frailty extension can be included as in the univariate model. 
Likelihood Estimation 
The likelihood estimation is an extension of the partial likelihood estimation in the single 
event Cox model (Ezell et al., 2001). The partial likelihood therefore becomes: 
  ( )  ∏ ∏[
      
∑          (   )
]
    
   
 
   
 
The parameter estimation process considers   sub-models (        ) in estimating 
model parameters. Only patients who are both observed at time   and in the      switching 
event as well as the persons who switched at time   contribute information to the stratum-
specific (i.e. the   events) likelihood function (Ezell et al., 2001). For example if      
patients at risk of switching and those who switched for the third time contribute 
information to parameter estimation. For the Weibull model the log likelihood function is;  
 ( )               (   )∑   
 
   
       ∑(    )
 
 
   
 
The log likelihood is formed as a combination of failures and censored observation. 
6.3.4 Results 
Data description 
Of the 3179 patients, 672 (21%) switched analgesia more than once. The mean number 
of switches was 2 (SD 4.0) with 1 as the median number of switches, IQR (1,4) and the 
maximum number of switches for an individual was 31. Of those initially prescribed weak 
analgesia or strong analgesia, 39% had more than one switch. 25% of those initially 
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prescribed basic analgesia, 30% of those initially prescribed moderate analgesia, 25% of 
those initially prescribed NSAIDs and 14% of those initially prescribed no medication 
switched more than once (Table 6.3.1). 
Table 6.3.1: Baseline Socio-demographic and clinical characteristics of patients switching 
analgesia once and more than once 
  Switch Analgesia 
Variable N No (%) At least 
once (%) 
More than 
once (%) 
Total 3179 1550(49) 1629(51) 672(21) 
Age (years)     
15-29 688 392(57) 296(43) 101(15) 
30-44 1068 556(52) 512(48) 186(17) 
45-59 953 435(46) 518(54) 220(23) 
60-74 369 132(36) 237(64) 126(34) 
Over 75 101 35(35) 66(65) 39(39) 
Gender     
Females 1293 580(45) 713(55) 322(25) 
Males 1886 970(51) 916(49) 350(19) 
Previous musculoskeletal 
consultation 
    
Yes 409 179(44) 230(56) 90(22) 
No 2770 1371(49) 1399(51) 582(21) 
Previous prescribed analgesia     
Yes 509 145(28) 364(72) 153(30) 
No 2670 1405(53) 1265(47) 517(19) 
Region of Pain     
Back 818 376(46) 442(54) 187(23) 
Knee 388 177(52) 161(48) 65(17) 
Hip 199 88(44) 111(56) 54(27) 
Foot and Ankle 219 104(47) 115(53) 47(21) 
Hand/upper limb 256 129(50) 127(50) 37(14) 
Shoulder 244 114(47) 130(53) 50(20) 
Neck 215 114(53) 101(47) 46(21) 
Other/unspecified 890 448(50) 442(50) 186(21) 
Co-morbidity     
Selected conditions 118 53(45) 65(55) 28(24) 
Other conditions/none 3061 1497(49) 1564(51) 644(21) 
Deprivation     
Most 1402 657(47) 745(53) 316(23) 
Moderate 1239 624(50) 615(50) 252(20) 
Least 538 269(50) 269(50) 104(19) 
Staff category     
GPs 2575 1255(49) 1320(51) 547(21) 
Other 604 295(49) 309(51) 125(21) 
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  Switch Analgesia 
Variable N No (%) At least 
once (%) 
More than 
once (%) 
Number of pain locations     
One 2472 1053(43) 1419(57) 533(22) 
More 707 497(70) 210(30) 139(19) 
Initial analgesia  (1st consultation)     
Basic analgesia 346 159(46) 187(54) 85(25) 
Weak analgesia 223 66(30) 157(70) 87(39) 
Moderate analgesia 47 18(38) 29(62) 14(30) 
Strong analgesia 160 47(30) 113(70) 63(39) 
NSAIDs 687 321(47) 366(53) 169(25) 
No medication 1716 939(55) 777(45) 254(14) 
The Cox and Weibull models modelling factors associated switching using all analgesia 
switches identified similar factors to those identified in the Cox and Weibull models 
modelling the risk of first analgesia switch only in the previous section. The factors are 
age, gender, previously prescribed analgesia, level of deprivation, multiple pain locations, 
number of prescriptions and initial analgesia potency as statistically significant.  
The factors have similar effects on the models, for example older age was associated with 
the risk of switching when multiple switches are taken into account as well as increased 
risk of first analgesia switch. The only variations are that pain location is associated with 
the risk of switching more than once, while it was not associated with a first analgesia 
switch.  
The number of consultations is not associated with the risk of switching once all switches 
are considered, but was previously associated with risk of a first switch (section 6.2.3.1). 
The Weibull model with gamma frailty identifies similar factors with the number of 
consultations associated with declining risk as in the first switch analysis, and the 
parameter estimates are slightly smaller for the frailty model.  
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6.3.4.1 The multiple-event switch models  
The Cox model  
The Cox model identified similar statistically significant covariates as the Weibull model 
with mostly identical hazard ratios.  
The Weibull model  
In the Weibull model, the 15-29 age group is less likely to switch analgesia compared to 
those aged 30-44 with all things equal (HR 0.81 [0.72, 0.90]), while the 60-74 and over 75 
are more likely to, with hazard ratios (HR 1.47 [1.32, 1.64] and 1.95 [1.65, 2.31]) 
respectively. Females are more likely to switch than males with (HR 1.16 [1.07, 1.25]), 
while those with previous prescribed analgesia are also more likely to switch analgesia, 
(HR 1.32 [1.20, 1.45]).  
The model also shows patients initially consulting for hip pain as more likely to switch 
analgesia with (HR 1.33 [1.16, 1.53]), while those with pain in the upper limb and shoulder 
were less likely compared to those with back pain, (HR 0.74 [0.62, 0.88] and 0.80 [0.69, 
0.93]) respectively. Those initially prescribed weak analgesia and strong analgesia with 
(HR 1.17 [1.01, 1.35] and 1.38 [1.17, 1.62]) respectively are more likely to switch, while 
those initially with no medication are less likely, HR 0.75 [0.67, 0.85] than those initially 
prescribed basic analgesia.  
The -2logL of 14732 is much smaller than that of the Cox model which suggests the 
Weibull is a better fit. The Weibull shape parameter of 0.56 [0.54, 0.58] suggests that the 
hazards of switching decline with time when multiple-event switches are considered in the 
model (Table 6.3.2). 
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Table 6.3.2: Cox and Weibull models that examine factors associated with time to switching when multiple-event analgesia switches are 
accounted for 
                                                                  Multiple-event switch models HR [95%CI] 
  Cox model Weibull model 
Variable   Unadjusted Adjusted  Unadjusted Adjusted  
Age Group 
30-44 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
15-29 0.78[0.70, 0.80] 0.80[0.72, 0.90] 0.79[0.71, 0.88] 0.81[0.72, 0.91] 
45-59 1.06[0.97, 1.16] 1.02[0.93, 1.18] 1.07[0.98, 1.16] 1.02[0.93, 1.12] 
60-74 1.57[1.42, 1.74] 1.47[1.32, 1.64] 1.55[1.40, 1.72] 1.47[1.31, 1.63] 
75+ 2.42[2.07, 2.84] 1.95[1.65, 2.31] 2.40[2.05, 2.82] 1.95[1.64, 2.31] 
Gender 
Male 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Female 1.27[1.19, 1.37] 1.16[1.08, 1.25] 1.26[1.18, 1.35] 1.16[1.07, 1.25] 
Previous prescribed analgesia 
No 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Yes 1.38[1.27, 1.51] 1.33[1.21, 1.46] 1.37[1.25, 1.49] 1.32[1.20, 1.45] 
Previous musculoskeletal consultation 
No 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Yes 0.97[0.88, 1.08] 0.90[0.80, 1.01] 0.97[0.88, 1.08] 0.90[0.80, 1.01] 
Comorbidity  
Selected 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
None 0.92[0.77, 1.09] 1.15[0.96, 1.37] 0.93[0.78, 1.10] 1.16[0.97, 1.38] 
Staff category 
GP 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Other 0.98[0.90, 1.07] 1.01[0.92, 1.11] 0.98[0.90, 1.07] 1.01[0.92, 1.11] 
  
140 
 
                                                      Multiple-event switch models HR [95%CI] 
  Cox model Weibull model 
Variable   Unadjusted Adjusted  Unadjusted Adjusted  
Deprivation  
Most 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Medium 0.84[0.78, 0.90] 0.86[0.79, 0.93] 0.83[0.77, 0.90] 0.86[0.79, 0.93] 
Least 0.78[0.71, 0.87] 0.79[0.70, 0.87] 0.78[0.70, 0.86] 0.78[0.70, 0.87] 
Pain Region  
Back 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Knee 0.95[0.84, 1.07] 1.05[0.92, 1.19] 0.98[0.84, 1.06] 1.05[0.92, 1.19] 
Hip 1.26[1.10, 1.44] 1.32[1.15, 1.52] 1.26[1.10, 1.44] 1.33[1.16, 1.53] 
Foot and Ankle 0.90[0.78, 1.04] 0.99[0.85, 1.15] 0.89[0.77, 1.03] 0.99[0.85, 1.15] 
Hand/upper limb 0.62[0.53, 0.74] 0.74[0.62, 0.87] 0.63[0.53, 0.74] 0.74[0.62, 0.88] 
Shoulder 0.77[0.67, 0.89] 0.80[0.68, 0.93] 0.77[0.66, 0.89] 0.80[0.69, 0.93] 
Neck 0.86[0.74, 1.01] 0.94[0.80, 1.10] 0.85[0.73, 0.99] 0.94[0.80, 1.10] 
Other/unspecified 0.88[0.80, 0.97] 1.01[0.91, 1.11] 0.88[0.80, 0.96] 1.00[0.90, 1.09] 
Initial analgesia  (1st consultation) 
Basic analgesia 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Weak analgesia 1.31[1.14, 1.51] 1.17[1.01, 1.35] 1.31[1.13, 1.50] 1.17[1.01, 1.35] 
Moderate analgesia 1.20[0.93, 1.54] 1.08[0.83, 1.39] 1.18[0.92, 1.52] 1.06[0.82, 1.08] 
NSAIDs 0.89[0.79, 1.01] 0.96[0.84, 1.09] 0.89[0.79, 1.00] 0.96[0.84, 1.08] 
Strong analgesia 1.65[1.43, 1.90] 1.39[1.18, 1.63] 1.64[1.42, 1.89] 1.38[1.17, 1.62] 
No medication 0.66[0.59, 0.74] 0.76[0.67, 0.85] 0.77[0.59, 0.74] 0.75[0.67, 0.85] 
Multiple location 
No 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Yes 1.05[1.03, 1.06] 1.06[1.04, 1.08] 1.05[1.03, 1.06] 1.06[1.04, 1.08] 
No. of consultations 1.00[1.00, 1.01] 1.00[0.99, 1.01] 1.00[0.99, 1.01] 1.00[0.99, 1.01] 
No. of Prescriptions 1.00[1.00, 1.02] 1.01[1.00, 1.02] 1.00[1.00, 1.01] 1.01[1.00, 1.02] 
-2logL - 48696 - 14732 
Weibull shape parameter - - - 0.56[0.54, 0.58] 
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6.3.4.2 Multiple-event switch Weibull model with Gamma frailty 
The multiple- event switch Weibull model with frailty also identified age, gender, 
medication history, deprivation, initial medication potency, multiple pain location over time, 
number of consultations and prescriptions as statistically significant covariates associated 
with the risk of multiple switches in a relatively short time interval.  
The hazard ratios are generally higher than those in the Weibull model without frailty and 
the CI’s were wider. The hazard ratios (HR 1.34 [1.08, 1.66] and 1.50[1.02, 2.18]) for the 
60-74 and over 75 age groups show an increased risk of switching for the older age 
groups. Females are more at risk than males (HR 1.40 [1.23, 1.59]), while the (HR 1.21 
[1.02, 1.44]) for previous prescribed analgesia also indicates a higher risk. 
 Patients from medium deprivation (HR 0.81 [0.70, 0.93]) and patients from least deprived 
(HR 0.78 [0.65, 0.94]) are both at a lesser risk of multiple-event analgesia switches 
compared to patients from most deprived locations. Patients initially prescribed weak 
analgesia and moderate analgesia are at higher risk of multiple-event medication switches 
than those initially on basic analgesia, hazard ratios (HR 1.50 [1.11, 2.03] and 2.33 [1.38, 
3.93]) respectively. Pain in multiple location (HR of 1.09 [1.05, 1.13]) is associated with a 
slightly higher risk, and an increasing number of prescriptions over time (HR 1.04 [1.03, 
1.05]) is also associated with a slightly increased risk of switching. Those with higher 
number of consultations had a marginally reduced risk (HR 0.99 [0.98, 0.99]).  
The frailty parameter with a value of 1.01 [0.92, 1.11] indicates that the frailty is not 
statistically significantly different from 1 suggesting that there is no evidence that frailty 
improves model fit to the data. The Weibull shape parameter 1.04 [0.99, 1.09] indicate 
that the hazards associated with the covariates will slightly increase over time if the 
unmeasured covariates are adjusted for through gamma frailty (Table 6.3.3) but it is not 
statistically significant.  
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Table 6.3.3: Weibull model with Gamma frailty that examines factors associated with time 
to switching when multiple-event analgesia switches are accounted for 
 
                                                                                Hazard Ratio [95% CI] 
Variable Gamma frailty Weibull 
model 
Weibull model 
Age Group 
30-44 
 
1.00 
 
1.00 
15-29 0.94[0.78, 1.12] 0.81[0.72, 0.91] 
45-59 0.99[0.85, 1.16] 1.02[0.93, 1.12] 
60-74 1.34[1.08, 1.66] 1.47[1.31, 1.63] 
75+ 1.50[1.02, 2.18] 1.95[1.64, 2.31] 
Gender 
Male 
 
1.00 
 
1.00 
Female 1.40[1.23, 1.59] 1.16[1.07, 1.25] 
Previous prescribed analgesia 
No 
 
1.00 
 
1.00 
Yes 1.21[1.02, 1.44] 1.32[1.20, 1.45] 
Previous musculoskeletal consultation 
No 
 
1.00 
 
1.00 
Yes 0.94[0.77, 1.14] 0.90[0.80, 1.01] 
Comorbidity  
Selected 
 
1.00 
 
1.00 
None 1.31[0.95, 1.82] 1.16[0.97, 1.38] 
Staff category 
GP 
 
1.00 
 
1.00 
Other 1.01[0.86, 1.18] 1.01[0.92, 1.11] 
Deprivation  
Most 
 
1.00 
 
1.00 
medium 0.81[0.70, 0.93] 0.86[0.79, 0.93] 
least 0.78[0.65, 0.94] 0.78[0.70, 0.87] 
Pain Region  
Back 
 
1.00 
 
1.00 
Knee 0.86[0.68, 1.07] 1.05[0.92, 1.19] 
Hip 1.08[0.81, 1.41] 1.33[1.16, 1.53] 
Foot and Ankle 0.89[0.68, 1.16] 0.99[0.85, 1.15] 
Hand/upper limb 0.80[0.61, 1.03] 0.74[0.62, 0.88] 
Shoulder 0.85[0.66, 1.10] 0.80[0.69, 0.93] 
Neck 0.79[0.60, 1.04] 0.94[0.80, 1.10] 
Other/unspecified 1.02[0.86, 1.22] 1.00[0.90, 1.09] 
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                                                                              Hazard Ratio [95% CI] 
Variable Gamma frailty Weibull model Weibull model 
Initial analgesia  (1st consultation) 
Basic analgesia 
 
1.00 
 
1.00 
Weak analgesia 1.50[1.11, 2.03] 1.17[1.01, 1.35] 
Moderate analgesia 2.33[1.38, 3.93] 1.06[0.82, 1.08] 
NSAIDs 0.96[0.76, 1.21] 0.96[0.84, 1.08] 
Strong analgesia 1.01[0.72, 1.41] 1.38[1.17, 1.62] 
No medication 0.94[0.76, 1.16] 0.75[0.67, 0.85] 
Time-varying   
Multiple location 
No 
 
1.00 
 
1.00 
Yes 1.09[1.05, 1.13] 1.06[1.04, 1.08] 
No. of consultations 0.99[0.98, 0.99] 1.00[0.99, 1.01] 
No. of Prescriptions 1.04[1.03, 1.05] 1.01[1.00, 1.02] 
-2logL 12198 14732 
Weibull shape parameter 1.04[0.99, 1.09] 0.56[0.54, 0.58] 
Frailty parameter 1.01[0.92, 1.11] - 
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6.4 Analysis 3 - Modelling rates of analgesia switching  
6.4.1 Methods 
Section 6.2 and 6.3 evaluated the socio-demographic and clinical factors associated with 
first analgesia switching and any switching of analgesia. In the analyses both the Weibull 
and the Cox models show that the baseline variables of age, gender, previous prescribed 
analgesia, and analgesia potency at onset of consultation are all statistically associated 
with switching under both circumstances. Fewer numbers of MSK consultations and 
increased number of analgesia prescriptions and consulting for pain in more than one 
location over time also increases the risk of switching analgesia. The level of 
neighbourhood deprivation and pain location become associated with switching if multiple-
event switches are accounted for. 
The risk of switching (and hence increased likelihood of adverse effects) can also be 
evaluated by a count of switching events that an individual experiences during follow up. 
This implies that the medication switches that take place over time can be considered to 
be a random process as the order in which the switches take place will vary from one 
individual to the other. While it is informative to quantify the hazards associated with time 
between the switches in multiple switches, knowing the rates of switching over the follow-
up period adds a different but essential dimension to the understanding of the switching 
process. 
The number of analgesia switches increases with time for some individuals but remains 
constant for some, as seen in Chapter 5 in which some individuals were prescribed all 
potency categories while some were prescribed a single analgesia throughout their follow-
up period. Considering that the study cohort is assumed to be first time consulters or an 
incident group of MSK consulters, an alternative approach to the first 2 analyses would be 
to determine the factors associated with the decreasing or increasing average rate of 
switches for the cohort over the 5 year follow-up period. This may help clinicians identify 
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for closer monitoring, patients who might have higher rates of switching over time and 
take that into account when designing their MSK management plan.  
The specific objective of this section is to; 
1. Determine the socio-demographic and clinical factors associated with rates of 
switching during follow-up time 
2. Assess value of using Poisson regression to model switching. 
6.4.2 Data management and study population 
All the patients identified and included in the analysis in the previous section were 
considered in this analysis. The number of analgesia potency changes will be determined 
for the entire period under follow up.  
Outcome variable  
The number of analgesia switches experienced by the patients throughout their follow up 
time is the dependent variable. 
Independent variables/ Covariates  
The clinical and the socio-demographic variables evaluated were the same as in the 
previous sections except for the number of prescribed analgesia and the number of MSK 
consultations. The number of MSK consultations and prescriptions were calculated for the 
entire follow-up period instead of up to the first switching event.  
6.4.3 Statistical Analysis 
The analgesia switch rate over follow-up time was evaluated, while adjusting for clinical 
and socio-demographic variables through Poisson regression.  
6.4.3.1 Poisson regression 
The outcome (dependent) variable is a count of the number of analgesia switches. 
Poisson regression models the log of the expected count as a function of the independent 
variables. Strength of association of the independent variables with number of switches is 
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shown using incident rate ratios (IRR) obtained by exponentiation of the log of the Poisson 
regression coefficients. See Cameron and Trivedi, (1998) for further description of 
Poisson regression. 
6.4.4 Results 
As stated in section 6.2.3, of the 3179 patients, 672 (21%) switched analgesia more than 
once. The mean number of switches was 2 (SD 4.0) with 1 as the median number of 
switches with an IQR (1, 4) and the maximum number of switches for an individual was 31 
The Poisson regression model identified factors associated with the rates of switching 
analgesia similar to the factors associated with the risk of switching analgesia if multiple 
switches are accounted for (section 6.3). The factors are age, gender, previous 
medication history, level of deprivation, initial region of pain consulted for, initial  analgesia 
potency level, multiple pain locations over time and number of prescriptions.  
All factors associated with the risk of first analgesia switch are also identified as 
associated with rates of switching with the variation being that being prescribed weak or 
strong analgesia is associated with increased risk of first analgesia switch but not 
associated with number of switches. The other variation is that increasing number of 
consultations is associated with increased rates of switching. All statistically significant 
incident rate ratios are highlighted in bold in Table 6.4.1.  
The incidence rate ratio (IRR 0.85 [0.76, 0.94]) for the 15-29 age group suggests that for 
this age group the rate of switching is less than in the 30-44 age group. There were also 
higher rates of switching for those aged 60-74 (IRR 1.35 [1.21, 1.50]) and 75 and over 
(IRR 2.04 [1.75, 2.39]. The IRRs of 1.08 [1.01, 1.15] and 1.30 [1.19, 1.42] for gender and 
medication history respectively, indicate that rates of switching are about 8% higher 
among females than males and 30% higher among those with previous analgesic 
medication history than those without. For deprivation, (IRR 0.90 [0.83, 0.96]) for medium 
deprivation and (IRR 0.79 [0.71, 0.87]) for least deprived indicates that the rates of 
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switching are 10% and 21% less than in the most deprived group respectively. When 
compared to initial pain in the back, the rate of multiple switching among those with initial 
hip pain, (IRR 1.47 [1.29, 1.68)] is higher, while for those with initial upper limb pain, (IRR 
0.76 [0.64, 0.89]) and initial shoulder pain (IRR 0.86 [0.74, 0.99]) is less. 
The rates were not affected by the type of initial analgesia potency issued except for those 
prescribed no medication on initial consultation (IRR 0.67 [0.60, 0.75]), which indicates a 
lesser rate than those initially prescribed basic analgesia. Those experiencing pain in 
multiple locations over time (IRR 1.41 [1.24, 1.56]) had a higher incidence rate than those 
who continue to consult for pain in the same location over time. Each extra consultation 
(IRR 1.06 [1.05, 1.07]) and each extra prescription for the same potency level over time 
(IRR 1.01 [1.01, 1.02] were associated with a 6% and 1% increase in the incidence rates 
of switching respectively.  
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Table 6.4.1: Poisson regression model that examines factors associated with incident 
rates of switching over unit follow-up time 
Variable Poisson  model 
Incident Rate Ratios- IRR [95% CI] 
 Unadjusted Adjusted 
Age Group 
30-44 
 
1.00 
 
1.00 
15-29 0.75[0.68, 0.84] 0.85[0.76, 0.94] 
45-59 1.06[0.97, 1.15] 0.97[0.89, 1.06] 
60-74 1.60[1.45, 1.77] 1.35[1.21, 1.50] 
75+ 3.03[2.63, 3.50] 2.04[1.75, 2.39] 
Gender 
Male 
 
1.00 
 
1.00 
Female 1.30[1.22, 1.39] 1.08[1.01, 1.15] 
Previous prescribed analgesia 
No 
 
1.00 
 
1.00 
Yes 1.45[1.34, 1.57] 1.30[1.19, 1.42] 
Previous musculoskeletal 
consultation 
No 
 
 
1.00 
 
 
1.00 
Yes 0.98[0.89, 1.08] 0.93[0.84, 1.03] 
Comorbidity  
Selected 
 
1.00 
 
1.00 
None 0.75[0.64, 0.87] 0.96[0.82, 1.12] 
Staff category 
GP 
 
1.00 
 
1.00 
Other 1.01[0.93, 1.09] 0.99[0.90, 1.08] 
Deprivation  
Most 
 
1.00 
 
1.00 
medium 0.82[0.77, 0.88] 0.90[0.83, 0.96] 
least 0.73[0.67, 0.81] 0.79[0.71, 0.87] 
Pain Region  
Back 
 
1.00 
 
1.00 
Knee 0.99[0.95, 1.20] 1.11[0.98, 1.25] 
Hip 1.25[1.11, 1.42] 1.47[1.29, 1.68] 
Foot and Ankle 0.81[0.71, 0.98] 0.97[0.83, 1.12] 
Hand/upper limb 0.56[0.48, 0.65] 0.76[0.64, 0.89] 
Shoulder 0.80[0.69, 0.92] 0.86[0.74, 0.99] 
Neck 0.80[0.70, 0.98] 0.93[0.80, 1.08] 
Other/unspecified 0.91[0.85, 1.00] 1.04[0.95, 1.15] 
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Variable Poisson  model 
Incident Rate Ratios- IRR [95% CI] 
 Unadjusted Adjusted 
Initial Potency level 
Basic analgesia 
 
1.00 
 
1.00 
Weak analgesia 1.43[1.25, 1.63] 1.13[0.99, 1.29] 
Moderate analgesia 1.10[0.86, 1.40] 1.03[0.80, 1.31] 
NSAIDs 0.82[0.73, 0.91] 0.90[0.80, 1.01] 
Strong analgesia 1.82[1.59, 1.98] 1.12[0.95, 1.30] 
No medication 0.51[0.46, 0.56] 0.67[0.60, 0.75] 
Multiple location 
No 
 
1.00 
 
1.00 
Yes 1.77[1.64, 1.92] 1.41[1.24, 1.56] 
No. of consultations  1.08[1.05, 1.09]  1.06[1.05, 1.07] 
No. of Prescriptions 1.01[1.01, 1.02] 1.01[1.01, 1.02] 
-2logL 10194 10194 
Unadjusted model = Individual variable in the model, Adjusted model = All variables included simultaneously 
6.5 Discussion 
The analysis in the first section (6.2) used the Cox and Weibull models to model factors 
associated with the risk of a first analgesia switch, the second section (6.3) analyses used 
the same models to model the factors associated with the risks of switching analgesia if 
multiple switches are accounted for. The third section (6.4) analysis used the Poisson 
model to model factors associated with the rates (counts) of switching, and despite some 
variation in parameter estimates, similar conclusions can be drawn from the results of 
these different approaches. That is, most of the factors associated with the risk of first 
analgesia switch are also associated with the risk of switching if multiple analgesia 
switches are accounted for and modelling rates of switching analgesia.   
It is however necessary to base the discussion and conclusions on the best models from 
each section. These are, for analysis of first-switch and multiple-event switches, the 
Weibull model with and without frailty, and for modelling rates of switching, the Poisson 
regression model. The factors are summarised in Table 6.5.1. 
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Table 6.5.1: Summary of statistically significant variables in all models 
Significant variables in the models 
 First switch Multiple-event switch Rates 
Variable Cox Weibull Frailty Cox Weibull Frailty Poisson 
Age Group 
30-44 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
15-29 No No No <Yes <Yes No <Yes 
45-59 No No No No No No No 
60-74 >Yes >Yes >Yes >Yes >Yes >Yes >Yes 
75+ >Yes >Yes >Yes >Yes >Yes >Yes >Yes 
Gender 
Male 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
Female >Yes >Yes >Yes >Yes >Yes >Yes >Yes 
Previous prescribed 
analgesia 
No 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
Yes >Yes >Yes >Yes >Yes >Yes >Yes >Yes 
Previous 
musculoskeletal 
consultation 
No 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
Yes No No No No No No No 
Comorbidity  
Selected 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
None No No No No No No No 
Deprivation  
Most 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
medium No No No <Yes <Yes <Yes <Yes 
least No No No <Yes <Yes <Yes <Yes 
Pain Region  
Back 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
Knee No No No No No No No 
Hip No No No >Yes >Yes No >Yes 
Foot and Ankle No No No No No No No 
Hand/upper limb No No No <Yes <Yes No <Yes 
Shoulder No No No <Yes <Yes No <Yes 
Neck No No No No No No No 
Other/unspecified No No No No No No No 
Initial Potency level 
Basic analgesia 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
Weak analgesia >Yes >Yes >Yes >Yes >Yes >Yes No 
Moderate analgesia No No No No No >Yes No 
NSAIDs No No No No No No No 
Strong analgesia >Yes >Yes >Yes >Yes >Yes No No 
No medication <Yes <Yes <Yes <Yes <Yes No <Yes 
Multiple location 
No 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
Yes >Yes >Yes >Yes >Yes >Yes >Yes >Yes 
No. of consultations <Yes <Yes <Yes No No <Yes >Yes 
No. of Prescriptions >Yes >Yes >Yes >Yes >Yes >Yes >Yes 
No= non-significant, <Yes=decreasing risk of switching, Yes>=increasing risk of switching, Reference category = - 
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The Weibull models with and without the frailty extension were chosen as they were a 
better fit to the data compared to the Cox, coupled with some advantages they have over 
the Cox as modelling techniques. While the Cox model has the property of not making any 
underlying distributional assumptions, the Weibull distribution is a flexible and versatile 
distribution (Collet, 2003; Marubini et al., 1995). The Weibull enables extrapolation of what 
may happen long term with the patients by considering the shape parameter, for example, 
a shape parameter less than one suggests that the effect of the covariates on the risks of 
switching declines with time, while a value greater than one suggests otherwise. If the 
distributional assumptions can be met, the Weibull model will fit the data better than the 
Cox model (Lee and Wang, 2003).  
While frailty can be modelled with the Cox model, if the choice of the Cox model was to 
avoid distributional assumptions, it is a contradiction to choose the Cox model then 
assume gamma distributed frailty. In some results presented here, there was a statistically 
significant frailty effect which declined over time. This may be expected because not all 
covariates associated with medication switching were measured, and by the nature of 
medical conditions, some patients are more pre-disposed to switch analgesia than others 
due to the severity of their conditions. However as time continues the effect of baseline 
variables, measured or unmeasured may decline as the underlying condition evolves.  
Poisson regression has a strong assumption in that the conditional variance equals the 
conditional mean.  If the Poisson model is a good fit, it enables estimation of expected 
rates of switching across covariates for the exposure period.  
Modelling first analgesia switch stratified by initially prescribed analgesia suggests that 
factors associated with switching were dependent on initially prescribed analgesia. For 
example being in the age group 60-74 was associated with increased risk of switching if 
they were initially prescribed basic analgesics or no medication but is not associated with 
risk of switching if they were initially prescribed moderate or strong analgesia. The smaller 
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sample sizes make the results however less reliable and hence should be treated with 
some caution. 
The underlying hypothesis of this analysis was that while switching analgesia is 
acceptable, it can expose patients to risks of adverse effects of analgesia and multiple 
switches or higher rates of switching imply increased potential for adverse effects. The 
analysis has highlighted both clinical and demographic factors associated with any 
switching of analgesia and the rates of switching, and those initially on strong analgesia 
were more likely to switch which may suggest GPs are aware of risks of adverse events 
as stated later. The results also suggest an increased risk of switching in the early days of 
initiation into analgesia treatment, only a small group of patients experience multiple-event 
switching, and that the risk of multiple-event switching decreases with time. 
There was a higher risk and rates of switching medication among the elderly, females, 
having been prescribed pain medication in the past, consulting for pain in the hip, and for 
more than one location over time, starting medication with weak or strong analgesia and 
with increased  number of repeat prescriptions received over time. There are declining 
risks of switching with increasing number of consultation although this is not consistent as 
the Poisson models of counts of switches suggested an increasing risk. There are 
declining risks with lower neighbourhood deprivation and receiving no prescribed 
medication on first consultation. These characteristics may help identify patients at higher 
risk of switching that clinicians should take note of, when they first present with MSK 
conditions so that the patients pain management regime may include increased 
consultation levels. 
The difference in the effect of the number of MSK consultations in the time to event 
Weibull models and the Poisson model may be attributed to that in the Weibull models, 
the number of consultations were calculated up to the first switch event while in the 
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Poisson, they were calculated for the entire follow-up period. Therefore in the Poisson 
model, some consultations may have occurred after switching. 
An increase in the number of consultations over time reduces the risk of switching 
medication. One Cochrane systematic review has shown that regular medical review has 
previously had a positive outcome on health issues in the primary care setting (Glynn et 
al., 2010). Potentially, therefore, attending for regular consultations ensures patients use 
their medication correctly through the GP having the opportunity to advise them to use it 
as prescribed, thereby maximising the analgesia effect. Conversely, an increase in the 
number of prescriptions of the same potency over time corresponds to an increased risk 
of switching to a different potency. Perhaps this is a reflection of pain severity and if GPs 
use the stepwise (WHO/NICE) approach (Ehrlich, 2003; NICE 2008), failure to control 
pain means progressing higher up the ladder of analgesia potency as one change does 
not control pain, so another change occurs. Multiple changes also suggest the patient is 
no better and requires continued pain relief. With time MSK problems deteriorate so the 
longer someone keeps getting prescriptions, the more potential for them to worsen, the 
more likely they might switch. 
Medication switching is part of a comprehensive evaluation of pain, adverse side effects 
and effectiveness of the management of pain procedure (Breckenridge and Clark, 2004; 
Schneider, 2010). Patients consulting more may have a well-managed regime of pain 
analgesia with regular feedback and assurance from their general practitioners, making 
them less likely to switch analgesia. The high number of prescriptions may indicate that 
the patient relies on medication to alleviate their pain at all times, which may mean that at 
some point they will need stronger analgesia, or after some time on strong analgesia, they 
might feel better; hence no need to continue on the stronger medication and they move to 
a lower potent medication. One of the known side effects of some strong analgesia is 
dependency (Curatolo and Bogduk, 2001). The higher number of prescriptions over time 
may be an indication of dependence for some patients. 
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The higher risk of switching medication among those aged over 60 reflects the increasing 
severity and discomfort of MSK problems that comes with age whilst MSK conditions also 
deteriorate with time.  A study by Jordan et al. (2009) showed that consultation prevalence 
for MSK problems was higher among older patients and that they were also more likely to 
have widespread problems. It is therefore likely that older patients experience more 
persistent and disabling pain (Thomas et al., 2007). Considering that, a stepped approach 
to the administration of pain medications is recommended (Ehrlich, 2003). Additionally, 
general practitioners may consider the side effects associated with prolonged use of 
analgesia and switch the patients, for example, NSAIDs have adverse gastro-intestinal 
side effects and increase cardiovascular risks, while opioids may result in constipation 
among older patients (Kroenke et al., 2009).    
The higher risk of females than males in switching analgesia may be attributed to the 
ability to effectively communicate their perceived pain levels to the general practitioner. 
The ability of the patient to communicate the level of pain they are experiencing is 
regarded as the strongest predictor of the strength of medication given (Eder et al., 2003). 
It is also difficult for the general practitioners to ascertain initial levels of pain, (Blank et al., 
2001) which makes it difficult to predict the level of pain relief that specific analgesia will 
provide. Consequently the patient’s communication of pain becomes essential, and 
female patients more effectively communicate their pain levels than males, (Eder et al., 
2003). Females are also perceived by GPs as experiencing more pain than males 
(Garbez and Puntillo, 2005; Curatolo and Bogduk, 2001). Females may therefore be more 
likely to have their medication switched, if after the initial or previously prescribed 
analgesia some level of pain still persists or changes. 
GPs will generally inquire from the patient about their medication use prior to consultation 
(Garbez and Puntillo, 2005). Consequently, in those that they identify as having used 
analgesia previously, there is subsequently a greater likelihood of them being at a higher 
risk of switching medication. The patients’ experience with the previous medication helps 
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them appreciate what works and what does not, hence their experience of pain relief, and 
or side effects, enables them to have an informed input into the decision making process. 
General practitioners will use their expertise in light of the patient’s previous experience, 
either good or bad, in switching analgesia potency levels (Ehrlich, 2003). 
Consulting for pain in multiple locations over time, increases risk of switching and multiple 
medication switching. Self-evidently, changes in prescribed analgesia are driven by the 
rationale for switching. The factors that can be associated with the need to switch 
analgesia range from the complexity of the medical condition or group of medical 
conditions (co-morbidities), side effects and the level of  relief in chronic pain achieved 
among others (Main, 2002; Brooks, 2006). Experiencing pain in more than one body 
region at a time might be an indication of widespread pain, leading to the patient having 
difficulty in coping with the pain, and clinicians may see it necessary to switch the patient 
to higher potency analgesia. Alternatively, experiencing pain in more than one body region 
over time may imply that pain levels and severity vary at each point of consultation; hence 
the potency levels prescribed are determined with respect to the level of pain at the time, 
leading to switching between potency levels. 
Initially consulting for pain in the hip is associated with increasing risk of switches may 
have a similar interpretation to the finding in Chapter 4, in which those initially consulting 
for pain in weight bearing joints were most likely to be prescribed analgesia. In this case 
clinicians will consider quickly changing analgesia if the pain in the hip is not controlled as 
the hip is a weight bearing joint that may restrict movement and execution of day to day 
activities. 
Those who are not prescribed pain medication on first consultation are less likely to 
change status over time, while those starting on weak analgesia and strong analgesia are 
more likely to switch analgesia. GPs consider multiple factors in deciding the analgesia 
and appropriate dose (Bope et al., 2004). GPs might not use medication in some 
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individuals since their clinical judgement is that the patient’s condition does not require it. 
Since these patients do not tend to go on in time to receive or switch medication, this 
would appear to qualify the GPs decision that their condition is not severe enough in the 
first instance to require prescribed analgesia.  These patients may also self-manage with 
paracetamol or other OTC medications therefore never need a prescription. 
Switching from weak and strong analgesia may be related to the known side effects of 
opioids including dependency and addiction (Saunders et al., 2010; Breckenridge and 
Clark, 2004).  General practitioners will most likely avoid keeping their patients on opioid 
analgesia for too long (Bhamb et al., 2006). This is particularly so since patients with pain 
may become depressed because of impact of symptoms on their lives and psychiatric 
disorders may increase the risk of addiction and dependence (Sullivan et al., 2005; 
Edlund et al., 2007), which is potentially more likely with opioids (Sproule et al., 2009).  
Pain is associated with emotional distress, low social support and low social participation 
that may be less common in the least deprived areas (Katz, 2002; Garbez and Puntillo, 
2005). Consequently, patients from the least deprived areas experience less significant 
pain and therefore are potentially less likely to switch medication with time compared to 
patients from most deprived areas. As suggested in Chapter 4, patients from least 
deprived areas may rely on over the counter medication, while those from deprived areas 
rely on their GPs’ prescriptions. 
The study findings however need to be interpreted with due consideration of the potential 
limitations. As discussed in Chapter 4, the non-randomised sample selection criteria may 
allow forms of selection bias and other forms of confounding induced by national 
prescription guidelines available to clinicians (Bedson et al., 2012). GPs may consider 
multiple factors including all co-morbidities, not evaluated for in this study, in choosing the 
appropriate analgesia to prescribe (Bope et al., 2004; Garbez and Puntillo, 2005; 
Schneider, 2010). There may be other variables not captured in the data, which may 
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influence prescribing and analgesia switching. Pain severity, weight, alcohol misuse and 
ethnicity might also impact on prescription of analgesia and decisions to switch 
(Breckenridge and Clark, 2004; Green et al., 2012) and these are not evaluated in the 
analysis. The study is also not designed to evaluate explicitly the clinical reasons for 
switching analgesia.  
However, the strengths of the study lie primarily in that the data used in the study is drawn 
from a high quality data set, CiPCA, which gives comparable consultation Figures for MSK 
problems as the larger national datasets Jordan et al., 2007). The study is naturalistic in 
that it is based on real-world data, large sample size and uses observational approach 
without pre-planned treatment changes over time. The inclusion of a frailty effect on the 
model also partly accounts for variation that unmeasured covariates may have in the 
models. The inclusion criterion ensures that it is reasonable to consider the patients as 
having no chronic pain prior to consulting, making it reasonable to assume that no 
patients with prior chronic conditions are included and that the pain management process 
unfolds after first consultation of 2006. 
6.6 Conclusion 
This study has found that in the pharmacological management of MSK conditions, the 
time to switching analgesia is associated with baseline and time-varying factors. Switching 
analgesia is a comprehensive process which is not only decided by prescription but also 
by clinical and socio-demographic considerations. While both the Cox model and Weibull 
model produced similar models, the Weibull model enables identification of the changing 
effect of covariates over time. The Poisson model suggests that most baseline factors 
associated with a switch of analgesia are also associated with total number of rates of 
switching. The factors associated with switching specifically to stronger analgesia 
(moderate and strong analgesia) are analysed in the next chapter. 
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Chapter 7 
7 Factors associated with time to switching from initially 
prescribed lower potency analgesia to stronger analgesia  
7.1 Introduction 
Chapter 6 suggested that the time to any analgesia change is associated with factors 
measured at time of initial MSK consultation (baseline), as well as those measured during 
follow up time. There is a higher risk and rates of switching analgesia among the elderly, 
females, having been prescribed analgesia in the past, consulting for pain in more than 
one location over time, starting medication with weak or strong analgesia and the number 
of repeat prescriptions received over time. There are declining risks with the increasing 
number of MSK consultations, low deprivation and receiving no prescribed medication on 
first consultation. The Weibull model with and without the extension of frailty is a viable 
alternative to the Cox model in modelling time to analgesia switch.  
If patients used the same analgesia potency level over follow up time, it may be assumed 
that there are negligible negative consequences of using the analgesia. If a patient 
changes to a lower potency medication; it may be assumed that the condition is not 
deteriorating further or they have experienced side effects. But if the medication potency 
level increases to or changes over time to stronger analgesia, it may suggest deterioration 
of the condition. The patient group subjected to increasing or stronger analgesia potency 
is also more exposed to potential side effects of analgesia. As indicated in Chapter 3, up 
to 80% of patients using opioid analgesia experience at least one of the side effects 
(Benyamin et al., 2008; Fitzcharles et al., 2010), hence clinicians may benefit from 
identifying patients at the onset of consultation that are at risk of switching to stronger 
analgesia.  
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The aim of this chapter is therefore to evaluate which of the identified socio-demographic 
and clinical factors are associated with higher risk of switching from no, basic and weak 
analgesia to stronger analgesia over time.  
In identifying which baseline characteristics are associated with being more likely to 
progress up the ladder and switch to stronger analgesia, GPs may be able to identify 
earlier, patients more at risk of needing stronger medication. Knowing the factors 
associated with such a switch might help GPs determine which painkiller to use first, that 
is, if the GP uses a weaker analgesia in a patient who is likely to switch to a stronger 
analgesia quite quickly, this results in two outcomes:  1) the patient continues to suffer 
pain unnecessarily and 2), the patient returns for another consultation that might have 
been avoided if the pain had been initially controlled. Knowing who will switch quickly 
might help avoid this.  
The specific objective of the chapter is therefore: 
1. To model factors associated with time to change from initial low medication 
potency level (no medication, basic analgesia and weak analgesia) to higher 
potency analgesia (moderate, strong analgesia).  
7.2 Methods 
This analysis considers patients who received lower potency analgesia (no medication, 
basic analgesia or weak analgesia) at their initial consultation and eventually switched to 
moderate or strong analgesia.  
Switching analgesia is defined as either a record of a prescription of moderate or strong 
analgesia (this may be in place of, or in addition to the initial analgesia (basic analgesia or 
weak analgesia)), or a record of moderate or strong analgesia if without a previous 
analgesia prescription on first consultation (Gore et al., 2012, Rahme et al., 2006; 
Schneider, 2010). Prescription of NSAIDs is not considered as a switch as NSAIDs cannot 
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be adequately placed in the potency hierarchy (Chapter 3). Stoppages are not considered 
in the analysis as only precise prescription dates and not stopping dates can be 
ascertained.  
The analgesia categories (HAC) were as defined in chapter 6, in which strong 
combination and strong single analgesia are combined to just strong analgesia. Patients 
prescribed the lower potency analgesia groups in analysis are ‘at the beginning of the 
treatment ladder’ and therefore potentially the ones that were likely to switch to stronger 
analgesia if their conditions deteriorated or experienced no pain relief.  
7.2.1 Data and study population 
Of the patients identified and included in the analysis in Chapter 6, only those whose initial 
medication was no medication, basic analgesia or weak opioids were considered. Patients 
initially prescribed moderate or strong analgesia and NSAIDs were excluded from the 
analysis. All variables adjusted for in chapter 6 were considered. The prescription of 
NSAIDs after initial analgesia but prior to strong analgesia switch was considered as a 
potential time-varying covariate but was left out of the analysis due to small numbers.  
Outcome variables 
The outcome of interest was time to switching from no medication, basic or weak 
analgesia to moderate or strong analgesia. The switch or time to the prescription of 
moderate or strong analgesia was calculated from first consultation date to the first issue 
date of moderate or strong analgesia. Those who did not switch medications had their 
times censored at the end of 2010 or deregistration date. 
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7.2.2 Statistical Analysis 
Kaplan-Meier curves were used as an exploratory analysis to decide if the times to 
change are different between categories of the independent variables, with particular 
interest in the initial analgesia potency levels. The univariate Weibull model with and 
without gamma frailty was used to model factors associated with time to switch. High risk 
or frail individuals will tend to have shorter times before switching to higher potency or 
stronger medication, and lower risk ones tend to take much longer. Frailty therefore 
accounts for possible unobserved or unmeasured covariates. 
The Weibull model was chosen with reference to the previous chapter. In Chapter 6, the 
Cox and Weibull models tended to produce similar models, and the Weibull was the 
preferred final choice for reasons stated in Chapter 6. Among them, the Weibull model 
tended to give a better fit (smaller -2logL values) and the shape parameter helps in 
understanding the changing effect of the variables in the model on the hazard function 
over time.  
Both models included clinical and socio-demographic variables. Two sets of models were 
fitted, with (full model) and without (baseline variables only) time-varying covariates. The 
baseline variable only models were fitted to evaluate the importance of baseline factors 
which the clinician will have knowledge of at initial consultation. Comparison of the -2logL 
values were used to evaluate whether the models fitted are different from each other.   
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7.3 Results 
7.3.1 Data description 
A total of 2285 patients were prescribed no medication (75%), basic analgesia (15%) and 
weak analgesia (10%) as their initial medication. 283 (12%) of the patients eventually 
switched to higher potency analgesia (moderate and strong analgesia), of which initial 
medication prescribed was 62% no medication, 18% basic analgesia and 20% weak 
opioids. The mean time to first switch was 753 days with a standard deviation of 469 days, 
median time 721, and IQR (354, 1123) days. The shortest switch time was 15 days while 
the longest was 1777 days. Table 7.3.1 shows a detailed description of patients switching 
to stronger analgesia by baseline characteristics. 
Survival estimates 
Figure 7.3.1 shows a constant rate of the patients whose initial medication was no 
medication, basic analgesia or weak analgesia switching to higher potency medication 
(moderate and strong analgesia) throughout follow up time. 
Figure 7.3.1: Overall survival estimates for first switch from no medication, basic analgesia 
and weak analgesia to moderate or strong analgesia 
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Figure 7.3.2 shows that there were differences in the switching rates for the three 
categories according to initial analgesia. Those with no medication initially have lower and 
more constant rates of switching to higher potency analgesia (moderate and strong 
analgesia) than those initially on basic analgesia, while those with weak analgesia have 
higher and less constant rates of switching than those initially on basic analgesia.  
Figure 7.3.2: Survival estimates for first switch from no medication, basic analgesia and 
weak analgesia to moderate or strong analgesia by initial analgesia 
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Table 7.3.1: Baseline Socio-demographic and clinical characteristics of patients switching 
from no medication and basic or weak analgesia to moderate or strong analgesia 
 Switch to Stronger Analgesia 
Variable N No (Row %) Yes (Row %) 
Total 2285 2002(88) 283(12) 
Age (years)    
15-29 566 511(90) 55(10) 
30-44 716 638(89) 78(11) 
45-59 643 567(88) 76(12) 
60-74 271 214(79) 57(21) 
Over 75 89 72(80) 17(20) 
Gender    
Females 947 813(86) 134(14) 
Males 1338 1189(89) 149(11) 
Previous musculoskeletal 
consultation 
   
Yes 292 252(86) 40(14) 
No 1993 1750(88) 243(12) 
Previous prescribed 
analgesia 
   
Yes 331 269(81) 62(19) 
No 1954 1733(89) 221(11) 
Region of Pain    
Back 496 430(87) 66(13) 
Knee 240 219(91) 81(9) 
Hip 148 128(86) 20(14) 
Foot and Ankle 154 141(92) 13(8) 
Hand/upper limb 205 177(86) 28(14) 
Shoulder 151 129(85) 22(15) 
Neck 144 131(91) 13(9) 
Other/unspecified 747 647(87) 100(13) 
Co-morbidity    
Selected conditions 86 74(86) 12(14) 
Other conditions/none 2199 1928(88) 271(12) 
Deprivation    
Most 1008 907(87) 133(13) 
Moderate 891 791(89) 100(11) 
Least 386 336(87) 50(13) 
Staff category    
GPs 1855 1621(87) 234(13) 
Other 430 381(89) 49(11) 
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 Switch to Stronger Analgesia 
Variable N No (Row %) Yes (Row %) 
Number of pain locations    
One 21795 1526(85) 269(15) 
More 490 476(97) 14(3) 
Analgesia  group (1st 
consultation) 
   
Basic analgesia 346 296(86) 50(14) 
Weak analgesia 223 166(74) 57(26) 
No medication 1716 1540(90) 176(10) 
7.3.2 The Weibull models for baseline variables  
The Weibull model and the Weibull model with gamma frailty identified the baseline socio-
demographic and clinical factors associated with time to switching from initially prescribed 
low potency analgesia (no medication, basic analgesia and weak opioids) to higher 
potency analgesia (moderate analgesia or strong analgesia) as age, having a previous 
prescribed analgesia, level of deprivation and initial analgesia potency. The models are 
given in Table 7.3.2 with the statistically significant variables highlighted in bold. All the 
other factors were not statistically significant at 5% level. 
The Weibull model 
 The Weibull model without frailty, (first column of Table 7.3.2) shows that when compared 
to those aged  30-44, the age groups 60-74, adjusted hazard ratio (HR 1.81; 95% CI 
[1.26, 2.58]) and 75+ (HR 1.91 [1.10, 3.31]) were more likely to switch to stronger 
analgesia when all other factors were held constant. Previous prescribed analgesia more 
than 12 months prior to new MSK consultation in 2006 was associated with increased risk 
of switching with (HR 1.53 [1.13, 2.07]). Weak analgesia prescribed at the onset of 
consultation was associated with increased risk of switching to higher potency analgesia 
over time, (HR 1.77 [1.19, 2.64]) compared to basic analgesia. Patients from medium 
deprivation neighbourhoods were less likely to be switched to higher potency analgesia, 
(HR 0.72 [0.55, 0.94]) compared to patients from most deprived neighbourhoods. 
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The frailty Weibull model 
 The frailty Weibull model, (second column of Table 7.3.2) identified similar variables as 
the model without frailty but with slightly inflated hazard ratios, whilst gender became 
significant. The model shows that when compared to the 30-44, the age groups 60-74 (HR 
2.29 [1.32, 3.96]) and 75+ (HR 2.23 [1.03, 4.79]) were at higher risk of switching to 
stronger analgesia. Weak analgesia prescribed at the onset of consultation (HR 2.09 
[1.18, 3.72]) were associated with higher risk of switching, while no pain medication at 
onset of consultation (HR 0.63 [0.39, 0.99]) were associated with decreasing risk when 
compared to basic analgesia. Females (HR 1.39 [1.03, 1.94]) were more likely than males 
to switch. Patients from medium deprivation neighbourhoods (HR 0.66 [0.46, 0.94]) were 
less likely to switch compared to those from most deprived neighbourhoods. 
 The distribution shape parameters for both models (with and without frailty) suggest that 
the variables may have an increasing effect on the hazard function over time. The -
2loglikelihood values suggest that the frailty model with statistically non-significant frailty 
parameter (3.05 [0.87, 10.6]) is a slightly better model. 
7.3.3 Weibull model for baseline and time-varying covariates 
The frailty Weibull model including both baseline and time-varying covariates showed that 
frailty was not statistically significant and was not considered. The Weibull model with 
baseline and time-varying covariates identified experiencing pain in multiple locations over 
time, the number of analgesia prescriptions of low potency over time and the number of 
MSK consultations over time as the only factors associated with the first switch to higher 
potency analgesia (moderate or strong analgesia). All the other factors were not 
statistically significant at 5% level.  
Experiencing pain in more than one location (HR 2.22 [1.74, 2.85]) was associated with 
higher risk of switching to stronger analgesia. The increasing number of prescribed 
analgesia over time (HR 1.04 [1.03, 1.05]) was associated with increased risk of switching 
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to stronger analgesia. The increasing number of consultations over time was associated 
with decreasing risk of switching to stronger analgesia (HR 0.40 [0.31, 0.50]). 
 Although not statistically significant at the 5% level, previous prescribed analgesia (HR 
1.34 [0.99, 1.81]) was associated with increased risk of switching at the 10% level. Initially 
prescribed weak analgesia (HR 1.39 [0.93, 2.08] compared to basic analgesia), although 
not statistically significant was associated with increased risk of switching. When 
compared to patients whose initial pain is in the back, patients with initial pain in the knee 
were less likely to switch to stronger analgesia (HR 0.62 [0.37, 1.03]) although not 
statistically significant. 
The distribution shape parameter (1.27 [1.13, 1.43]) suggests that the variables have 
increasing effect on the hazard function over time, that is, the risk of switching to stronger 
analgesia is expected to increase with time. 
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Table 7.3.2: Weibull models evaluating factors associated with first switches from no medication, basic analgesia and weak analgesia to 
moderate or strong analgesia  
Variable    HR[95% CI] 
 Baseline variables Weibull 
Model  
Gamma frailty Weibull Model  Baseline + time-varying 
covariates Weibull model 
 Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted 
Age Group 
30-44 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
15-29 0.96[0.68, 1.36] 0.93[0.66, 1.33] 0.93[0.62, 1.40] 0.91[0.59, 1.40] 0.96[0.68, 1.36] 0.91[0.64, 1.30] 
45-59 1.01[0.74, 1.39] 0.97[0.70, 1.34] 1.01[0.69, 1.46] 0.93[0.62, 1.39] 1.01[0.74, 1.39] 0.90[0.65, 1.25] 
60-74 1.96[1.39, 2.77] 1.81[1.26, 2.58] 2.38[1.39, 4.07] 2.29[1.32, 3.96] 1.96[1.39, 2.77] 1.33[0.91, 1.94] 
75+ 2.61[1.54, 4.42] 1.91[1.10, 3.31] 3.32[1.57, 7.04] 2.23[1.03, 4.79] 2.61[1.54, 4.42] 1.16[0.65, 2.04] 
Gender 
Male 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Female 1.36[1.07, 1.71] 1.24[0.98, 1.57] 1.45[1.05, 2.00] 1.39[1.03, 1.94] 1.36[1.07, 1.71] 1.15[0.90, 1.46] 
Previous prescribed 
analgesia 
No 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
1.00 
Yes 1.67[1.26, 2.21] 1.53[1.13, 2.07] 1.74[1.19, 2.56] 1.67[1.10, 2.54] 1.67[1.26, 2.21] 1.34[0.99, 1.81] 
Previous musculoskeletal 
consultation 
No 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
 
1.00 
 
1.00 
Yes 1.08[0.77, 1.52] 0.96[0.67, 1.37] 1.10[0.76, 1.60] 1.00[0.63, 1.58] 1.08[0.77, 1.52] 1.04[0.73, 1.48] 
Comorbidity  
Selected 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Other/none 0.92[0.51, 1.64] 1.32[0.72, 2.38] 0.91[0.49, 1.69] 1.47[0.67, 3.22] 0.92[0.51, 1.64] 1.29[0.71, 2.33] 
Staff category 
GP 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Other 0.87[0.64, 1.18] 0.95[0.70, 1.31] 0.85[0.60, 1.20 0.88[0.59, 1.31] 0.87[0.64, 1.18] 0.79[0.57, 1.08] 
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Variable    HR[95% CI] 
 Baseline variables Weibull 
Model  
Gamma frailty Weibull Model  Baseline + time-varying covariates 
Weibull model 
 Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted 
Deprivation  
Most 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
medium 0.70[0.54, 0.92] 0.72[0.55, 0.94] 0.69[0.51, 0.94] 0.66[0.46, 0.94] 0.70[0.54, 0.92] 0.81[0.62, 1.06] 
least 0.81[0.58, 1.12] 0.76[0.54, 1.06] 0.80[0.56, 1.13] 0.69[0.44, 1.06] 0.81[0.58, 1.12] 0.91[0.65, 1.27] 
Pain Region  
Back 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Knee 0.65[0.40, 1.07] 0.75[0.45, 1.25] 0.65[0.40, 1.07] 0.79[0.43, 1.48] 0.65[0.40, 1.07] 0.62[0.37, 1.03] 
Hip 1.05[0.63, 1.73] 1.13[0.68, 1.89] 1.05[0.63, 1.73] 1.18[0.61, 2.29] 1.05[0.63, 1.73] 0.95[0.57, 1.59] 
Foot and Ankle 0.60[0.33, 1.09] 0.68[0.37, 1.24] 0.60[0.33, 1.09] 0.61[0.29, 1.29] 0.60[0.33, 1.09] 0.62[0.33, 1.13] 
Hand/upper limb 1.04[0.66, 1.62] 1.27[0.81, 2.01] 1.04[0.66, 1.62] 1.42[0.72, 2.57] 1.04[0.66, 1.62] 1.10[0.70, 1.73] 
Shoulder 1.07[0.66, 1.74] 1.14[0.69, 1.87] 1.07[0.66, 1.74] 1.18[0.63, 2.22] 1.07[0.66, 1.74] 1.13[0.69, 1.86] 
Neck 0.65[0.35, 1.17] 0.76[0.41, 1.39] 0.65[0.35, 1.17] 0.75[0.36, 1.55] 0.65[0.35, 1.17] 0.67[0.37, 1.24] 
Other/unspecified 1.04[0.76, 1.42] 1.16[0.84, 1.60] 1.04[0.76, 1.42] 1.25[0.82, 1.91] 1.04[0.76, 1.42] 0.90[0.65, 1.23] 
Initial Potency  
Basic analgesia 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
Weak analgesia 1.89[1.29, 2.76 1.77[1.19, 2.64] 2.22[1.25, 3.95] 2.09[1.18, 3.72] 1.89[1.29, 2.76 1.39[0.93, 2.08] 
No medication 0.66[0.48, 0.90] 0.73[0.52, 1.09] 0.60[0.39, 0.91] 0.63[0.39, 0.99] 0.66[0.48, 0.90] 0.91[0.65, 1.27] 
Time-varying       
Multiple location 
No 
 
- 
 
- 
 
- 
 
- 
 
1.00 
 
1.00 
Yes - - - - 2.04[1.96, 3.02] 2.22[1.74, 2.85] 
No. of consultations - - - - 0.72[0.66, 0.79] 0.40[0.31, 0.50] 
No. of Prescriptions - - - - 1.00[1.00, 1.01] 1.04[1.03, 1.05] 
-2logL - 2160 - 2156 - 1882 
Weibull shape parameter - 1.02[0.92, 1.14] - 1.18[0.97, 1.43] - 1.27[1.13, 1.43] 
Frailty parameter - - - 3.05[0.87, 10.6] - - 
Unadjusted model = Individual variable in the model, Adjusted model = All variables included simultaneously
170 
 
7.4 Discussion 
The Weibull model has been employed to evaluate the factors associated with switch from 
no medication, basic analgesia and weak analgesia to moderate or strong analgesia. The 
models with only variables measured at baseline evaluated the importance of the baseline 
variables without time-varying covariates while the model with time-varying covariates 
measured the associations related to the course of the pharmacological management of 
MSK conditions. Patients who were initially prescribed no medication, basic analgesia and 
weak analgesia are at higher risk of switching to moderate or strong analgesia if they are 
60 or over, if they were previously prescribed analgesia, or if they were prescribed weak 
analgesia on initial consultation, while those from medium deprivation areas are at lower 
risk. When time-varying covariates are included in the model, only time-varying covariates 
(pain in more than one location, number of MSK consultations and number of analgesia 
prescriptions) are statistically associated with time to switch.  
The models were fitted with and without a gamma frailty function. The frailty models 
showed that the effect of frailty was not statistically significant, with the frailty model with 
both time-varying and baseline factors not very different from the model without frailty. 
The frailty model with baseline factors only exhibited higher hazard ratios compared to the 
non-frailty model and gender was identified as statistically significant. The frailty model is 
a better fit as seen from the -2logL.  
The high risk of older patients, aged 60+, to switch to higher potency analgesia  probably 
reflects that MSK conditions tend to deteriorate and get worse with age (Pergolizzi and 
Raffa, 2009) hence highlighting the levels of discomfort and severity among this group of 
patients (Carrington et al., 2010). Clinicians therefore might be inclined to consider a 
switch to higher potency medication if there is no adequate pain relief. Older patients are 
more susceptible to co-morbidities (Fitzcharles et al., 2010), hence clinicians may take 
that into account and decide to switch to stronger analgesia to help control pain. While 
NSAIDs may provide pain relief better than basic analgesia and weak analgesia, clinicians 
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may opt for moderate or stronger analgesia due to more frequent occurrence of adverse 
effects (fluid retention, hypertension, congestive heart failure and possible increased 
cardiac mortality, acute renal failure) in older patients with NSAIDs (Fitzcharles et al., 
2010). The clinicians’ judgement could be that NSAIDs associated adverse effects are 
more likely for this age group than stronger analgesia adverse effects. 
The switch from weak analgesia to stronger analgesia  could be a calculated move by 
clinicians as opioid rotation is an effective strategy in the management of negative effects 
(tolerance and dependence) of opioids (Joseph et al., 2009) and can sometimes improve 
analgesia success (Pergolizzi and Raffa, 2009). General practitioners will most likely 
avoid keeping their patients on the same opioid analgesia for too long to avoid negative 
effects (Bhamb et al., 2006).  
Pain that interferes with daily life increases with age and is more prevalent among 
females. Additionally, older females were also likely to report pain in more than one 
location (Thomas et al., 2007), which may require stronger analgesia to control (Joseph et 
al., 2009; Reid et al., 2010). As suggested in Chapter 4, the ability of the patient to 
communicate the level of pain they are experiencing is regarded as one of the strongest 
predictors of the strength of medication given, and females have been shown to be better 
at that, hence the perceived level of pain may lead their clinicians to switch them to 
stronger analgesia. 
Patients with prescribed analgesia history prior to their 2006 consultation and those 
prescribed weak analgesia on initial consultation were at risk of switching to higher 
potency analgesia. As suggested in Chapter 4 and 6, clinicians consider patients’ 
response to previous medication. . 
Patients from medium deprivation areas were at a lesser risk of switching to stronger 
analgesia. Patients from least deprived areas had reduced risk but this was not 
statistically significant. However, there are similarities in the identified association of 
172 
 
deprivation with prescription of analgesia and strength (Chapter 4) and analgesia 
switching (Chapter 6), It may be that the level of pain  associated with emotional distress, 
low social support and low social participation that may be more common in most 
deprived areas (Katz, 2002; Garbez and Puntillo, 2005). This potentially leads to higher 
levels of pain among this group of patients leading to clinicians switching them to stronger 
analgesia. 
The number of analgesia prescriptions and acquiring new pain sites over time increases 
the risk of switching to moderate and strong analgesia. Pain interference in daily activities 
is more prevalent among patients with more than one pain location (Thomas et al., 2007) 
which may require stronger analgesia to alleviate.  
The number of MSK consultations over time reduces the risk of switching to higher 
potency analgesia suggesting that switching to stronger analgesia can be greatly reduced 
with higher number of consultations. As suggested in the previous chapter , medication 
switching is part of a comprehensive evaluation of pain, adverse side effects and strategic 
management of pain (Breckenridge and Clark, 2004; Schneider, 2010), and more 
consultations may lead to strengthened adherence to the therapeutic plan with regular 
feedback, assurance, positive reinforcement from their general practitioners or health 
professionals (Fitzcharles et al., 2010). Routinely and frequently evaluating patients for 
their degree of analgesia requirements, functional daily activities, adverse events, and 
adherence to medication routines may minimise switching to stronger analgesia.  
Patients with initial pain in the knee were less likely to switch to stronger analgesia 
although not statistically significant. Knee pain might be more likely to have an 
inflammatory cause and therefore NSAIDs may be more suited to it than stronger 
analgesia (Schneider, 2010; Breckenridge and Clark, 2004; Bope et al., 2004). Hence 
switching to stronger analgesia instead of NSAIDs becomes less likely.  
173 
 
The Weibull shape parameter in the model with time-varying covariates suggests that the 
risk of switching to stronger analgesia will increase with time in the presence of the 
measured time-varying covariates. This makes clinical sense, as stated in the previous 
chapters, MSK conditions tend to deteriorate with time, hence the need to switch to 
stronger analgesia to control increasing levels of pain. 
Limitations of this analysis have been discussed in previous Chapters (for example, 
unmeasured covariates). The reasons behind switching from lower potency analgesia are 
not known however, the factors identified as important are logical under the projected 
possible reasons for switching. Time-varying covariates seem to have more influence in 
the models than baseline variables. This does not however diminish the fact that the 
management of MSK is multifaceted, which means that understanding the baseline 
factors is as important as understanding the time-varying covariates and that there are 
baseline factors which seem to predispose a patient to being more likely to switch 
medication. These factors, e.g. age and gender, may also be related to the important 
time-varying measures (number of consultations and prescriptions). The advantage of the 
Weibull model is that it is able to indicate that baseline variables may become less 
important as time progresses but the risk of switching increases with time in the presence 
of time-varying covariates. 
7.5 Conclusion 
Clinicians need to be more vigilant with patients who at initial consultation are of older age 
(≥60), female and have received prescribed analgesia in the past as well as those they 
prescribe weak analgesia as they have higher risks of switching to moderate or strong 
analgesia. More frequently scheduled MSK consultations may help to minimise the risk of 
switching, and the implications of this will be discussed in more detail in Chapter 10. While 
time-varying covariates are most important, modelling baseline factors separately may 
help identify patients at higher risk of switching at the onset of consultation. 
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Chapter 8 
8 Modelling the effect of patient reported variables on switching 
analgesia 
8.1 Introduction 
The previous Chapters (6 and 7) have demonstrated that 51% of first time MSK consulters 
switch from the analgesia they were initially prescribed, with switching most common 
amongst those initially prescribed weak analgesia (70%). Switching analgesia was 
associated with socio-demographic variables such as age, gender, level of deprivation as 
well as initial pain location, initial analgesia potency level and previous medication history. 
The number of consultations for MSK problems and repeat prescriptions were also 
associated with switching as was consulting over time for pain in other body regions.  
The previous analyses have been on consulters for new (incident) MSK conditions, and 
have been restricted to assessing association with switching of socio-demographic and 
clinical characteristics that are routinely recorded in primary care. This chapter aims to 
utilise a dataset that links self-reported information to medical records to evaluate the 
generalizability of these findings in a cohort of patients with prevalent MSK conditions 
aged 50+, the age where MSK problems are most common. The dataset has the benefit 
of incorporating additional patient-specified variables that might be of clinical importance, 
for example the level of pain interference and physical function, which were not available 
in the CiPCA (chapter 6 and 7) database. Pain interference and physical function are a 
proxy measure of the patient’s quality of life in the presence of their MSK condition, as 
they may indicate the difficulties they have in executing their daily activities.  
The aim of the analysis reported in this Chapter is to evaluate the association of clinical 
and socio-demographic variables with analgesia switching in the presence of patient-
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reported variables to help determine the generalizability and limitations of the statistical 
models derived in Chapter 6 and 7. The patient specific variables are more personal, and 
therefore more likely to further inform us of the initial characteristics associated with future 
switching which may give an idea of what input patients have, and the effect of their input 
in the prescription process. For example, if a patient has used over the counter 
medication, what effect does it have on the choice of analgesia prescribed. 
The specific objectives of the chapter are: 
1. To assess if the same factors identified previously to be related to switching in an 
incident MSK consulting group are also the key factors associated with switching 
in a prevalent MSK consulting group aged 50+ years. 
2. To evaluate whether patient-reported factors are also related to switching 
analgesia.  
These objectives will be achieved through two different analyses, factors associated with, 
i)  switch to stronger analgesia, ii) switching analgesia in which multiple-event, non-
ordered switches within the follow up time are accounted for.  
8.2 Methods 
8.2.1 Data and study population 
The patients were drawn from the North Staffordshire Osteoarthritis Project, cohorts 1 and 
2 (NorStOP1 and NorStOP2) described in Chapter 3. The baseline and follow-up data 
collection surveys were carried out at different times. NorStOP 1 was established through 
a baseline two stage postal survey in April 2002 and consenting responders followed up in 
a further two stage postal survey in April 2005. NorStOP 2 was established through a 
baseline two-stage postal survey from July/August 2002 – July/August 2003 with 
consenting responders further followed up 3 years later (October 2005 – September 
2006). 
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 This therefore was a combined cohort of adults aged 50 years registered with 6 general 
practices. The baseline survey consisted of health questionnaires that collected 
information on several areas of life including socio-demographics, physical function and 
interference of pain in their daily lives (Thomas et al., 2004).  
The NorStOP study was designed to describe the prevalence of joint pain and pain 
interference with activities, to determine the course of joint pain and disability and the 
factors associated with their onset and persistence, and to describe the prevalence, 
distribution, and associated features of participation restriction in community-dwelling 
adults aged 50 years and over (Thomas et al., 2004).  
The analysis reported here included respondents who consented to medical record review 
and responded to baseline and 3 year follow up surveys. As in the CiPCA data, the linked 
primary care medical record data included prescriptions (BNF chapter, the drug item, 
issue date) and medical conditions consulted for (see Chapter 4). 
For this analysis patients were included who: 
i. Responded to baseline and 3 year follow-up surveys and consented to record 
review,  
ii. Had no MSK consultation and no analgesia prescribed in the month before the 
baseline survey,  
iii. Had a MSK consultation within the 6 months after the baseline survey.  
The logic in the inclusion criteria was to minimise the influence of prior prescribed 
analgesia on the patient-reported variables recorded during the baseline survey, e.g. the 
level of physical function and pain interference. The 6 months period after the survey 
enabled the establishment of a possible connection between the baseline patient-
reported factors with any initial prescription of analgesia. In the evaluation of factors 
associated with switching to stronger analgesia, only the participants prescribed no 
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medication, basic analgesia and weak analgesia on first consultation were considered. 
These switches represent an upward increase in the potency levels of analgesia. 
8.2.2 Baseline variables 
The socio-demographic and clinical variables extracted from the medical records and 
measured prior to, or at time of baseline survey considered in this analysis were those 
used previously in the analysis of CiPCA: age, gender, deprivation, co-morbidity, region of 
pain (e.g. knee, back), MSK consultation history, analgesia prescription history (within the 
2 years prior to baseline survey) and the potency level prescribed on first consultation 
after baseline survey (Chapter 4, section 4.2.3). In modelling the time to switch to stronger 
analgesia, having been prescribed an NSAID prior to the switch was included in the 
switching to stronger analgesia model.  The socio-demographic and clinical variables 
were defined and categorised as stated in Chapter 6 and 7 (CiPCA data)  
The NorStOP data contains a wide range of patient-reported variables, but the variables 
used here were marital status, body mass index (BMI), widespread pain, alcohol 
consumption, smoking history, depression, GP access, physical function, pain 
interference and over the counter medication (OTC) within 1 month prior to baseline 
survey date (none, painkillers/creams, natural medicine/glucosamine). The variables were 
collected through health survey questionnaires at baseline, which contained general 
health status (SF-36 Physical Function subscale (Ware, 200)), social (Berkman-Syme 
Social Network Index (Lubben, 1988)), psychological profile (Hospital Anxiety and 
Depression Scale (Zigmond et al., 1983)), participation restriction (Keele Assessment of 
Participation (Wilkie et al., 2004)) and regional pain severity (Western Ontario and 
McMaster Universities Osteoarthritis Index (Ehrich et al., 2000)).  
Age was categorised into four groups: 50-59, 60-69, 70-79 and 80+. The marital status 
was a dichotomous variable, 1 represents those married or cohabiting and 0 otherwise, 
BMI is a 3-category variable (1, underweight or normal, 2, overweight or obese, 3, 
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unknown), widespread pain is defined as, 1, axial (back/neck) plus contralateral upper and 
lower limb and 0 otherwise (Thomas et al., 2004). Also measured were alcohol 
consumption (1, drinks most of the time or sometimes, 0, no or rarely), and smoking 
history (1, never smoked, 2, previously smoked, 3, currently smoking). 
Depression was measured using the Hospital Anxiety and Depression Scale. This scale 
has 7 items relating to depression with scores ranging from 0 to 21. Scores of 8 or more 
indicate possible depression. Physical function was considered as a continuous variable, 
measured using the SF-36 Physical Function subscale with scores ranging from 0 to 100, 
higher scores indicating better physical function. Pain interference was measured using 
the SF-36 which has five ratings for the question on how pain interferes with their daily 
activities. The ratings were combined into a binary variable: 1 represents pain interferes 
with life, moderately/quite a bit/extremely and 0 for no/little interference from pain.  GP 
access was coded as 1, adequate access, 0, inadequate access to a GP based on the 
question asking participants if they have good access to their doctor (GP), as and when 
they need.  
These variables have been shown to be related to pain levels and prescription of 
analgesia (Green et al., 2012; Meyers et al., 2007; Thomas et al 2004; Thomas et al., 
2007). Most of these variables may be perceived to represent a self-assessment of the 
patient’s MSK condition and its impact on the patient’s quality of life, their own attempts to 
manage their condition, as well as the physical and psychological manifestations. 
Outcome variables 
The outcome variables of interest are i) switch from basic analgesia or weak analgesia to 
moderate or strong analgesia or starting use of a moderate or strong analgesia if initially 
prescribed no medication (switching defined as in section 7.2); ii) any analgesia switching 
in which multiple-event switches (more than one switch) are accounted for (section 6.3.1). 
For the first analysis of switching to a stronger analgesia, time was measured from the 
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prescription date of the baseline medication (medication prescribed within 14 days of a 
MSK consultation date in the six months after baseline survey) to the first switch to 
moderate or strong analgesia. For those who did not switch, time was measured to the 
end of the 3 year follow-up.  
The counting process approach (Chapter 6) was used to calculate time between events in 
multiple-event switches. Multiple-event switch analysis considers any change in 
analgesia, regardless of whether the switch is to lower or higher potency analgesia, or 
back to a previously prescribed analgesia. As such, some individuals incur multiple-events 
during follow up. All individuals in the analysis were followed up to 3 years. 
8.2.3 Statistical methods 
The Kaplan-Meier curves were used as an exploratory analysis to graphically assess the 
overall survival estimates and Weibull models used to evaluate the association of baseline 
factors with time to switching analgesia (described in Chapter 6). For each of the 
analyses, two models are fitted; one without patient-reported factors to allow comparison 
to the models reported in Chapters 6 and 7, and then adding patient-reported factors. 
Frailty models were considered, and as in the previous chapter were found to be not 
statistically significant, hence left out of the analysis. 
The sensitivity analyses involved fitting two more models, both adjusted and unadjusted 
and comparing the -2logL to that of the final model. The missing physical function values 
(continuous) were replaced by the median physical function score. For the categorical 
variables two extremes were assumed, for example one model assumed that all those 
with missing values in the depression variable had depression and the other model 
assumed that they all did not have depression. 
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8.3 Results 
8.3.1 Study population and Data description 
At the onset of data collection, 20214 people were sent health survey questionnaires, of 
whom 13,986 (69%) responded to the baseline questionnaire. 10,432 (75%) of those who 
responded at baseline consented to medical record review. 5015 (48%) responded to both 
baseline and 3 year follow-up survey.  
Figure 8.3.1: Schematic illustration of the inclusion criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
10432 North Staffordshire Osteoarthritis Project (NorStOP 1 and 2) consenting to 
medical record review  
 5417 did not 
respond to both 
baseline and 3 
year follow-up 
5015 (48%) responded to both baseline and 3 year surveys 
 
1610 (32%) consulted within 6 months from baseline 
and had no prescribed analgesia 28 days before 
3405 had no 
consultation within 6 
months from baseline 
survey or were 
prescribed analgesia 
within 28 days before 
 
845 (52%) were prescribed analgesia within 14 
days of their consultation 
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Of the 5015 who consented to medical record review and responded to both baseline and 
3 year follow-up survey, 1610 (32%) fitted the inclusion criteria of having no prescribed 
pain medication within the last month prior to the baseline survey and consulting for a 
MSK condition within 6 months from the baseline survey  (Figure 8.3.1). 
Studies that have been carried out and compared responders and non-responders within 
the NorStOP database have found some minor differences.A study by Jordan et al. (2008) 
investigating social risks for disabling pain in older people found that at baseline, males 
and the younger aged were less likely to respond but responders at 3 year follow-up were 
younger than those who were not followed up with a mean difference in age of 4.7 years. 
In a study by Lacey et al. (2013) which compared consenters and non-consenters to 
medical record review, slight variations were noted. Compared to those who responded 
but did not consent to record review, consenters were slightly younger (mean 66.2 years 
vs. 67.4), had a lower proportion who were female (54% vs. 62%) and reported more joint 
pain (79% vs. 70%). In a study by Hill et al. (2007) investigating illness perceptions 
associated with health and behavioural outcomes in people with musculoskeletal hand 
problems, the study population were on average younger (mean age 65.4 years, S.D. 9.6) 
than those who reported hand problems but refused further contact (mean age 70.1 years, 
S.D. 10.6).  
8.3.2 Initial analgesia prescribing by baseline characteristics  
Out of the 1610 patients, 845 (52%) were prescribed analgesia within 14 days of their 
MSK consultation date. Of all patients prescribed analgesia, basic analgesia were 
prescribed to 52 (6%) patients, weak analgesia to 492 (58%) patients, moderate analgesia 
to 27 (3%) patients, strong analgesia to 138 (16%) patients and NSAIDs to 136 (16%) 
patients. Table 8.3.1 shows the prevalence of analgesia prescription by baseline 
characteristics. 
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Table 8.3.1: Baseline socio-demographic, clinical and patient-reported characteristics of patients prescribed analgesia 
 
Variable 
 
 
Total 
 
No 
medication 
(%)a 
 
All 
analgesia 
(%)a 
 
Basic 
analgesia 
(%)b 
 
Weak 
analgesia 
(%)b 
 
Moderate 
analgesia 
(%)b 
 
Strong 
analgesia 
(%)b 
 
 
NSAIDs 
(%)b 
Total 1610 765(48) 845(52) 52(6) 492(58) 27(3) 138(16) 136(16) 
Age         
50-59 532 293(55) 239(45) 19(8) 112(47) 3(1) 55(23) 50(21) 
60-69 507 241(48) 266(52) 14(5) 165(62) 10(4) 35(13) 42(16) 
70-79 383 160(42) 223(58) 11(5) 141(63) 12(8) 32(14) 27(12) 
80+ 188 71(38) 117(62) 8(11) 74(63) 2(3) 16(14) 17(15) 
Gender         
Males 701 336(48) 365(52) 26(7) 201(55) 8(2) 61(17) 69(19) 
Females 909 429(47) 480(53) 26(5) 291(61) 19(4) 77(16) 67(14) 
Married         
No 467 195(42) 272(58) 12(4) 170(63) 10(4) 35(13) 45(17) 
Yes 1443 570(60) 573(40) 40(7) 322(56) 17(3) 103(18) 91(16) 
Deprivation         
Most 713 328(46) 385(54) 25(6) 238(62) 19(5) 51(13) 52(13) 
Medium 713 328(46) 385(54) 25(6) 207(54) 6(2) 73(19) 74(19) 
Least 184 109(59) 75(41) 2(3) 47(63) 2(3) 14(19) 10(13) 
Region of Pain         
Back 252 79(31) 173(69) 6(3) 97(56) 9(5) 37(21) 24(14) 
Knee 192 88(46) 104(54) 12(12) 53(51) 2(2) 16(15) 21(20) 
Hip 354 199(56) 155(44) 9(6) 98(63) 3(2) 23(15) 22(15) 
Foot/ Ankle 204 106(52) 98(48) 6(6) 59(60) 4(4) 9(9) 20(20) 
Hand/limb 186 89(48) 97(52) 9(9) 53(55) 3(3) 9(9) 23(24) 
Shoulder 199 97(49) 102(51) 5(5) 58(57) 3(3) 24(24) 12(12) 
Neck 223 107(48) 116(52) 5(4) 74(64) 3(3) 20(19) 14(13) 
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Variable 
 
 
Total 
 
No 
medication 
(%)a 
 
All 
analgesia 
(%)a 
 
Basic 
analgesia 
(%)b 
 
Weak 
analgesia 
(%)b 
 
Moderate 
analgesia 
(%)b 
 
Strong 
analgesia 
(%)b 
 
 
NSAIDs 
(%)b 
Co-morbidity         
Other /none 916 446(49) 469(51) 29(6) 254(54) 14(3) 84(18) 88(19) 
Select-conditions 695 319(46) 376(54) 23(6) 238(63) 13(3) 54(14) 48(13) 
Widespread pain         
No 1328 643(48) 685(52) 41(6) 396(58) 21(3) 110(16) 117(17) 
Yes 282 122(43) 160(57) 11(7) 96(60) 6(4) 28(18) 19(12) 
Previous musculoskeletal consultation         
No 31 19(61) 12(39) 0(0) 4(33) 0(0) 5(42) 3 (25) 
Yes 1579 746(47) 833(53) 52(6) 488(59) 27(3) 133(16) 133(16) 
Previous prescribed analgesia         
No 717 464(65) 253(35) 25(10) 124(49) 10(4) 37(15) 57(23) 
Yes 893 301(34) 592(66) 27(5) 368(62) 17(3) 101(17) 79(13) 
OTC medication         
None 252 153(61) 99(39) 8(8) 49(49) 6(6) 13(13) 23(23) 
Painkillers/creams 733 733(44) 408(56) 19(5) 244(60) 11(3) 82(20) 52(13) 
Glucosamine/other 625 287(38) 338(62) 25(10) 199(59) 10(3) 43(13) 61(18) 
BMI         
Normal /underweight 579 273(47) 306(53) 21(7) 169(55) 9(3) 58(19) 49(16) 
Overweight /obese 966 465(48) 501(52) 29(6) 298(59) 18(4) 76(15) 80(16) 
Unknown 65 27(42) 38(58) 2(5) 25(66) 0(0) 4(11) 7(18) 
Depression         
No 1310 653(50) 657(50) 40(7) 377(57) 17(3) 107(16) 116(18) 
Yes 300 112(37) 188(63) 12(6) 115(61) 10(5) 31(16) 20(11) 
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Variable 
 
 
Total 
 
No 
medication 
(%)a 
 
All 
analgesia 
(%)a 
 
Basic 
analgesia 
(%)b 
 
Weak 
analgesia 
(%)b 
 
Moderate 
analgesia 
(%)b 
 
Strong 
analgesia 
(%)b 
 
 
NSAIDs 
(%)b 
Pain interference         
None 748 407(54) 341(46) 30(9) 181(53) 11(3) 51(15) 68(20) 
Yes 862 358(42) 504(58) 22(4) 311(62) 16(3) 87(17) 68(13) 
GP Access         
Yes 1446 680(47) 766(53) 48(6) 441(58) 22(3) 129(17) 126(16) 
No 164 70(59) 67(41) 4(6) 43(64) 3(4) 9(13) 8(12) 
Alcohol         
Mostly/sometimes 916 313(58) 381(42) 18(5 242(64) 17(4) 50(13) 54(14) 
Never/rarely 694 452(33) 464(67) 34(7) 250(54) 10(2) 88(19) 82(18) 
Smoke         
Never smoked 663 341(51) 322(49) 18(6) 192(60) 10(3) 49(15) 53(16) 
Previously 733 328(45) 405(55) 26(6) 234(58) 13(3) 66(16) 66(16) 
Currently 214 96(45) 118(55) 8(7) 66(56) 4(3) 17(14) 17(14) 
a = x/Total, b = x/all analgesia 
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The mean age of the 1610 patients fitting the inclusion criteria was 65 years with a 
standard deviation of 10.2, with 909 (56%) of the participants female. The entire cohort 
was used in the analysis of switches to any analgesia accounting for multiple switches.  
The age-group 50-59 constitutes the highest category, 33%, while the 80 and over had 
the least, 12%, with 60-69 and 70-79 accounting for 31% and 24% respectively (Table 
8.3.2).  
Altogether, 1309 (81%) of the cohort fitting the inclusion criteria were prescribed no 
medication, basic analgesia or weak analgesia at their first consultation after baseline 
survey. These are the participants used in analysing switching to stronger analgesia. 
Throughout the 3 year follow-up period, 407 (31%) switched to moderate or strong 
analgesia (Table 8.3.2). 
The outcome variables (switching or not and time to switching) were complete with no 
missing values. This can be attributed to the inclusion criteria which required participants 
to have responded to both the baseline and 3 year follow-up surveys. The prescription 
dates used to calculate time to switching were derived from the computerised 
prescriptions database which is a complete dataset. This means that participants either 
had a date of switching event or those who did not were censored at 3 year follow-up 
date.  
Some of the baseline variables had missing values, because the survey participants 
intentionally or erroneously left some of the survey questions unanswered. The variables 
age, gender, deprivation, co-morbidity, pain location, previous MSK consultation and 
previous analgesia prescription which were derived from the medical record data were 
complete except, as previously reported for the CiPCA analysis, for pain location (see 
Chapter 4). The survey data derived variables (patient-reported) of marital status, over the 
counter medication (OTC), GP access and widespread pain were also complete.  
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21 (2%) participants in the cohort of 1309 had missing data in at least one of the 
remaining self-reported variables: pain interference, depression, physical function, body 
mass index (BMI), alcohol consumption, and smoking history. Those with missing data 
were on average slightly older, 67 years versus 65 years with a standard deviation of 
13.5. There were more females 54% than males compared to 56% in the entire cohort. All 
participants with missing self-reported data on any variable were excluded in the final 
models but sensitivity analyses were done to assess the effect of excluding participants 
with missing data. 
When both models were compared to the final model, both adjusted and unadjusted 
parameter estimates differed from those of the final model by less than 0.05 and the -
2logL were not statistically different from that of the final model. 
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Table 8.3.2: Baseline Socio-demographic, clinical and patient specified characteristics of 
patients switching medication 
 Any medication switch Strong analgesia switch 
Variable Total No (%) Yes (%) Yes (%) 
Total 1610 889(55) a 721(45) a 407(31)b 
Age     
50-59 532(33) 331(62) 201(38) 120(23) 
60-69 507(31) 283(56) 224(44) 136(27) 
70-79 383(24) 190(50) 193(50) 110(29) 
80+ 188(12) 85(45) 103(55) 41(22) 
Gender     
Males 701(44) 412(59) 289(41) 150(21) 
Females 909(56) 477(52) 432(48) 257(28) 
Married     
No 467(29) 224(48) 243(52) 137(29) 
Yes 1443(71) 665(58) 478(42) 270(19) 
Deprivation     
Most 713(44) 386(54) 327(46) 189(27) 
Medium 713(44) 384(54) 329(46) 180(25) 
Least 184(12) 119(65) 65(35) 38(20) 
Region of Pain     
Back 252(16) 121(48) 131(52) 63(10) 
Knee 192(12) 114(59) 78(41) 32(16) 
Hip 354(22) 204(58) 150(42) 90(25) 
Foot/ Ankle 204(13) 116(57) 88(43) 50(25) 
Hand/limb 186(11) 104(56) 82(44) 45(24) 
Shoulder 199(12) 103(52) 96(48) 58(29) 
Neck 223(14) 127(57) 96(43) 69(31) 
Co-morbidity     
Other /none 916(57) 532(58) 383(42) 201(22) 
Select-conditions 695(43) 357(51) 338(49) 206(30) 
Widespread pain     
No 1328(82) 746(56) 582(44) 321(24) 
Yes 282(18) 143(51) 139(49) 86(30) 
Consultation 
history 
    
No 31(2) 26(84) 5(16) 5(16) 
Yes 1579(98) 863(55) 716(45) 402(25) 
Medication history     
No 717(45) 548(76) 169(24) 91(13) 
Yes 893(55) 341(38) 552(62) 316(35) 
Initial analgesia     
None 765(47) 521(77) 174(23) 177(23) 
Basic analgesia 52(3) 52(100) 0 0 
Weak analgesia 492(31) 107(22) 385(78) 230(47) 
Moderate analgesia 27(2) 20(74) 7(26) - 
NSAIDs 136(8) 80(59) 56(41) - 
Strong analgesia 138(9) 39(28) 99(72) - 
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 Any medication switch Strong analgesia switch 
Variable Total No (%)a Yes (%)a Yes (%)b 
OTC medication     
None 252(16) 177(70) 75(30) 44(17) 
Painkillers/creams 733(45) 369(50) 364(50) 217(30) 
Glucosamine/other 625(38) 343(54) 282(45) 146(23) 
BMI     
Normal 
/underweight 
579(36) 326(56) 253(44) 130(22) 
Overweight /obese 966(60) 532(55) 434(45) 259(27) 
Unknown 65(4) 31(48) 34(52) 18(28) 
Depression     
No 1310(81) 754(58) 556(42) 307(23) 
Yes 300(19) 135(45) 165(55) 100(33) 
Pain interference     
None 748(46) 498(67) 250(33) 139(19) 
Yes 862(54) 391(45) 471(55) 268(31) 
GP Access     
Yes 1446(91) 797(55) 649(45) 361(25) 
No 137(9) 76(55) 61(45) 41(30) 
Alcohol     
Mostly/sometimes 916(57) 533(58) 383(42) 215(23) 
Never/rarely 694(43) 356(51) 338(49) 192(28) 
Smoke     
Never smoked 663(41) 387(58) 276(42) 146(22) 
Previously 733(46) 388(53) 345(47) 202(28) 
Currently 214(15) 114(53) 100(47) 59(28) 
a = n/1610, b= n/1309, - =excluded 
The mean time to a moderate or strong opioid switch from baseline for those initially 
prescribed no medication, basic analgesia, or weak analgesia was 715 days (SD 586.62), 
median 548 days, and IQR (223, 1092) days in those who switched.  
The survival estimates are illustrated in Figure 8.3.1. The Kaplan-Meier curve suggests 
rates of switching to moderate or strong analgesia from low potency (no medication, basic 
and weak analgesia) was evenly spread over time. Figure 8.3.2 suggests that there was 
variation in the rates of switching by initial analgesia prescribed. The Kaplan-Meier curves 
showing switching rates by individual variables are included in Appendix B. 
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Figure 8.3.1: Overall survival estimates for first switch from no medication, basic analgesia 
and weak analgesia to moderate or strong analgesia 
 
Figure 8.3.2: Survival estimate curves by analgesia prescribed on initial consultation 
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8.3.3 Stronger analgesia switch models 
Two models adjusting for baseline variables were fitted to evaluate their association with 
switching to higher potency analgesia (moderate opioids or strong opioids) for those 
initially prescribed no medication, basic analgesia or weak analgesia. The first models 
consisted of only socio-demographic, clinical variables from the medical records; the 
second, extensions of the first, also included patient-reported variables (Table 8.3.3). The 
variables statistically significant at 5% level are highlighted in bold in Table 8.3.3. 
Socio-demographic, clinical and patient-reported variables associated with 
switching to stronger analgesia 
In the model only including clinical and socio-demographic variables identified from the 
medical records, factors associated with switching to stronger opioids were younger age, 
for example, for those aged 80 and over compared to those aged 50-59 (HR 0.63; [95% 
CI [0.42, 0.96]), females (HR 1.30 [1.04, 1.64]), comorbidity (at least one of diabetes, 
chronic obstructive pulmonary disease (COPD), depression, cardiovascular, chronic 
kidney, gastro-intestinal and neoplasm), (HR 1.66 [1.32, 2.08]) and having a previously 
prescribed analgesia (HR 2.62 [1.96, 3.51]). Those initially prescribed a weak opioid were 
more likely to switch to stronger analgesia (HR 3.47 [2.65, 4.55]) compared to those on no 
initial analgesia, whilst more MSK consultations over time (HR 0.99 [0.98, 0.99]) and not 
having a prior NSAID prescribed were related to being less likely to switch, (HR 0.59 
[0.45, 0.79]). The Weibull shape parameter (0.96 [0.87, 1.06]) suggests a probable 
constant hazard function over time.  
Age, previous prescribed analgesia and number of MSK consultations were also identified 
in the analysis of incident MSK consulters in CiPCA in Chapter 7. In Chapter 7, the age 
group 75 and over was associated with increased risk of switching to opioids compared to 
those aged 30-44, in contrast with age 80 and over being associated with reduced risk 
compared to those aged 50-59 seen here. Both medication history and being initially 
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prescribed weak analgesia were associated with increased risk in the analysis of incident 
MSK consulters in Chapter 7, while an increased number of MSK consultations were 
associated with a slightly reduced risk as in this analysis. Co-morbidity and prescribed 
NSAID were not statistically significant in Chapter 7. 
There was no change in the strength of association of socio-demographic and clinical 
variables with switching to stronger analgesia when the patient-reported variables were 
added to the model (Table 8.3.3).   
The patient-reported variables associated with switching to stronger analgesia were being 
overweight/obese (HR 1.37 [1.05, 1.78]) compared to normal weight and previously been 
a smoker (HR 1.70 [1.30, 2.21]) compared to never smoked. A higher (better) baseline 
physical function score was associated with a reduced likelihood of switching hazard ratio 
0.99[0.98, 0.99] per unit score. Unadjusted association of pain interference with switching 
disappeared in the final adjusted model. 
The Weibull shape parameter (0.94 [0.85, 1.03]) suggests the possibility of a constant 
hazard rate over time. Comparison of the -2logL suggest that the model with added 
patient specific variables is a better fit to the data.  
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Table 8.3.3: Models of baseline socio-demographic, clinical and patient-reported variables 
associated with time to switching to stronger analgesics and to NSAIDs  
 Weibull models without and with patient specified variables 
Hazard Ratio [95% CI] 
Variable Stronger 
analgesia switch 
Stronger 
analgesia switch a 
Stronger analgesia 
switch b 
 Unadjusted Adjusted Adjusted 
Age    
50-59                                      1.00 1.00 1.00 
60-69                                      1.23[0.96, 1.37] 0.90[0.68, 1.20] 0.94[0.69, 1.28] 
70-79                                      1.41[1.01, 1.83] 0.96[0.71, 1.32] 0.94[0.66, 1.33] 
80+                                         1.16[0.81, 1.66] 0.63[0.42, 0.96] 0.58[0.35, 0.95] 
Gender    
Males                                  1.00 1.00 1.00 
Females                                    1.38[1.13, 1.69] 1.30[1.04, 1.64] 1.51[1.16, 1.96] 
Previous musculoskeletal 
consultation     
   
No                                       1.00 1.00 1.00 
Yes                                          1.70[0.70, 4.12] 2.92[0.70, 1.28] 1.75[0.42, 1.31] 
Previous prescribed 
analgesia 
   
No                                        1.00 1.00 1.00 
Yes                                       3.38[3.68, 4.27] 2.62[1.96, 3.51] 2.60[190, 3.55] 
Deprivation    
Most                                        1.00 1.00 1.00 
Medium                                   0.92[0.75, 1.12] 1.05[0.83, 1.32] 1.09, 0.85, 1.39] 
Least                                       0.69[0.49, 0.98] 0.82[0.55, 1.21] 0.87[0.57, 1.33] 
Region of Pain    
Back                                          1.00 1.00 1.00 
Knee                                        0.66[0.43, 1.02] 0.73[0.45, 1.17] 0.81[0.49, 1.35] 
Hip                                           10.5[0.76, 1.45] 1.25[0.87, 1.81] 1.42[0.94, 2.15] 
Foot/ Ankle                        0.98[0.68, 1.43] 1.07[0.70, 1.63] 1.08[0.67, 1.74] 
Hand/limb                     0.96[0.65, 1.41] 1.18[0.76, 1.83] 1.40[0.87, 2.24] 
Shoulder                                 1.24[0.86, 1.77] 1.09[0.72, 1.66] 1.27[0.81, 2.01] 
Neck                                       1.27[.090, 1.79] 1.45[0.98, 2.13] 1.68[1.10, 2.56] 
Co-morbidity    
Other /none           1.00 1.00 1.00 
Select-conditions               1.46[1.20, 1.78] 1.66[1.32, 2.08] 1.57[1.24, 2.00] 
Initial Analgesic    
None 1.00 1.00 1.00 
Basic  0 0 0 
Weak opioids  4.52[3.58, 5.71] 3.47[2.65, 4.55] 3.06[2.29, 4.09] 
NSAID    
No 1.00 1.00 1.00 
Yes 0.62[0.49, 0.78] 0.59[0.45, 0.79] 0.67[0.49, 0.90] 
No. of MSK consultations 0.99[0.98, 1.00] 0.99[0.98, 0.99] 0.99[0.99, 0.99] 
No. of Prescriptions 1.00[0.99, 1.01] 0.99[0.99, 1.01] 0.99[0.98, 1.01] 
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 Weibull models without and with patient specified variables 
Hazard Ratio [95% CI] 
Variable Stronger 
analgesia switch 
Stronger 
analgesia switch a 
Stronger analgesia 
switch b 
 Unadjusted Adjusted Adjusted 
Patient-reported    
Married    
No                                        1.00 - 1.00 
Yes                                           0.71[0.58, 0.88] - 0.91[0.69, 1.20] 
Widespread pain    
No                                         1.00 - 1.00 
Yes                                       1.26[0.69, 1.60] - 0.81[0.59, 1.12] 
OTC 
medication 
   
None                                      1.00 - 1.00 
Painkillers                              1.02[0.62, 1.82] - 0.85[0.56, 1.27] 
Glucosamine 1.03[0.83, 1.84] - 0.70[0.46, 1.08] 
BMI    
Normal                                  1.00 - 1.00 
Overweight /obese                                 1.17[0.95, 1.45] - 1.37[1.05, 1.78] 
Unknown                                  1.38[0.84, 2.27] - 1.25[0.68, 2.28] 
Depression    
No                                         1.00 - 1.00 
Yes                                    1.64[1.31, 2.06] - 1.09[0.81, 1.46] 
Pain interference    
None                                    1.00 - 1.00 
Yes                    1.87[1.52, 2.30] - 1.06[0.77, 1.45] 
GP Access    
Yes                                    1.00 - 1.00 
No                                        1.25[0.90, 1.72] - 1.01[0.69, 1.46] 
Alcohol    
Mostly 1.00 - 1.00 
Never                                  0.78[0.64,1.15] - 1.16[0.90, 1.49] 
Smoke    
Never smoked                    1.00 - 1.00 
Previously            1.33[1.08, 1.65] - 1.70[1.30, 2.21] 
Currently              1.36[1.00, 1.84] - 1.27[0.87, 1.86] 
Physical function 0.98[0.98, 0.99] - 0.99[0.98, 0.99] 
Weibull shape parameter - 0.94[0.85, 1.03] 0.96[0.87, 1.06] 
-2logL - 1886 1700 
a Weibull model with patient-reported variables excluded, b Weibull model with patient reported factors included 
Unadjusted model = Individual variable in the model, Adjusted model = All variables included simultaneously
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8.3.4 Any switch models 
Two models were fitted to evaluate factors associated with any analgesia switching taking 
into account time to multiple switches from analgesia prescribed on first consultation. The 
first model consisted of only socio-demographic and clinical variables recorded in the 
medical records; the second, an extension of the first, also included patient-reported 
variables (Table 8.3.4). The variables statistically significant at 5% level are highlighted in 
bold (Table 8.3.4).The mean number of switches was 4, with a median of 3 and IQR of 5. 
The maximum number of switches was 47. 
Socio-demographic, clinical and patient-reported variables model 
The first model showed that being aged 70-79, (HR 1.17 [1.06, 1.28]) compared to 50-59, 
females (HR 1.23 [1.15, 1.32]), having comorbidity (HR 1.26 [1.18, 1.35]) and previous 
analgesia prescription prior to baseline survey (HR 1.83 [1.87, 2.01]) were associated with 
increased risk of switching when multiple-event analgesia switches are accounted for. 
When compared to no initial analgesia, those prescribed initially weak analgesia (HR 1.48 
[1.35, 1.63]) and strong analgesia (HR 1.45 [1.28, 1.64]) had an increased risk of 
switching, while initial prescription of moderate analgesia (HR 0.25 [0.14, 0.43]) and 
NSAIDs (HR 0.61 [0.51, 0.72]) were associated with reduced risk, as were having a higher 
number of MSK consultations (HR 0.99 [0.98, 0.99]).   
The variables age, gender, medication history, initial analgesia and number of 
consultations were also identified in the analysis of incident MSK consulters in CiPCA in 
Chapter 6 as being associated with switching when multiple event switches are accounted 
for. In Chapter 6, age 75 and over was associated with increased risk compared to age 
30-44, similar to the increased risk for those aged 70-79 compared to 50-59 found here. 
Co-morbidity was not statistically significant in Chapter 6 but significant in this analysis, 
while number of prescriptions was associated with increased risk and medium and least 
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deprivation were associated with reduced risk in the CiPCA analysis, but both were non-
significant in this analysis. 
When adding patient-reported variables to the model, the patient-reported variables 
associated with increased risk were using over the counter glucosamine/natural 
medication (HR 1.14 [1.00, 1.32]) compared to no over the counter medication, having 
interfering pain at baseline (HR 1.13 [1.03, 1.24]), reporting inadequate GP access (HR 
1.15 [1.03, 1.30]), and previous smoking (HR 1.70 [1.30, 2.21]) compared to never 
smoked. Having widespread pain (HR 0.85 [0.77, 0.93]) and higher (better) physical 
function score, (HR 0.99[0.98, 0.99]) were associated with a reduced risk. 
The Weibull shape parameters (0.42 [0.40, 0.43]) for the socio-demographic and clinical 
variable model, and (0.42 [0.41, 0.43]) for the socio-demographic, clinical and patient-
reported variables suggest that the statistically significant covariates have a decreasing 
effect on the hazard function over time, that is over time, the variables become less 
associated with switching as multiple-event switches decline with time. The -2logL 
suggest that the model with patient specific variables is a better fit to the data. 
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Table 8.3.4: Models of baseline socio-demographic, clinical and patient specified 
characteristics associated with multiple-events switching to any analgesia  
Weibull models without and with patient specified variables 
Hazard Ratio [95% CI] 
Variable  Multi-switch a Multi-switch b 
 Unadjusted Adjusted Adjusted 
Age    
50-59                                      1.00 1.00 1.00 
60-69                                      1.27[1.17, 1.39] 1.07[0.98, 1.06] 1.05[0.96, 1.53] 
70-79                                      1.48[1.36, 1.62] 1.17[1.06, 1.28] 1.09[0.99, 1.21] 
80+                                         0.98[0.79, 1.01] 0.91[0.81, 1.03] 0.83[0.72, 0.96] 
Gender    
Males                                  1.00 1.00 1.00 
Females                                    1.31[1.22, 1.40] 1.23[1.15, 1.32] 1.25[1.15, 1.35] 
Previous musculoskeletal 
consultation     
   
No                                       1.00 1.00 1.00 
Yes                                          1.98[1.43, 2.74] 1.36[0.98, 1.91] 2.79[1.64, 4.77] 
Previous analgesia 
prescription 
   
No                                        1.00 1.00 1.00 
Yes                                       3.55[3.27, 3.86] 1.83[1.87, 2.01] 1.67[1.53, 1.85] 
Deprivation    
Most                                        1.00 1.00 1.00 
Medium                                   1.01[0.94, 1.09] 1.06[0.99, 1.13] 1.10[1.02, 1.19] 
Least                                       0.78[0.69, 0.88] 0.95[0.84, 1.07] 0.97[0.85, 1.10] 
Region of Pain    
Back                                          1.00 1.00 1.00 
Knee                                        0.97[0.86, 1.11] 1.09[0.96, 1.23] 1.05[0.92, 1.21] 
Hip                                           0.92[0.83, 1.12] 1.05[0.94, 1.18] 1.11[0.99, 1.25] 
Foot/ Ankle                        0.90[0.80, 1.02] 1.01[0.89, 1.15] 1.00[0.87, 1.15] 
Hand/limb                     0.93[0.82, 1.05] 1.08[0.95, 1.23] 1.14[0.99, 1.30] 
Shoulder                                 1.01[0.89, 1.14] 1.04[0.92, 1.18] 1.14[0.99, 1.30] 
Neck                                       1.11[0.98, 1.25] 1.11[0.99, 1.25] 1.14[1.01, 1.29] 
1st Analgesia    
None 1.00 1.00 1.00 
Basic  0 0 0 
Weak analgesia 3.97[3.67, 4.30] 1.48[1.35, 1.63] 1.42[1.28, 1.56] 
Moderate analgesia  0.47[0.28, 0.81] 0.25[0.14, 0.43] 0.22[0.12, 0.40] 
NSAIDs  1.00[0.86, 1.21] 0.61[0.51, 0.72] 0.65[0.54, 0.78] 
Strong analgesia 3.15[2.81, 3.54] 1.45[1.28, 1.64] 1.43[1.25, 1.62] 
Co-morbidity    
Other /none           1.00 1.00 1.00 
Select-conditions               1.28[1.20, 1.37] 1.26[1.18, 1.35] 1.20[1.12, 1.29] 
No. of MSK consultations 0.98[0.98, 0.99] 0.99[0.98, 0.99] 0.99[0.98, 0.99] 
No. of Prescriptions 0.99[0.99, 1.01] 0.99[0.98, 1.01] 0.99[0.97, 0.99] 
Weibull models without and with patient specified variables 
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Hazard Ratio [95% CI] 
Variable  Multi-switch a Multi-switch b 
 Unadjusted Adjusted Adjusted 
Patient-reported    
Married    
No                                        1.00 - 1.00 
Yes                                           0.78[0.73, 0.89] - 0.97[0.90, 1.06] 
Widespread pain    
No                                         1.00 - 1.00 
Yes                                       0.95[0.71, 0.96] - 0.85[0.77, 0.93] 
OTC medication    
None                                      1.00 - 1.00 
Painkillers                              2.03[1.79, 2.29] - 1.05[0.92, 1.21] 
Glucosamine 2.10[1.86, 2.38] - 1.14[1.00, 1.32] 
BMI    
Normal                                  1.00 - 1.00 
Overweight                                   1.18[1.10, 1.26] - 1.06[0.98, 1.14] 
Unknown                                  1.30[1.10, 1.53] - 1.08[0.89, 1.30] 
Depression    
No                                         1.00 - 1.00 
Yes                                    1.47[1.37, 1.59] - 1.00[0.92, 1.10] 
Pain interference    
None                                    1.00 - 1.00 
Yes                    2.00[1.86, 2.14] - 1.13[1.03, 1.24] 
GP Access    
Yes                                    1.00 - 1.00 
No                                        1.17[1.05, 1.31] - 1.15[1.03, 1.30] 
Alcohol    
Mostly 1.00 - 1.00 
Never                                  0.81[0.76, 1.11] - 1.02[0.95, 1.10] 
Smoke    
Never smoked                    1.00 - 1.00 
Previously            1.16[1.08, 1.24] - 1.14[1.05, 1.23] 
Currently              0.99[0.89, 1.11] - 0.98[0.87, 1.10] 
Physical function 0.99[0.98, 0.99] - 0.99[0.98, 0.99] 
Weibull shape parameter - 0.42[0.40, 0.43] 0.42[0.41, 0.43] 
-2logL - 11708 10606 
a Weibull model with patient-reported variables excluded, b Weibull model with patient reported factors included 
Unadjusted model = Individual variable in the model, Adjusted model = All variables included simultaneously 
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8.4 Discussion 
The aim of this analysis was to investigate if factors identified previously to be related to 
switching in an incident MSK consulting group (Chapters 6 and 7) are also the key factors 
associated with switching in a prevalent and older aged MSK consulting group, and to 
determine the importance in the switching process of initial patient-reported factors. The 
common factors associated with switching between incident and prevalent MSK groups 
were age, gender, previous prescribed analgesia, initial analgesia (weak and strong 
analgesia) prescribed and number of MSK consultations. They were associated with 
switching to stronger analgesia as well as any switch. In contrast to the incident group, co-
morbidity was a significant factor in this older aged prevalent group, while the level of 
deprivation and the number of prescribed analgesia were significant only in the incident 
group. 
 The significant patient-reported factors in the presence of socio-demographic and clinical 
factors were using over the counter medication, BMI (obesity or overweight), pain 
interference, inadequate access to GP, smoking history and level of physical function. 
Smoking history was associated with increased risk, while better physical function was 
also associated with reduced risk of switching to stronger analgesia, or having any switch. 
Inadequate access to GP increased the risk of switching taking into account multiple-
switches, while obesity or overweight increased the risk of stronger opioid switch. 
The analysis in this population of prevalent MSK consulters aged 50+ identified common 
factors, but also some differences to the incident population (Chapter 6 and 7). The 
variations might be partially explained by that in the CiPCA analysis, only new episode 
MSK consulters aged 15+ were considered, while the analysis in this chapter included 
consulters aged 50+ who may have on-going or new MSK episodes and may be well into 
an episode of care. The original intention was to investigate new consulters but there were 
inadequate number of cases in this population. Table 8.3.1 summarises variables 
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associated with switching in this analysis (prevalent) as well as those in the incident 
cohort analysis. 
This analysis also brings out some variables as associated with the risk of switching 
analgesia that were not in the previous analysis, for example comorbidity associated with 
an increased risk of switching analgesia and initially prescribed moderate analgesia 
associated with reduced risk of switching analgesia. While the datasets are different by 
age and other baseline factors, it is not entirely clear why this is happening, but can only 
be postulated where possible. 
The existence of select comorbidities makes the management of chronic pain a difficult 
proposition, particularly in the older aged. For example in the presence of cardiovascular 
and kidney diseases, clinicians have to be cautious and assess absolute risks with 
medications such as NSAIDs (Adam et al., 2011) and stronger analgesia use (Boulanger 
et al., 2011).  It is possible that in attempting to alleviate pain whilst avoiding causing 
adverse effects clinicians try to balance the associated risks of medication and the need to 
control the impact of pain, but the level of pain the patient is experiencing may dictate the 
use of and switching to stronger analgesia.  
The prescription of opioids does not necessarily result in improved outcomes (Ashworth et 
al., 2013), which implies that switching to stronger analgesia may not necessarily bring 
about statistically significant improvement on the patient’s condition even if the switch to 
stronger opioids is a better alternative to the previous analgesia. The initial prescription of 
moderate analgesia was associated with a very low risk of switching in this older-aged 
population, if a patient’s condition is not improving when initially prescribed moderate 
analgesia, there is not many choices to switch to.  
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Table 8.4.1: Summary of factors associated with switching analgesia  
 Prevalent cohort Switching 
(NorSTOP) 
Incident cohort (CiPCA) 
Switching 
Variable To strong 
analgesia 
Multiple-event 
Switching 
To strong 
analgesia 
Multiple-event 
Switching 
Age     
50-59                                      - - - - 
60-69                                      No No Yes>a Yes>a 
70-79                                      No No Yes>a Yes>a 
80+                                         <Yes <Yes Yes>a Yes>a 
Gender     
Males                                  - - - - 
Females                                    Yes> Yes> Yes> Yes> 
Previous prescribed 
analgesia 
    
No - - - - 
Yes Yes> No Yes> Yes> 
Deprivation     
Most                                        - - - - 
Medium                                   No Yes> <Yes <Yes 
Least                                       No No No <Yes 
Region of Pain     
Back                                          - - - - 
Knee                                        No No No No 
Hip                                           No No No Yes> 
Foot/ Ankle                        No No No No 
Hand/limb                     No No No <Yes 
Shoulder                                 No No No <Yes 
Neck                                       No Yes> No No 
Co-morbidity     
Other /none           - - - - 
Select-conditions               Yes> Yes> No No 
Initial analgesia     
No medication - - - <Yes 
Basic analgesia  - - - - 
Weak analgesia Yes> Yes> Yes> Yes> 
Moderate analgesia   - No - No 
Strong analgesia - Yes> - Yes> 
No. of MSK 
consultations 
<Yes <Yes <Yes <Yes 
No. of Prescriptions No <Yes Yes> Yes> 
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 Prevalent cohort Switching 
(NorSTOP) 
Incident cohort (CiPCA) 
Switching 
Variable To strong 
analgesia 
Multiple-event 
Switching 
To strong 
analgesia 
Multiple-event 
Switching 
Patient-reported     
OTC medication     
None                                      - - - - 
Painkillers                              No No NM NM 
Glucosamine No Yes> NM NM 
Pain interference     
None                                    - - - - 
Yes                    No Yes> NM NM 
BMI     
Normal                                  - - - - 
Overweight /obese                                 Yes> No NM NM 
Widespread pain     
No                                         - - - - 
Yes                                       No <Yes NM NM 
GP Access     
Yes                                    - - - - 
No                                        Yes> Yes> NM NM 
Smoke     
Never smoked                    - - - - 
Previously            Yes> Yes> NM NM 
Currently              No No NM NM 
Better Physical function <Yes <Yes NM NM 
No= non-significant, <Yes=decreasing risk of switching, Yes>=increasing risk of switching, Reference category= -, Not part 
of model =NM, a = CiPCA age categories different to NorSTOP 
The significance of patient-reported factors which resulted in an improved model fit 
reinforces the fact that patient input may be essential in GPs considerations prior to 
deciding whether to prescribe analgesia and what potency level, and can influence the 
clinicians’ perception of pain level (Chapter 4). They added further knowledge about 
factors associated with prescription patterns and switching to stronger analgesia, but the 
importance of the socio-demographic and clinical factors identified from medical records 
previously (Chapter 6 and 7) are not overshadowed as they remain statistically important 
factors. 
 Physical function tends to deteriorate with age (Clifton et al., 2011) implying that older 
age group will have lower physical function levels, and as seen in previous chapters, the 
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elderly with MSK are more likely to be prescribed stronger analgesia (chapter 4), and 
once MSK conditions manifest themselves, they may be life-long and get worse with age 
with increasing levels of pain leading to a poor prognosis (Sarzi-Puttinni et al., 2012). 
Clinicians’ may switch to stronger analgesia to improve or maintain physical function 
levels.   
Access to the GP is essential in the management of MSK conditions as the effectiveness 
of therapies can be fully realised through frequent re-evaluation of the cause of the 
chronic pain and its impact on the general physical, emotional as well as the medical state 
of the patient (Kean, et al., 2008). The management of MSK conditions should be tailored 
to individual needs (Bergbom et al., 2011) and should address issues of knowledge, 
beliefs and coping with pain (Brown et al., 2010; Ryan et al., 2007). The more access to 
clinicians and medical staff patients have through increased consultation schedules, the 
more likely these issues are to be met. This concurs with the fact that increased rates of 
consultation and having good access to the GP over time appears to reduce the risk of 
switching to stronger analgesia. 
Smoking history was associated with increased risk of switching analgesia, while 
overweight or obesity was associated with switching to stronger analgesia. A study by 
(Green et al., 2012) also found that smoking and obesity was associated with the 
prescription of opioids in adults aged 50 and above. Smoking and obesity are associated 
with poor health outcomes, and poor health outcomes increase reliance on professional 
medical help, hence the prescription of stronger analgesia to alleviate pain may be 
deemed necessary. Loss of excess weight is a recommended step in the non-
pharmacological treatment of MSK pain (Brown et al., 2010). Obesity usually coincides 
with multi-morbidity which might mean elevated levels of pain in the presence of MSK. 
An aim of this analysis was to help determine the generalizability and limitations of the 
statistical models derived in Chapter 6 and 7. It has shown that baseline socio-
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demographic and clinical factors identified as associated with switching analgesia in an 
incident MSK group are also generally important in a prevalent MSK group even with the 
inclusion of patient reported factors. The statistical models derived in this analysis and the 
previous chapters can be generalized to both prevalent and incident MSK groups, with the 
exception of frailty models. As suggested in Chapter 6, frailty attempts to account for 
unmeasured variables, hence with a larger number of variables, frailty ceased to be 
important. 
The significance of patient-reported factors suggests patients contribute to the prescription 
of analgesia in the management of MSK conditions. This suggests that the 
pharmacological management of MSK conditions is multifaceted, taking into account 
socio-demographic, clinical and patient-reported variables, and not just about clinicians 
following prescription guidelines.  
This analysis concurs with the previous analysis, that is, there are factors that can be 
controlled to reduce the risk of switching analgesia in general and switching to stronger 
analgesia, for example improving access to GPs, increasing consultation frequency in risk 
groups and reduction of levels of obesity. Reducing the risk of switching to stronger 
analgesia implies reducing the risk of exposure to a wide spectrum of adverse effects of 
analgesia. 
However, the results should be interpreted with due consideration of the study limitations. 
The main limitation is that there was a large number of variables adjusted for in the 
models with a relatively smaller sample size, which may have affected the statistical 
significance of some variables. The sample size also limits analysis options that may 
further help in interpreting the results, for example, with a larger sample size; the factors 
associated with switching from individual potency levels could be explored. For example 
the fact that there was no one switching from basic analgesics may be attributed to the 
small number that was prescribed basic analgesia on initial consultation in this cohort. It is 
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still possible that despite the large number of variables, unmeasured important variables 
may still exist. The other limitation is that participants with missing data were excluded 
from the final models. However sensitivity analysis, imputing the extremes of the missing 
variables did not significantly affect the results of the final model, and the excluded 
participants were not very different from the entire cohort by gender composition and age. 
 In comparison to the chapter 6 and 7 analyses, there are variations in follow-up time (5 
years versus 3 years) and the composition of the cohorts by age and gender. However 
despite these variations similar factors were identified as associated with switching 
analgesia which suggests the studies complement each other, hence despite the 
limitations, the findings may be generalized to a larger population. 
8.5 Conclusion 
The findings showed that the socio-demographic, clinical as well as patient-reported 
factors are associated with the analgesia switching process. Despite the differences 
between the MSK incident and prevalent groups there are common factors identified, 
which validate findings seen in Chapter 6 and 7.  An insight in the impact of the switching 
processes on the outcomes of patients will be provided by the next chapter which 
evaluates how switching impacts on changes in physical function and pain interference 
over time. The strengths and limitations of this chapter are discussed further in the next 
chapter as the two chapters are interlinked. 
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Chapter 9 
9 The association of switching patients’ analgesia with long term 
physical function and pain interference 
9.1 Introduction  
The previous chapters identified that the time to switching of prescribed analgesia and the 
use of varying analgesia potency in the treatment of MSK conditions is associated with 
socio-demographic and clinical variables, as well as variables that may reflect on the 
lifestyle or quality of life of the patients. For example, low physical function may represent 
a person’s diminished quality of life due to limitations in one’s ability to perform their day to 
day activities without feeling pain.  
The main types of switching following the initial MSK consultation examined were: 1) 
progressing to stronger analgesia, 2) any switching of analgesia which may include 
multiple switches over time. It is assumed that the predominant reason to switch to 
stronger analgesia is necessitated primarily by the need to control pain (Mercadante and 
Bruera, 2012), since stronger analgesia is needed.  Switching should aim to improve the 
quality of life among MSK pain sufferers, which for example may be signified by improved 
physical function levels and less pain interference with daily activities.  
Switching analgesia is an integral aspect of managing long-term MSK, but what the 
medium to long term impact of switching on controlling pain and improving quality of life is 
uncertain. It is assumed that stronger analgesia are more likely to be effective but also 
more likely to yield side effects (Kean et al., 2008). However there is not enough evidence 
to suggest that the use of stronger analgesia might in the long run be beneficial, as 
demonstrated in a study by Ashworth et al. (2013) evaluating the association of prescribed 
stronger analgesia at baseline and self-reported disability. That study found that being 
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prescribed stronger analgesia was associated with increased Self-reported disability at six 
months follow-up, but it was also noted that there were baseline differences in those 
prescribed stronger analgesia and those who were not, suggesting that the prescription of 
stronger analgesia alone may not be entirely indicative of self-reported future disability.  
This chapter concerns the estimation of the association of switching with future quality of 
life taken into account confounding factors. The quality of life is measured by level of 
physical function, and pain interference. A lower level of physical function suggests that 
the patient has increased levels of physical disability which may be a consequence of 
pain, while pain interference implies that their pain directly limits the activities they can 
perform in executing their daily routines.  
The aim of this chapter was to model the association between switching to stronger 
analgesia, and any switching, with changes in physical function and pain interference.  
The objectives of the chapter are: 
1. To investigate whether progressing to stronger analgesia within 3 years is linked to 
reduced reporting of pain interference and reporting improved physical function at 
the end of the 3 year period, 
2. To investigate whether an increasing number of analgesia switches within 3 years 
is linked to reporting reduced pain interference and improved physical function at 
the end of the 3 year period. 
9.2 Methods 
The chapter investigates if switching to stronger analgesia or an increasing number of 
switches improves the quality of life among patients with MSK problems. However it is 
unrealistic to assume that there are no confounding factors.  Confounding factors, i.e. 
those believed to be associated with both switching and quality of life, therefore need to 
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be adjusted for. This was performed here by using a propensity score approach (see 
statistical methods section 9.2.2.1). 
9.2.1 Data management and study population 
The participants in this chapter were drawn from the North Staffordshire Osteoarthritis 
Project (NorStOP) using the inclusion criteria described in Chapter 8. This was a cohort of 
1610 adults aged 50 years and over registered with 6 general practices. The patients 
included in this analysis are those who consulted for a MSK condition within 6 months of 
the baseline survey date and had received no prescribed analgesia in the 28 days prior to 
the baseline survey (Chapter 8).  All 1610 participants were used in modelling the effect of 
an increased number of analgesia switches, but only the 1309 (81%) who were initially 
prescribed no medication, basic analgesia and weak analgesia were used to determine 
the effect of switching to stronger analgesia on quality of life outcomes.  
Patient Variables 
The baseline variables investigated for association with time to switching in Chapter 8 
were considered as confounders (that is potentially related to switching and the outcome 
variables). The factors considered were age, gender, deprivation, co-morbidity, region of 
pain (e.g. knee, back), previous MSK consultation and prescription history before baseline 
survey, marital status, body mass index (BMI), alcohol consumption, smoking history, 
depression, GP access, baseline pain interference, baseline physical function level, 
existence of widespread pain and reporting over the counter medication. These variables 
were selected as they were associated with switching analgesia either in the unadjusted 
models and/or when adjusted for the other variables (Chapter 8). The variables are as 
described in Chapter 8.  
 
 
208 
 
9.2.1.1 Outcome variables 
The outcome variables were physical function score and pain interference measured at 
the 3 year survey. Physical function was considered as continuous, measured using the 
SF-36 Physical Function subscale with scores ranging from 0 (worst physical function) to 
100 (best). Pain interference was an item from the SF36 measured using the question on 
how pain interferes with daily activities. The question was: “During the last 4 weeks, how 
much did pain interfere with your work (including both work outside the home and house 
work)” and the response choices were; not at all, a little bit, moderately, quite a bit and 
extremely. The ratings were combined into a binary variable, 1 represents existence of 
moderate/quite a bit/extreme pain interference and 0 for no/little pain interference as 
previously defined (Jordan et al. 2008; Thomas et al., 2004).  
9.2.2 Statistical methods 
The potentially confounding effects of the baseline socio-demographic and clinical factors 
were adjusted for though the use of propensity scores as detailed in Section 9.2.2.1 
below. Initially, analyses exploring the relationship between switching analgesia and 
individual baseline variables (unadjusted models) were carried out to illustrate the 
importance of each of the variables in estimating the propensity scores. The propensity 
scores were then estimated using a logistic model adjusting for all baseline variables at 
the same time.  
The propensity score is a measure of the likelihood or propensity of someone to switch 
given their baseline characteristics.  Briefly, in the first stage logistic regression models 
with switching as the outcome were used to calculate the propensity scores for each 
patient within the context of the type of switch. The outcomes for these first stage logistic 
regression models were: 1) progressing to stronger analgesia and 2) any analgesia switch 
(for the purpose of modelling the effect of number of switches of analgesia). 
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When analysing the association of number of switches with 3-year outcomes, the 
propensity to switch to any analgesia was first identified.  The choice to use the propensity 
to switch to any analgesia is based on the assumption that the factors associated with 
further switches are likely to be similar to those of the first switch.  
In the second stage, the propensity scores for each individual were included as an 
independent variable in the final models modelling the association of switching analgesia 
with 3 year pain interference and physical function.  
9.2.2.1 Propensity score model 
Propensity scores are a statistically efficient method of adjusting for multiple baseline 
factors (confounders) potentially associated with both switching analgesia and physical 
function and pain interference. In this case it estimates the probability of an individual 
switching analgesia given their baseline characteristics (Cameron and Trivedi, 1998; 
Becker and Ichino, 2002). It enables the individual effects of the confounding variables to 
be collated into a single variable (the propensity score) in the final model.  
Using the example of switching from no analgesia, basic analgesia or weak analgesia to 
stronger analgesia within a three year period from baseline survey, the propensity score 
 (  )  can be defined as the conditional probability for individual   of switching to stronger 
analgesia given their vector of patient covariates (baseline characteristics)    recorded at 
the time of the baseline survey;  (  )    (           )  
Where          indicates switching to stronger analgesia occurred, and 0 if not 
(D’Agostino, 1998).  The assumption is that including this propensity score in the model 
efficiently adjusts for the likelihood of switching and hence should reduce confounding by 
these observed covariates (Rubin, 2001). This effectively collates the effects of the 
individual baseline variables into a single measure (propensity score) for each individual. 
The propensity scores were estimated using two separate logistic regression models with 
each of the two types of switch (i.e. stronger analgesia switch and any analgesia switch) 
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as the outcome variables and the baseline variables as explanatory covariates. Once 
propensity scores have been estimated, checks should be performed that those who 
switch and those who do not switch but have similar propensity scores are comparable 
(balanced) on the baseline characteristics. If not, the propensity scores need to be re-
estimated which may include interactions of the “offending” variables which are not 
balanced (D’Agostino, 1998).  
Balancing implies that conditional on the propensity score, the distribution of the 
measured baseline characteristics is similar between patients who switched and those 
who did not switch analgesia. The statistical modelling steps to establish the propensity 
(probability) to switch analgesia for each switching scenario can be summarised as:  
1. Fit the logistic model with switching as the outcome and all potential confounders 
included as explanatory variables. 
2. Determine propensity score for each individual (i.e. probability of switching given 
their baseline characteristics) from the fitted logistic regression model 
3. Split the sample into   equally spaced intervals (subclasses) of the propensity 
scores to assemble   groups. Within each group the distribution of covariates 
should be balanced between those who switched and those who did not. Balance 
of covariates within groups allows the attribution of any observed difference in 
outcomes to be the effect of switching rather than differences in observed 
covariates. Five or six intervals (subclasses) are usually used initially (Rubin 
2001), and this analysis used the software default staring number of intervals,  =5. 
4. Test (through uses of t-tests) that the mean propensity score of those who 
switched and those who did not are not different within each interval (balanced), 
and that the ratio of the variances of the propensity score in those who switched 
and those who did not is close to one (F-test). If the test fails, return to step 3 to 
change the number of intervals (for example, from  =5 to  =6), and test again.  
211 
 
5. If the tests fail within an a priori set number of intervals (usually up to 10) (Rubin 
2001), consider including interactions of the variables or higher order terms in the 
logistic model and repeat the process outlined. 
The propensity score estimation steps above can be user specified or executed by default 
by the statistical package Stata (Becker and Ichino, 2002). The default execution by the 
statistical package was used in this analysis.  
Propensity score matching 
After derivation of propensity scores, the next stage was to match patients who switched 
analgesia to those who did not   switch but had closely similar propensity scores (Rubin, 
2001). Propensity score matched sets mimic randomisation in that those who switch can 
be assumed to be similar to those who did not switch, by baseline characteristics, such 
that the difference between the two group outcomes is largely attributed to the effect of 
switching analgesia. 
There are several approaches to matching propensity scores, but this analysis used the 
nearest-neighbour matching technique. In the matching process, each individual who 
switched analgesia is paired with one or more comparable (in terms of propensity score) 
individuals who did not switch analgesia within the same interval from the final logistic 
regression model (where balance was achieved). A more detailed statistical description of 
the propensity score model and matching approaches are described by Becker and Ichino 
(2002) and Rubin (2001).  
The nearest-neighbour matching technique (the closest propensity scores within the 
interval)  has the advantage that it can be used with and without replacement, such that it 
allows a many to one matching, all switched individuals hence find at least one match 
(Becker and Ichino, 2002).  
The matched propensity scores were used as a covariate adjustment (Rubin, 2001). This 
means that a sub-sample consisting of patients who switched analgesia and those who 
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did not with similar propensity score were used in the regression model. Those who did 
not switch and were not matched with those who switched in terms of propensity scores 
were excluded in the regression model. The outcome variables (physical function and pain 
interference) were regressed on the binary variable indicating switching status and the 
matched propensity scores as described in the next sections. 
9.2.3 Modelling the effect of switching to stronger analgesia  
The binary logistic regression model was used with pain interference at 3 years as the 
outcome variable. The unadjusted model considered only the switch binary variable 
(switch=0 or 1) as the independent variable and the adjusted model included the matched 
propensity scores in addition to the switch variable as the independent variables. 
The linear regression model was used to examine the association between physical 
function at three years and switching to stronger analgesia. As in the logistic model, the 
unadjusted model considered only the switch binary variable as the independent variable 
and the adjusted model included the matched propensity scores in addition to the switch 
variable as the independent variables. 
9.2.4 Modelling the effect of multiple switches  
 As in section 9.2.3, the binary logistic regression model was used with pain interference 
at 3 years as the outcome variable. The unadjusted model considered only the number of 
switches as a continuous variable (number of switches=0, 1, 2 …) as the independent 
variable, and the adjusted model included the matched propensity scores in addition to 
the number of switches as the independent variables.  
Linear regression model was also used to examine the association between physical 
function at three years and number of analgesia switches. The unadjusted model 
considered only the number of switches as the independent variable and the adjusted 
model included the matched propensity scores in addition, as the independent variables. 
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9.3 Results 
9.3.1 Data description 
The baseline characteristics of the patients included in this analysis are described in 
Chapter 8.  
For evaluating the association of switching to stronger analgesia with 3 year outcomes, 
1309 patients on lower potency analgesia at baseline were included. Of these, 13% 
switched to strong analgesia within 3 years and prior to follow up survey date. At 3 year 
follow-up, their mean physical function score of those who switched was 42 (SD 30.2) 
compared to 61 (SD 29.3) for those who did not switch.  
The proportion of those switching who reported pain interference at 3 years was 70% 
compared to 42% of those who did not switch. The mean physical function scores for 
those who switched to stronger analgesia were lower than those who did not switch at 
both baseline and 3 year follow-up. For those who switched, the mean scores were 
slightly lower at follow-up (baseline 44 (SD 30.4) vs follow-up 42 (SD 30.2)). 
The prevalence rates of reporting pain interference were lower for those who switched 
than those who did not at both baseline and follow-up. Of those who switched, the 
prevalence rate at follow-up was slightly lower than the baseline rate (Table 9.3.1 and 
Table 9.3.2). 
1610 patients were included in the analysis assessing the association of an increasing 
number of switches with three year outcomes. Of these, 28% had at least 1 any analgesia 
switch. At 3 year follow-up, the mean physical function scores for those who switched to 
any analgesia was 48 (SD 30.4) compared to 66 (SD 28.0) for those do did not switch. 
The proportion of those switching who reported pain interference at 3 years was 63%, 
compared to 34% of those who did not switch.   
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Table 9.3.1: Mean follow-up and baseline physical function scores by type of switch 
 Baseline Scores  3 year Follow-up Scores 
 Switched Did not Switch Switched Did not Switch 
Switch type n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) 
Any analgesia 449 50 (30.8) 1161 65 (28.8) 449  48 (30.4) 1161  66 (28.0) 
Strong Analgesia 169 44 (30.4) 1140 61 (29.9) 169  42 (30.2) 1140  61 (29.3) 
Table 9.3.2: Baseline and follow-up pain interference by type of switch 
 Baseline pain interference  3 year Follow-up pain interference 
 Switched Did not Switch Switched Did not Switch 
Switch type n Yes (%) n Yes (%) n Yes (%) n Yes (%) 
Any analgesia 449 65 1161 43 449 63 1161 34 
Strong Analgesia 169 70 1140 50 169 70 1140 42 
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The mean physical function scores for those who switched to any analgesia were lower 
than those who did not switch at both baseline and 3 year follow-up. For those who 
switched, the mean scores were slightly lower at follow-up (baseline 50 (SD 30.8) vs 
follow-up 48 (SD 30.4)).  
A similar trend to those switching to stronger analgesia in the mean physical function 
scores was observed, but the prevalence rates of reporting pain interference were similar 
at baseline and follow-up in this cohort (Table 9.3.1 and Table 9.3.2). 
9.3.2 Derivation of propensity scores  
The baseline factors used to estimate propensity scores for any analgesia switch and 
strong analgesia switch were older age, female gender, co-morbidity, previous medication 
history, consultation history, over the counter medication use, depression, pain 
interference, smoking history, married, less deprivation, pain location, rare or no alcohol 
consumption and physical function. The unadjusted association of the variables with 
switching were evaluated to illustrate their individual importance before using them in an 
adjusted model to estimate the propensity scores (Table 9.3.3). 
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Table 9.3.3: Unadjusted logistic models of baseline variables with switching as the 
outcome 
 
Variable 
Unadjusted Logistic models 
Odds Ratio -  OR [95% CI] 
 Any analgesia 
switch 
Strong Analgesia switch 
Age   
50-59                                      - - 
60-69                                      1.30[1.02, 1.67] 1.27[0.95, 1.78] 
70-79                                      1.67[1.28, 2.18] 1.60[1.13, 2.27] 
80+                                         1.99[1.42, 2.79] 1.34[0.86, 2.09] 
Gender   
Males                                  - - 
Females                                    1.29[1.05, 1.57] 1.50[1.15, 1.974] 
Married   
No                                        - - 
Yes                                           0.66[0.53, 0.82] 0.68[0.52, 0.90] 
Deprivation   
Most                                        - - 
Medium                                   1.01[0.82, 1.24] 0.89[0.68, 1.16] 
Least                                       0.64[0.46, 0.90] 0. 55[0.34, 0.91] 
Region of Pain   
Back                                          - - 
Knee                                        0.63[0.43, 0.92] 0.97[0.57, 1.63] 
Hip                                           0.67[0.49, 0.93] 1.11[0.71, 1.73] 
Foot/ Ankle                        0.70[0.48, 1.01] 1.01[0.61, 1.69] 
Hand/limb                     0.72[0.49, 1.06] 1.00[0.59, 1.70] 
Shoulder                                 0.86[0.59, 1.24] 1.50[0.93, 2.43] 
Neck                                       0.69[0.48, 1.03] 1.38[0.86, 2.21] 
Co-morbidity   
Other /none           - - 
Selected conditions               1.31[1.07, 1.60] 1.80[1.38, 2.33] 
Previous analgesia prescription   
No                                         - - 
Yes                                       5.24[4.21, 6.53] 3.35[2.47, 4.53] 
Previous musculoskeletal consultation   
No                                       - - 
Yes                                          4.31[1.64, 11.2] 1.95[0.59, 6.49] 
Widespread pain   
No                                        - - 
Yes                                       1.24[0.96, 1.61] 1.20[0.86, 1.67] 
OTC medication   
None                                      - - 
Creams/ Painkillers                              2.32[1.71, 3.16] 2.07[1.34, 3.19] 
Glucosamine                          1.94[1.41, 2.65] 1.48[0.95, 2.32] 
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Variable 
Unadjusted Logistic models 
Odds Ratio -  OR [95% CI] 
 Any analgesia switch Strong Analgesia switch 
BMI   
Normal / Underweight                             - - 
Obese/ Overweight                            1.05[0.85, 1.29] 1.20[0.91, 1.59] 
Unknown                                  1.41[0.84, 2.36] 1.51[0.80, 2.84] 
Depression   
No                                         - - 
Yes                                    1.65 [1.28, 2.13] 1.78[1.31, 2.41] 
Pain interference   
None                                    - - 
Yes                  2.39 [1.95, 2.93] 2.42[1.83, 3.20] 
GP Access   
Yes                                    - - 
No                                        0.98[0.69, 1.40] 1.19[0.76, 1.85] 
Alcohol   
Sometimes/mostly - - 
Rarely/Never                                  0.75[0.62, 0.92] 0.77[0.59, 1.00] 
Smoke   
Never smoked                    - - 
Previously smoked             1.24[1.01, 1.54] 1.52[1.14, 2.02] 
Currently smoking 1.22[0.90, 1.67] 1.32[0.87, 2.00] 
Physical function 0.98[0.97, 0.99] 0.98[0.97, 0.98] 
Unadjusted model = Individual variable in the model 
For propensity score estimation for stronger analgesia switching, balancing was achieved 
with 6 intervals (  =6) and the propensity scores were estimated. The mean propensity 
score (probability to switch to stronger analgesia) was 0.17 (range 0.01 to 0.61) with a 
standard deviation of 0.11.  
For propensity score estimation of switching to any analgesia, balancing was achieved 
with 7 intervals ( =7). The mean propensity score was 0.45 with a standard deviation of 
0.21 (range 0.08 to 0.84).  The analysis used the Stata software default starting value of 
number of intervals ( =5) and balancing was achieved without need to include 
interactions. 
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9.3.3 The effect of switching to stronger analgesia on reported physical function 
and pain interference 
Switching to stronger analgesia was associated with increased risk of reporting pain 
interference at 3 years follow-up. In The unadjusted odds ratio (OR) for the association of 
switching to stronger opioids on pain interference at 3 years was 3.20 with 95% CI [2.22, 
4.58]. After adjustment for propensity score, the OR fell to 1.50 [1.01, 2.27], but the 
association of switching to stronger opioids with pain interference remained statistically 
significant. The adjusted odds ratio was much smaller than the unadjusted coefficient, 
suggesting there was some confounding. 
The unadjusted association of switching to stronger analgesia with 3 year physical 
function scores was statistically significant (coefficient -19.4; 95% CI -24.33, -14.63) but 
after adjusting for propensity scores, it was significant only at the 10% level (coefficient -
4.35[-9.09, 0.39]). Switching was associated with a reduction in the mean physical 
function score of 4.35 points on the 0-100 scale.  
9.3.4 The effect of increasing number of analgesia switches on reported physical 
function and pain interference 
Both the unadjusted analysis (OR 1.37; 95% CI 1.27, 1.48) and the adjusted analysis, 
(OR 1.17; 95% CI 1.08, 1.27) suggest that an increasing number of switches of analgesia 
over the follow-up period was associated with increased risk of reporting pain interference 
at 3 year follow-up. That is, for the adjusted OR, a unit increase in the number of switches 
is associated with a 17% increase in the odds of reporting pain interference. 
The unadjusted coefficient for the association of number of switches with the physical 
function score was (-4.12 [-4.85, -3.39]). This remained statistically significant after 
adjusting for the propensity scores (coefficient -2.11[-2.90, -1.33]). A unit increase in the 
number of analgesia switches before 3 year follow-up is associated with just over a 2 unit 
reduction on the physical function score at follow-up. 
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9.4 Discussion 
Switching to stronger analgesia and multiple switching of analgesia within a three year 
period was significantly associated with patient-reported pain interference at the end of 
the 3 years. The results also showed that patients with an increased number of switches 
to any analgesia were more likely to report worse physical function. However, there was 
less evidence of an association between switching to stronger analgesia and physical 
function. To my knowledge, this is the first analysis of the effect of switching analgesia 
within general MSK conditions and other chronic pain settings.  
The switching between opioid analgesia can sometimes be a calculated move by 
clinicians as opioid rotation is an effective strategy in the management of opioid adverse 
effects (Joseph et al., 2009), as suggested in Chapter 7. While not all potential benefits of 
stronger analgesia switching are assessed in this research (for example, pain relief and 
ability to return to work), the analysis presented here suggests that switching to stronger 
analgesia prescriptions does not improve physical function or pain interference. However 
unmeasured confounding (discussed further below), for example interaction of 
medications or patient adherence to dosage instructions, may have an effect on the 
conclusions drawn from the results. It is possible that those who switch to stronger 
analgesia have a very poor prognosis which may be even worse without switching to 
stronger analgesia. The fact that the explicit reasons for switching to stronger analgesia 
are not known makes it difficult to rule out the benefits of stronger analgesia switches. 
GPs attempt to alleviate the pain their patients experience, but realistically are at best 
likely to gain some limited control over the painful condition, whilst in some instances will 
effect no improvement at all. As a part of this, switching to stronger analgesia might be the 
only feasible option available to them, but this choice is complex and analgesia use has a 
multifactorial aetiology (Fitzcharles et al., 2010). Their final selection of analgesia is more 
than just a balance between the need to control pain and the adverse effects.  What can 
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be said is that of those patients who do switch, they do not necessarily have significantly 
better outcomes.  
These findings seem to concur with findings in a study by Ashworth et al. (2013) which 
aimed to explore in patients with back pain in primary care, the relationship between 
prescribed stronger analgesia at baseline and self-reported disability at 6 months follow-
up. That study also found that being prescribed stronger analgesia at baseline was not 
associated with improved outcomes at follow-up.  These findings also seem to be related 
to the findings of the study by Franklin et al. (2008). That study examined whether 
prescription of stronger analgesia within 6 weeks of low back injury is associated with 
work disability at 1 year and found that the prescription of stronger analgesia for more 
than 7 days for workers with acute back injuries is a risk factor for long-term disability. 
This suggests that levels of disability due to chronic pain are not necessarily alleviated by 
prolonged use of opioids. 
The findings of this thesis also highlight the need for further investigation of the long-term 
consequences of switching to stronger analgesia as the effect of switching to stronger 
analgesia on patient outcomes are not conclusive. The results appear to suggest that 
identifying those patients with the highest chances of switching from the onset of medical 
care, and monitoring them closely through rigorous consultation as well as prolonged use 
of alternative medication may be the way forward (as discussed in Chapters 7 and 8).  
Multiple switches may be an indication of less stable conditions or patients’ susceptibility 
to the adverse effects of analgesia. Consequently the relief brought about by the 
prescribed analgesia is only short term because of a deteriorating condition, or the change 
in analgesia becomes necessary to alleviate adverse effects. The findings of this study 
suggest that quickly switching to the next available option which may lead to multiple 
switches later does not always produce the desired effects on the patients’ physical 
function and their perception of pain interference. 
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The strength of this analysis was the use of propensity scores to adjust for confounding. 
The use of propensity scores to adjust for multiple potential confounders is more efficient 
than the conventional regression techniques adjusting for multiple covariates (Rubin, 
2001). This leads to reduced bias through the matching of those who switched and those 
who did not, leading to more precise parameter estimates compared to using all baseline 
variables which may result in unreliable parameter estimates due to sparse data resulting 
from too many variables (Rubin, 2001).  
The propensity scores of those who switched to stronger analgesia and those who did not 
switch were adequately balanced, meaning that adjusting for propensity to switch makes 
those who switched and those who did not, statistically comparable to each other, while 
reducing the number of variables in the final model.  
A limitation of our analysis is that is it mixes people who always switch upwards in 
potency, those who switch downwards and those who move up then down which may be 
assumed to indicate different reasons for switching. The other limitation is that the 
analysis considers the propensity to switch to any analgesia then evaluates the impact of 
multiple switches on the 3 year patient outcomes. However we are concerned with 
switching as a marker of a changing clinical situation, worse or better, and as such allows 
us to examine those factors which predominantly influence this process. This allows us to 
inform doctors of patient characteristics they might need to be aware of when prescribing 
for patients, such that they might seek to limit the need to switch analgesia and avoid the 
unnecessary exposure of patients to unwanted adverse events that might drive the 
process of switching even further.  
Physical condition and pain levels can change considerably over a three year period and 
the measurement at 3 year follow-up may be sometime after the switch occurred. Further, 
the presence of a prescribed stronger analgesia switch amongst the analgesia used over 
time could be an indication of the individuals’ declining physical function or the increase in 
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pain interference not as a result of the MSK condition but other co-morbidities. This could 
also be reflective of that this is an older aged group and findings may be different in 
younger age groups.  
Also as stated earlier, the other limitation is that there may be unobserved or unmeasured 
confounders which, if included in the estimation of propensity scores, may result in 
different propensity scores, and in turn result in a different adjusted association of 
switching with the patient outcomes. Further changes occurring after baseline may be 
more responsible for the switching, for example, the key associated variables with 
switching identified in previous chapters were the time-varying factors (e.g. number of 
consultations) which were not included in this analysis. However, the main aim was to 
adjust for the available baseline variables that are potential confounders, to investigate the 
effects of switching analgesia, and to flag patients at higher risk of switching based on 
baseline characteristics, such that clinicians may be aware of the indicative factors.  
The other limitations related to the above are that it is based on an older and prevalent 
cohort and patients who responded at both baseline and follow-up surveys, such that the 
results may be different in younger age groups, in patients with new MSK problems and if 
the non-responders at follow-up were included. 
9.5 Conclusion 
Switching analgesia will always be a fundamental component of the management of pain 
in MSK conditions, as indicated by the WHO guidelines (Ehrlich, 2003). However, this 
analysis suggests it may not improve long term patient outcomes. However, further 
research is necessary on the association of switching analgesia on changes in pain 
interference and physical function in MSK consulters.  The next chapter summarises the 
main findings of this thesis, the clinical and statistical implications as well as opportunities 
for future research in assessing long term pharmacological management of MSK 
conditions in primary care. 
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Chapter 10 
10 Discussion and Conclusion 
The aim of this thesis was to use robust statistical methods to evaluate current practices 
in the pharmacological management of MSK pain in primary care, explore and understand 
the pharmacologic, clinical and socio-demographic factors associated with switching 
analgesia, and to evaluate long term success or failure of analgesia switching. The study 
was designed to examine analgesia prescription patterns and associated patient 
characteristics in incident and prevalent MSK conditions, as well as reviewing and 
establishing appropriate statistical methods to model prescription data.  
This chapter briefly reviews the main findings of the thesis, what the findings add to the 
current knowledge of analgesia prescribing in the management of pain in primary care 
MSK conditions, and reflects on the statistical methodology used in modelling the 
prescription patterns. The clinical and methodological implications of the research to the 
treatment of MSK conditions and primary care medical research in general are explored, 
as well as possible future research.  
10.1 Summary of main findings 
This thesis has contributed to the knowledge base applying a categorisation of analgesia 
available in primary care (the HAC) to interpret the WHO analgesia prescription ladder in 
the management of MSK conditions, and findings  suggest current prescription practices 
reflect evidence of adherence to the WHO and NICE guidelines. Profiles of analgesia 
management over time can be identified from prescription data, which are associated with 
patient characteristics. Certain patient characteristics were consistently associated with 
the initial analgesia strength and switching to stronger analgesia over time. With regards 
to statistical approaches to modelling switching, the Weibull model appeared a preferable 
alternative to the Cox model for modelling time to switching. 
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10.1.1 Phase 1 - Statistical methods used in modelling medication switching: a 
systematic review  
The systematic review of statistical methods used in modelling medication switching in 
phase 1 of the thesis revealed that analysing factors associated with switching medication 
in general is increasing, but is less prevalent within the primary care setting and in MSK 
diseases. The most commonly used statistical approaches were the logistic regression 
model if switching is considered as a dichotomous switch / not switch outcome in a set 
period of time, and the Cox proportional hazards model when time to switch is considered. 
The reasons for using these approaches are generally not explicitly stated but can be 
inferred from study objectives. Parametric statistical methods like the Weibull model have 
not been used in switching medication analyses; hence their appropriateness and 
feasibility cannot be established from available literature. 
10.1.2 Phase 2 - Pain medications prescriptions issued at first MSK consultation 
The first analysis established that of 3236 new MSK consulters, 47% were not prescribed 
any analgesia at that initial consultation. Older patients and patients who have been 
prescribed any analgesia in the past (more than 12 months previously) were more likely to 
be prescribed analgesia on first consultation. The analgesia prescribed most frequently 
was NSAIDs followed by basic analgesia (e.g. paracetamol). Patients from medium or 
least deprived localities and patients experiencing pain in the hand or foot were less likely 
to be prescribed analgesia, and if they were, it was more likely to be less strong 
analgesia. There was variation by registered general practice in whether patients were 
prescribed analgesia, and the potency level prescribed. 
10.1.3 Phase 2 - Primary care pain medication profiles over five years: A latent class 
analysis (LCA) 
LCA was used to detect the presence of common analgesia prescription profiles over 5 
years in new MSK consulters. A three cluster model was identified as the best fitting 
model for the data. The basic analgesics or no medication cluster consisted of patients 
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who received mainly either no analgesia or basic analgesia throughout the five year 
period and a few who received a combination of basic analgesia and weak combination 
analgesia. Patients in this cluster were predominantly in the age group 15 to 29. No 
dominant region of pain, for example the back or upper limb was identified in this group.  
The NSAIDs cluster consisted of patients who were mostly prescribed NSAIDs. They were 
predominantly aged 45 to 59, were characterised by a having a higher proportion of 
males, and significantly more likely to have pain in the back and shoulder. Most had 
received pain medication on first consultation and had been prescribed some form of 
analgesia in the past. The oldest age groups (60-74 and over 75) were less likely to be in 
this cluster. The multiple-potency cluster contained patients who received three or more 
(more than 70% of the cluster) of the five potency levels (for example, basic analgesia, 
NSAIDs, moderate strength analgesia). This cluster had a higher proportion of females 
than males, higher proportions of people with pain in the back, hip and shoulder, and 
higher proportion aged 45-59 and 60-74 than the other clusters. The first cluster, those 
prescribed no medication or basic analgesia was the most common, while the third 
cluster, those prescribed multiple potency levels, was the least common.  
10.1.4 Phase 3- Modelling time to change of medication potency level among 
incident musculoskeletal consulters 
The objectives of this section were to compare the Cox and Weibull models in evaluating 
patient characteristics associated with switching to any analgesia, and switching from 
lower potency analgesia (no medication, basic analgesia and weak analgesia) to stronger 
analgesia. The gamma frailty extension to the Weibull models was explored. The concept 
of frailty is based on the heterogeneity amongst individuals, that is, not all individuals are 
the same due to the nature of their condition or through unmeasured covariates. The 
Poisson regression model was also used to model patient characteristics associated with 
rate of switching analgesia. It quantifies the rates of switching across covariates for the 
period under exposure 
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The parameter estimates of the Cox and Weibull models were similar but the Weibull 
models were the final preferred choice as they fitted the data better than the Cox models. 
Frailty was statistically significant in the time to first switch models (switching from initially 
prescribed analgesia to stronger analgesia), but not statistically significant in analysing 
multiple event switches using the Weibull model. 
The analysis highlighted both clinical and demographic factors associated with switching 
analgesia and the rates of switching. There was a higher risk, and increased rates of 
switching analgesia in general among the elderly, females, those prescribed pain 
medication in the past, those consulting for pain in more than one location over time, 
those starting medication with weak or strong analgesia and those with increasing number 
of prescriptions from their initial analgesia category over time. There is declining risk of 
switching with increasing number of MSK consultations, low deprivation and receiving no 
prescribed medication on first consultation.  
10.1.5 Phase 4 - Modelling time to change of medication potency level among 
prevalent older aged musculoskeletal consulters 
The objectives of this phase were to evaluate if the clinical and socio-demographic factors 
identified as associated with analgesia switching amongst incident MSK consulters were 
also associated in a prevalent and older MSK cohort, and also when further adjusted for 
patient reported factors. Further, to identify self-reported health and demographic factors 
not recorded routinely in primary care that are associated with switching analgesia. A 
linked medical record-survey dataset was used for this purpose. 
The common factors associated with time to switching analgesia for the incident and 
prevalent MSK groups were age, gender, previously prescribed medication, initial 
analgesia (weak and strong analgesia) prescribed and number of MSK consultations. In 
contrast to within the incident group, co-morbidity was a significant factor in the older aged 
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prevalent group, while the level of deprivation and the number of prescribed analgesia 
were significant only in the incident group.  
The patient-reported factors related to switching identified in addition to routinely recorded 
socio-demographic and clinical factors were: using over the counter medication, BMI 
(obesity or overweight), reporting interference from pain, inadequate access to GP, 
smoking history and worse physical function. Worse physical function was associated with 
slightly increased risk of switching to stronger analgesia, and switching taking into account 
all switches. Reporting inadequate access to GP increased the risk of multiple switches, 
while obesity or overweight increased the risk of stronger analgesia switch.  
10.1.6 Phase 4 - Impact of switching analgesia on 3 year pain interference and 
physical function level 
The objectives of this section were to investigate whether switching or progressing to 
stronger analgesia, and experiencing multiple switches within 3 years is linked to reporting 
reduced pain interference and improved physical function at the end of the 3 year period. 
Potential confounding by baseline variables was adjusted for through use of propensity 
scores. The analysis suggested that switching to stronger analgesia and multiple 
switching of analgesia within a three year period was significantly associated with more 
patient-reported interference from pain at the end of the 3 years. The results also showed 
that patients with an increased number of switches to any analgesia were more likely to 
report worse physical function. However, there was no statistical evidence of an 
association between switching to stronger analgesia and physical function. 
10.2 Strengths and limitations 
The findings of this thesis add to the knowledge of analgesia switching among MSK 
patients, but the findings need to be interpreted with due consideration of the strengths 
and limitations of the study. 
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The strength of the study lies primarily in that the main dataset used a high quality data 
set, CiPCA, which gives comparable consultation Figures for MSK problems as the larger 
national datasets (Jordan et al., 2007). The practices contributing data to CiPCA are 
trained and assessed in morbidity recording (Porcheret, 2004) and prescriptions are 
complete as clinicians have to use the computer to prescribe medication. The study is 
naturalistic in that it is based on real-world data, large sample size and uses an 
observational approach without pre-planned treatment changes over time.  
This study used a wide range of complementary statistical methods to thoroughly 
interrogate the data to highlight the prescription patterns of analgesia in MSK conditions in 
primary care before drawing conclusions from the results. For example, it used both the 
Cox and Weibull models before deciding on the approach most suitable in modelling 
switching.  
In multiple event switches the times between successive switches are known to be 
correlated which may lead to over inflated parameter estimates (Collet, 2003). However 
the time between event counting processes, employed in the analysis ensures that the 
correlation is accounted for. The use of the Poisson regression model to evaluate the 
rates of switching within the total exposure time identified factors associated with higher 
rates of switching are similar to factors associated with any switching when taking into 
account all switches from the Cox and Weibull models. The Poisson model validated that 
the factors identified are indeed associated with multiple switches of analgesia. The study 
lays a foundation for further research in future in the evaluation of prescription patterns 
and switching of analgesia through its clinical findings and successful application of 
statistical methods that have not been used before within the context of MSK condition. 
Some of the clinical findings of the thesis on time to switching initially prescribed analgesia 
are comparable to the study by Gore et al. (2012). The Gore study modelled factors 
associated with therapy switching, and used The Health Improvement Network (THIN) 
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database, which is a medical research database of anonymised patient records. The 
database contains data from 429 practices across the UK and 7.7 million patients. The 
Gore study found that most switches from initially prescribed therapy occur within the first 
100 days and also identified that the patients who were initially prescribed weak analgesia 
and strong analgesia were at higher risk of switching therapy. These findings are similar to 
the findings of this thesis. 
In comparison with the study by Gore et al. (2012), this thesis explores a wider range of 
factors associated with prescription patterns and considers patients with incident and 
prevalent MSK conditions separately. It tackles different switching scenarios separately to 
account for movement up the analgesia ladder as well as multiple event switching and 
follows prescription patterns over a longer period of time.  
The study by Gore et al. (2012) is the only study that was found to model factors 
associated with switching analgesia in a similar way to approaches used in this thesis. 
They found that patients aged above 55 years were less likely to switch therapy. However 
the Gore study explored age as a binary variable of above or below 55 without clinical 
justification of their choice and explored few socio-demographic and clinical variables. In 
contrast this thesis explores age as a five category variable which has highlighted that 
there are variations in prescription patterns and switching across the five categories, and 
considers a large pool of socio-demographic, clinical and patient-reported characteristics.  
This thesis brings into focus that prescription patterns and analgesia switching in both 
prevalent and incident MSK consulters is associated with a wide range of factors in 
contrast to the study by Gore et al. (2012).  Amongst the factors adjusted for in this thesis 
which are not in study by Gore are the regions in which pain was located, number of MSK 
consultations, presence of co-morbidity and a range of patient-reported variables (such as 
physical function and pain interference). While it is not possible to measure and adjust for 
all possible variables, having a wider pool of variables helps as some measured variables 
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may be strongly related to or proxies for unmeasured ones. For example, the study 
identified that an increased number of consultations is related to a reduced risk of 
switching, which may be correlated with adherence to prescribed medication as patients 
who have regular contact with medical professionals may be more likely to follow their 
treatment regimens (Schneider, 2010).  
Research by Gore et al. (2012) attempted to model switching between differing types of 
analgesia with varying levels of analgesia effect for MSK conditions but did not examine 
the full spectrum of available analgesia, adjusted for fewer factors, and did not distinguish 
patients switching to stronger analgesia, but only considered any change in analgesia. 
The implication from this approach is that all kinds of switches are of equal importance, 
which is a contradiction to the fact that stronger analgesia are likely to have more adverse 
effects even if they do control pain better (Chou et al., 2005; Rahme et al., 2006). 
The potential limitation of this study is that the data was not initially designed for medical 
research but routinely collected as consultation and prescription records and there are 
only 12 general practices contributing to it. It is therefore possible that some important 
baseline variables not measured in the database were not included in the analysis, for 
example patient preference, a better measure of comorbidity, severity of pain and use of 
over the counter medication among others. The non-randomised sample selection criteria 
coupled with a small number of participating general practices may allow forms of 
selection bias due to regional or practice variations such as the population composition 
within the area covered by the general practices. However the number of participants in 
the main models was more than the minimum sample size suggested (720) for such a 
study, making the results more reliable. 
The results could also be affected by other forms of confounding induced by national 
prescription guidelines available to general practitioners, For example advice against use 
of coproxamol in 2005 resulted in an immediate decline in the use of opioids with a steady 
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rise there after (Bedson et al., 2012). The prevalence of MSK conditions and average age 
may vary differently across the wider population. Further, GPs may consider multiple 
factors in deciding the medication and appropriate potency level (Bope et al., 2004; 
Garbez and Puntillo, 2005; Schneider, 2010). This study was not designed to evaluate 
explicitly the clinical reasons for switching analgesia, but to evaluate baseline and time 
varying factors that clinicians should be aware might be related to a specific prescription 
pattern or treatment profile eventually. 
One limitation of the study could be the presence of missing data in the analyses within 
the NorStOP dataset and exclusion of those with missing data from the final model. 
Multiple imputation techniques could have been used to impute missing data. However 
from the descriptive analysis it can be seen that the overall proportion of missing data is 
small and the participants with missing data are not very different from the whole cohort 
by age and gender. Sensitivity analyses assuming those with missing data would have 
reported the extremes on those variables did not change conclusions. 
One major limitation of the findings is that there is potentially a relationship between 
length of time and some of the variables, for example, the number of consultations before 
the switching event. An increased number of consultations were associated with a 
reduced likelihood to switch analgesia. It is possible those generally more likely to switch 
will do so early before they have had the opportunity to make multiple consultations, whilst 
those less likely to switch have a longer time in which they can increase their number of 
consultations. Therefore interpreting the findings to mean that consulting more reduces 
the likelihood of switching may be a biased interpretation.  
Another limitation of the study is lack of pain measurement in the CiPCA cohort with 
incident MSK conditions; as such we use change of prescription and analgesia potency 
level as a proxy measure of the changes in pain levels. As discussed earlier, the 
prescription patterns or switching analgesia may not necessarily be an indication of pain 
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level or pain resulting from the MSK condition. For example co-morbidity and adverse 
effects may be the underlying causes of the changes (Rahme et al., 2006).  Pain was 
measured at baseline for the cohort with prevalent MSK, it had less association with 
switching than physical function levels.  However, this was baseline pain and not pain 
measured within the proximity of the change in analgesia. There are potentially other 
factors that may influence the level of pain on a day to day basis such that the measured 
pain may be an exaggeration or underestimation of the actual pain emanating from the 
MSK condition. Another limitation is the lack of OTC measurement which will be important 
for basic analgesia, and lack of information on alternative management such as advice to 
exercise and referral to physiotherapy. Knowing the potency of OTC medication taken by 
the patients prior to switching and other alternative management strategies will help 
understanding and interpretation of the reasons for switching analgesia. 
This study considers a wide range of MSK conditions amongst the patients selected for 
analysis without focussing on specific problems. Different MSK conditions have varying 
levels of pain severity and therefore require different treatment approaches which may 
account to some extent for the variations in treatment profiles or prescription patterns and 
time to switching analgesia (Hunt et al., 2007; Schneider, 2010). However, adjusting for 
pain location accounts for some of the variation in prescription patterns, for example, pain 
in the hand and wrist is less likely to be related to prescription of stronger analgesia 
compared to pain in the back. 
In evaluating the effect of switching analgesia on the patients’ physical function and level 
of pain interference, the study looks at patient outcomes recorded after three years. There 
is no conclusive statistical evidence of the effect of switching analgesia on the patient 
outcomes. Three years is a long time hence it is difficult to link all switching of analgesia 
with outcome considering that the earliest medication switches occurred just 15 days of 
initiation into treatment. There is also the potential effect of the unmeasured confounders 
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on the results. However the use of matching propensity scores ensures that those who 
switched and those who did not are comparable on measured covariates. 
The HAC is a consensus model and is not representative of the entirety of clinicians’ 
views and convictions in classifying analgesia. The HAC classification has six categories 
by definition but due to inadequate patient numbers in some categories, some had to be 
combined which may have affected the parameter estimates in the models and the validity 
of the conclusions drawn from the results. For example strong combination opioids and 
strong single opioids were combined into a single category of strong analgesia. However, 
there is clinical evidence that the two categories are similar to each other (Zernikow et al., 
2009), such that merging the categories does not affect the clinical interpretation of the 
results.  
The main limitation of LCA is the underlying assumption of local independence which 
means that the potency categories of analgesia prescribed are assumed to be 
independent within clusters. Violation of this assumption may lead to patients being 
placed into incorrect groups (Magidson and Vermunt, 2004). It is possible this may have 
occurred in this study, even though the results of tests suggest this did not happen to a 
great extent. The mean posterior probabilities for members in a cluster were greater than 
0.7 but not very close to 1 which means there is a small degree of uncertainty in cluster 
membership. No previous studies using latent class analysis models in analysing 
prescription patterns and patient profiles were identified which could be compared to this 
study. 
The other limitation of this thesis is that in the systematic review of statistical methods 
used in modelling medication switching only covered the period 2000-2010, and some 
papers modelling medication switching were not included, for example the  study by Gore 
et al. (2012). However the study used the Cox model which implies that the conclusions 
drawn from the review would not have been affected. 
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The findings interpreted with due consideration of the strengths and limitations of the 
study illustrates that there are still gaps in the current knowledge of prescription patterns 
and switching of analgesia in the management of MSK conditions. 
10.3 Current knowledge gaps in switching analgesia in the 
management of musculoskeletal conditions 
The findings in this research suggest that there is an absence of primary care research 
evaluating the current prescribing practices and patterns based on the WHO and NICE 
guidelines for  the pharmacological management of MSK conditions. There is also a 
paucity of relevant literature with respect to the evaluation of factors associated with being 
prescribed analgesia, the potency level prescribed at the onset of consultation, the explicit 
relationship between prescription patterns during follow-up and patient characteristics.  
The evaluation of factors associated with medication switching in MSK conditions is 
generally focussed on the clinical aspects and partly on socio-demographic factors. 
Studies by Rahme et al. (2005) and Bennett et al. (2003) evaluating switching between 
NSAIDs and COX2s (which is an entirely different context to this thesis) evaluated the 
association of age, gender, prior health check, previous diagnoses, prior medication and 
dose and previous switches, while Gore et al. (2012) evaluating therapy switching in 
chronic low back pain and OA, further looked at co-morbidities such as mental disorders 
and headaches. The potential effects on pain medication management of using over the 
counter medication, pain interference, physical function, pain location, the number of 
consultations prescriptions prior to switching and body weight have never (to our 
knowledge) been evaluated in switching of analgesia in MSK conditions. However body 
weight, pain interference and physical function have been shown to be related to 
prescription of opioids (Green et al., 2012), while deprivation level, income levels and 
other medications such as anti-depressants have been shown to be predictors of 
medication selection among patients (Boulanger et al., 2011). 
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There is evidence of limited use of a wide variety of statistical approaches in analysing 
and evaluating prescription patterns and switching of analgesia, as seen through the 
systematic review in Chapter 2. The approaches, if time to switch is the outcome, tend to 
be heavily reliant on the proportional hazards assumption. Henderson and Oman (1999) 
analysing the effects of frailty (heterogeneity or unmeasured covariates) in survival 
analysis models suggested that frailty is always present in most medical data, and if 
ignored and so the model misspecified, underestimation of the standard errors occurs. 
The consequences underestimated standard errors are failure of the goodness-of-fit tests 
to detect departures from assumed model, resulting in unreliable models.  
The literature review in Chapter 2 highlighted that switching analgesia has been evaluated 
only in the context of switching from one specific drug to another, and never from one 
potency category to another.  The existence of over 300 analgesia medications (BNF 65 
2013) that clinicians can prescribe made the examination of their use in general practice, 
a difficult proposition but the development of the hierarchical analgesia categorisation 
(HAC) by specialist clinicians in the field has laid the foundation of this analysis (Bedson 
et al., 2012). Previous knowledge on switching analgesia in MSK conditions remains 
largely specific to individual drugs and have not been generalised according to potency 
levels of analgesia. The factors associated with the generic change from one category of 
equipotent analgesia to another have not been rigorously explored but have been based 
on results from switching between individual drugs within or across potency categories 
(Chapter 2). 
10.4 Statistical implications  
Latent class analysis is an effective approach to identifying clusters of MSK consulters as 
defined by prescription patterns. This approach can help in future research in that it can 
be used to identify groups of patients at high risk of exposure to the adverse effects of 
analgesia, as seen through the multiple-potency cluster identified in Chapter 5.  The LCA 
approach used here did not take into account the order analgesia were prescribed. The 
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LCA approach within the context of prescription patterns in MSK can be extended to 
include longitudinal latent class analysis (LLCA) and latent class growth analysis (LCGA) 
(Henry and Muthen, 2010; Vermunt and Magidson, 2008). These approaches will enable 
clustering of patients based on the trajectories of analgesia changes over time, including 
the order they occur. The follow-up time can be split into smaller discrete time periods so 
that the potency levels of analgesia can be established for each time period as well for the 
entire follow-up period.  
The main limitation of the Weibull model is that the Weibull is a parametric model which 
may not always be suitable (Collet, 2003). The parameter estimates of a Weibull and a 
Cox model are expected to be similar if the probability density function of the data is 
indeed Weibull (Collet, 2003). However since the Weibull is a good fit to this data, 
exploiting the advantages of the Weibull model (such as not assuming proportional 
hazards) over the Cox model can only help to further understand the analgesia switching 
in MSK conditions, as we can now attach an underlying distribution to the switch times.  
The precision of the Weibull model together with the extension of frailty modelling in this 
thesis could have positive implications in the use of parametric statistical methods in 
modelling time to switching analgesia in MSK conditions in primary care. The Weibull 
model is not reliant on the proportional hazards assumption as the Cox model, it 
summarises the hazard function in a few parameters, model based predictions of survival 
rates at a given time are not difficult to estimate and model extrapolation is possible. For 
example in this thesis, the Weibull shape parameter enabled the projection that the risk of 
switching to stronger analgesia may decrease with time. The Weibull model can now be 
considered as a viable alternative to the Cox model in this context. The study raises the 
possibility that some patient clinical and socio-demographic variables are not only 
associated with time to switching but actually accelerate the time can be explored, 
considering that most patients switched analgesia within the first 100 days, and the 
Weibull model has the characteristic of accelerated failure time.  
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Frailty models account for more variation and changing hazards over time. This may 
suggest that if there are suspected important unmeasured covariates, frailty model 
extension should be explored or if the hazard is constant, an exponential model may be 
explored too.  
10.5 Clinical implications 
The clinical findings from this thesis have implications which may be important to 
clinicians, practitioners and research, within the context of MSK conditions and 
prescription of analgesia. Considering that most patients with a new MSK consultation did 
not get a prescription at first consultation, the majority were initially on low dose 
prescriptions and switched later to higher strengths analgesia, we can hypothesise that 
practitioners do seem to follow the WHO and NICE guidelines in the management of 
MSK, but some patients conditions prove more difficult to deal with. This is seen in the 
latent class analysis model which shows some groups who prescribed at least three 
categories, predominantly the over 60 age group. The over 60 group is also associated 
with the multiple event switches.  
Considering among other reasons that switching may be necessitated by the need to 
alleviate increasing pain (Boulanger et al., 2011; Benyamin et al., 2008), these findings 
concur with the current knowledge that MSK conditions deteriorate with age and there is 
higher risk of adverse effects of NSAIDs and stronger opioids in the older patients 
(Boulanger et al., 2011; Mercadante and Bruera, 2012). The association of increased 
consultation with reduced risk of switching suggests that while older patients are more 
vulnerable, there are potentially some underlying issues that need further investigation. 
For example re-assurance, supervision and individual strategies of coping with pain and 
their condition may be at play. This suggests that based on baseline characteristics, 
clinicians should identify and consider recommending more frequent consultations for 
some patients than others. In the presence of side effects, clinicians may have to 
prescribe additional medication to control for side effects instead of switching. For 
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example some patients may experience nausea with stronger opioids. This might lead to 
non-compliance, but could be avoided if at a timely review this adverse effect was 
identified and anti-emetics prescribed until the patient develops tolerance to nausea. In 
the absence of such a review the patient might determine that the medication and side 
effects are something they are not prepared to tolerate again and so at some future 
consultation might decide they would prefer an alternative analgesia.  
There are patients at higher risk of switching that clinicians should take note of, when they 
first present with MSK conditions so that their pain management regime may include 
increased consultation levels. Varying levels of vigilance might be appropriate, the more 
boxes a patient ticks on the ‘at risk’ of switching factors, the more priority to review should 
be given. For example, the patients who may be considered at higher risk of switching are 
females, elderly and lower social class patients.  
10.6 Future research 
The design of a future study could ensure that different pain locations or types of MSK 
conditions are considered separately. The reasons for the change in the analgesia can be 
investigated by location or condition. The consistency of risk factors and the effects of 
frailty across different causes (MSK conditions, pain locations) of switching analgesia can 
be explored. Prescribed analgesia and change can be additionally analysed in time 
periods of say 1 year segments over the follow-up period. As such with adequate data, 
longitudinal and multilevel models could be fitted accounting for either each location or 
type of MSK condition as a random effect.  
With adequate data, the switching of analgesia can followed through to establish which 
switching combinations are effective in the long term. For example if the patients under 
observation eventually moved to secondary care, and if moving into secondary care is 
considered a negative outcome, then the role of switching associated with this outcome 
can be modelled. More measures, for example physical function and pain interference can 
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be measured within the time vicinity of the switches in order to capture not only the reason 
of switching but the immediate effect of switching, and the trajectory of the MSK condition 
with respect to treatment can be followed and modelled.  
In modelling the latent classes of prescription patterns, longitudinal latent class analysis 
(LLCA) or latent class growth analysis (LCGA) can be employed. Clusters can then be 
identified and defined by the trajectory (in a longitudinal rather than cross-sectional way) 
and followed with respect to potency levels at time intervals, for example, potentially a 
cluster may consist of patients with a trajectory of increasing potency levels in successive 
time intervals. 
The significance of frailty in this thesis suggests the possible presence of accelerated 
failure time effects. Accelerated failure time models are parametric models for modelling 
time to event data which consider that the measured covariates are not only associated 
with time to the event, but actually accelerate the time to the event. The Weibull model 
has the special characteristic that it can used in both accelerated failure models as well as 
when proportional hazards are assumed. Hence exploring further the use of parametric 
failure time models in evaluating time to switching is recommended.  
10.7 Conclusion 
This study has evaluated prescription patterns from first consultation for MSK condition in 
primary care and followed up over a five year period, accounting for socio-demographic, 
clinical and patient-specified factors associated with the changes. The study applied a 
wide range of statistical techniques to establish model and clinical validity and accuracy. 
The Weibull model is an effective approach to modelling time to medication switching in 
MSK conditions. It has been shown that there are baseline clinically relevant patient 
characteristics associated with being prescribed analgesia, the strength of the analgesia 
prescribed, and the prescribed medication profile over time. GPs might take account of 
these factors in planning future management. 
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Appendix A 
Table A.1: Snapshot of 50 Read Codes under Chapter 1 
                                                                  
 50.       16J1                        Swollen toe         foot  
 49.       16J0                       Swollen calf    lower leg  
 48.       16CZ               Backache symptom NOS         back  
 47.       16CA           Mechanical low back pain   lower back  
 46.       16C9              Chronic low back pain   lower back  
                                                                 
 45.       16C7              C/O - upper back ache   upper back  
 44.       16C6    Back pain without radiation NOS         back  
 43.       16C6       Back pain without radiat NOS         back  
 42.       16C5                C/O - low back pain   lower back  
 41.       16C4        Back pain worse on sneezing         back  
                                                                 
 40.       16C3            Backache with radiation         back  
 39.       16C2                           Backache         back  
 38.       16C1                        No backache         back  
 37.        16C                   Backache symptom         back  
 36.       16BZ               Bruising symptom NOS   unspecifie  
                                                                 
 35.       16B4            Post-traumatic bruising   unspecifie  
 34.       16B3               Spontaneous bruising   unspecifie  
 33.       16B2                     Bruises easily   unspecifie  
 32.        16B                   Bruising symptom   unspecifie  
 31.       16AZ             Stiff neck symptom NOS         neck  
                                                                 
 30.       16A3                   Wry neck symptom         neck  
 29.       16A3              Torticollis - symptom         neck  
 28.       16A3               Wry neck/torticollis         neck  
 27.       16A2                         Stiff neck         neck  
 26.       16A1                      No stiff neck         neck  
                                                                 
 25.        16A                 Stiff neck symptom         neck  
 24.      14V50               H/0: arthrodesis toe         foot  
 23.       14V5                   H/O: arthrodesis   unspecifie  
 22.       14T5              H/O: artificial joint   unspecifie  
 21.       14OD   At risk of osteoporotic fracture   unspecifie  
                                                                 
 20.       14O9            At risk of osteoporosis   unspecifie  
 19.      14N30                 H/O Spinal surgery         back  
 18.       14J2                 H/O: facial injury         head  
 17.       14J1                   H/O: head injury         head  
 16.        14J                        H/O: injury   unspecifie  
                                                                 
 15.       14H5       H/O: cong. dislocation - hip          hip  
 14.       14GZ     H/O: musculo-skeletal dis. NOS   unspecifie  
 13.       14G8            H/O: vertebral fracture   neck & bac  
 12.       14G7                  H/O: hip fracture          hip  
 11.       14G4                  H/O: back problem         back  
                                                                 
 10.       14G3                  H/O: knee problem         knee  
  9.       14G2                H/O: osteoarthritis   unspecifie  
  8.       14G1          H/O: rheumatoid arthritis   unspecifie  
  7.        14G                     H/O: arthritis   unspecifie  
  6.       12IZ      FH: Musculo-skeletal dis. NOS   unspecifie  
                                                                 
  5.       12I2                 FH: Osteoarthritis   unspecifie  
  4.       12I1           FH: Rheumatoid arthritis   unspecifie  
  3.        12I                      FH: Arthritis   unspecifie  
  2.       1268                   FH: Osteoporosis   unspecifie  
  1.       1229                No FH: Osteoporosis   unspecifie  
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Table A.2: Snapshot of 50 Read Codes under Chapter N 
 
                                                                 
215.      N0110       Sex acqd reac arthrop-unspec   unspecifie  
                                                                 
214.       N011      Sex acquired reactive arthrop   unspecifie  
213.      N010z                Pyogenic arthr.-NOS   unspecifie  
212.      N010y      Pyogenic arthr.-other specif.   unspecifie  
211.      N010x     Pyogenic arthr.-multiple sites   unspecifie  
210.      N010A          Arthritis in Lyme disease   unspecifie  
                                                                 
209.      N0109     Pneumococc arthrit & polyarthr   unspecifie  
208.      N0108     Staphylococc arthrit/polyarthr   unspecifie  
207.      N0107         Pyogenic arthr.-ankle/foot   ankle/foot  
206.      N0106          Pyogenic arthr.-lower leg    lower leg  
205.      N0105       Pyogenic arthr.-pelvic/thigh   pelvis/thi  
                                                                 
204.      N0104               Pyogenic arthr.-hand         hand  
203.      N0103           Wrist pyogenic arthritis      forearm  
202.      N0102          Pyogenic arthr.-upper arm    upper arm  
201.      N0101     Pyogenic arthr.-shoulder regn.     shoulder  
200.      N0100     Pyogenic arthr.-site unspecif.   unspecifie  
                                                                 
199.       N010                   Septic arthritis   unspecifie  
198.        N01        Arthropathy with infections   unspecifie  
197.       N00z               Collagen disease NOS   unspecifie  
196.      N00y1            Fibrosclerosis systemic   unspecifie  
195.      N00y0             Eosinophilic fasciitis   unspecifie  
                                                                 
194.       N00y      Other spec.diff.collagen dis.   unspecifie  
193.       N006          Antiphospholipid syndrome   unspecifie  
192.       N005              Adult Still's Disease   unspecifie  
191.       N004                       Polymyositis   unspecifie  
190.      N003X        Dermatopolymyositis, unspec   unspecifie  
                                                                 
189.      N0031     Dermatopolymyosit,neoplast dis   unspecifie  
188.      N0030           Juvenile dermatomyositis   unspecifie  
187.       N003             Poikilodermatomyositis   unspecifie  
186.       N002          Sicca (Sjogrens) syndrome   unspecifie  
185.       N002         Keratoconjunctivitis sicca   unspecifie  
                                                                 
184.       N002         Sicca (Sjogren's) syndrome   unspecifie  
183.      N0012     Syst scleros induc drugs/chems   unspecifie  
182.      N0011                     CREST syndrome   unspecifie  
181.      N0010     Progressive systemic sclerosis   unspecifie  
180.       N001                 Systemic sclerosis   unspecifie  
                                                                 
179.       N001                        Scleroderma   unspecifie  
178.      N000z   Systemic lupus erythematosus NOS   unspecifie  
177.      N000z     Systemic lupus erythematos.NOS   unspecifie  
176.      N0004              SLE with pericarditis   unspecifie  
175.      N0003     Syst lup eryth + organ/sys inv   unspecifie  
                                                                 
174.      N0002      Drug-ind systemic lupus eryth   unspecifie  
173.      N0001               Libman-Sacks disease   unspecifie  
172.      N0000      Disseminated lupus erythemat.   unspecifie  
171.       N000       Systemic lupus erythematosus   unspecifie  
170.        N00     Diffuse connective tissue dis.   unspecifie  
                                                                 
169.      N0-99                Arthritis/arthrosis   unspecifie  
168.         N0                Arthritis/arthrosis   unspecifie  
167.         N0     Arthropathies and related dis.   unspecifie  
166.          N         Connective tissue diseases   unspecifie  
165.          N     Musculoskelet/connectiv tissue   unspecifie  
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Table A.3: Snapshot of 50 Read Codes under Chapter R 
 
                                                                
3151.      R090G                [D] Perineal pain       pelvis  
                                                                
3150.      R090G                  [D] Pelvic pain       pelvis  
3149.      R090G      [D]Pelvic and perineal pain       pelvis  
3148.      R090C                     [D]Loin pain       pelvis  
3147.      R090B                    [D]Groin pain       pelvis  
3146.      R0661                    [D]Chest lump        chest  
                                                                
3145.       R066      [D]Swelling mass lump chest        chest  
3144.      R065z                [D]Chest pain NOS        chest  
3143.      R065D            [D]Central chest pain        chest  
3142.      R065C       [D]Retrosternal chest pain        chest  
3141.      R065B        [D]Non cardiac chest pain        chest  
                                                                
3140.      R065B        [D]Non-cardiac chest pain        chest  
3139.      R065A    [D]Musculoskeletal chest pain        chest  
3138.      R0659        [D]Parasternal chest pain        chest  
3137.      R0652      [D]Anterior chest wall pain        chest  
3136.      R0650        [D]Chest pain unspecified        chest  
                                                                
3135.      R0650      [D] Retrosternal chest pain        chest  
3134.       R065                    [D]Chest pain        chest  
3133.      R04zz    [D]Head and neck symptoms NOS    head/neck  
3132.       R04z    [D]Head and neck other sympt.    head/neck  
3131.       R04z                   [D]Lesion face         head  
                                                                
3130.      R0422          [D]Lump in head or neck    head/neck  
3129.      R0420      [D]Swelling in head or neck    head/neck  
3128.      R0420                 [D]Swelling face         head  
3127.       R042      [D]Swell.masslump head/neck    head/neck  
3126.       R042       [D]Neck swelling/mass/lump         neck  
                                                                
3125.      R040z                      [D]Jaw pain         head  
3124.      R040z              [D]Pain in head NOS         head  
3123.      R0400                   [D]Facial pain         head  
3122.        R04        [D]Head and neck symptoms    head/neck  
3121.       R027        [D]Spontaneous ecchymoses   unspecifie  
                                                                
3120.       R027          [D]Spontaneous bruising   unspecifie  
3119.      R022K              [D]Buttock swelling      buttock  
3118.      R022H                    [D]Wrist lump        wrist  
3117.      R022G                   [D]Finger lump         hand  
3116.      R022F                 [D]Lump on thigh        thigh  
                                                                
3115.      R022D                   [D]Lump on leg   lower limb  
3114.      R022C                  [D]Lump on knee         knee  
3113.      R022B                  [D]Lump on hand         hand  
3112.      R022A                 [D]Shoulder lump     shoulder  
3111.      R0229                     [D]Foot lump         foot  
                                                                
3110.      R0225     [D]Loc swelmass/lumplow limb   lower limb  
3109.      R0224     [D]Loc swellmass/lumpup limb   upper limb  
3108.      R01zz    [D]Nerv/musculoskel.sympt.NOS   unspecifie  
3107.      R01z2          [D]Musculoskeletal pain   unspecifie  
3106.      R01z1         [D]Growing pains - limbs         limb  
                                                                
3105.       R01z   [D]Nerv/musculoskel.symp.other   unspecifie  
3104.        R01   [D]Nerv/musculoskeletal sympt.   unspecifie  
3103.        R01      [D]Musculoskeletal symptoms   unspecifie  
3102.      R00z2              [D]Pain generalized   unspecifie  
3101.      R00z2       [D]General aches and pains   unspecifie  
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Appendix B 
Kaplan Meier curves of survival estimates for the baseline variables 
The appendix contains Kaplan Meier curves illustrating differences in survival rates 
between the categories of selected baseline variables for chapter 6, 7 and 8. Figure B.6.1 
to B.6.9 illustrate the survival estimates for switching to any analgesia for chapter 6 
analysis. 
Figure B.6.1: Survival estimate curves by age group 
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Figure B.6.2: Survival estimate curves by gender 
 
Figure B.6.3: Survival estimate curves by presence of comorbidity 
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Figure B.6.4: Survival estimate curves by level of deprivation 
 
Figure B.6.5: Survival estimate curves by pain location 
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Figure B.6.6: Survival estimate curves by registered general practice 
 
Figure B.6.7: Survival estimate curves by member of staff consulted 
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Figure B.6.8: Survival estimate curves by previous prescribed analgesia 
 
Figure B.6.9: Survival estimate curves by previous musculoskeletal consultation 
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Figure B.7.1 to B.7.8 illustrate the survival estimates for switching from low potency 
analgesia (no medication, basic and weak analgesia) to stronger analgesia (moderate and 
strong analgesia) for chapter 7 analysis. 
Figure B.7.1: Survival estimate curves by age groups 
 
Figure B.7.2: Survival estimate curves by gender 
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Figure B.7.3: Survival estimate curves by the presence of comorbidity 
 
Figure B.7.4: Survival estimate curves by levels of deprivation 
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Figure B.7.5: Survival estimate curves by pain location 
 
Figure B.7.6: Survival estimate curves by member of staff consulted 
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Figure B.7.7: Survival estimate curves by previous prescribed analgesia 
 
Figure B.7.8: Survival estimate curves by previous MSK consultation 
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Figure B.8.1 to B.8.13 illustrate the survival estimates for switching from low potency 
analgesia (no medication, basic and weak analgesia) to stronger analgesia (moderate and 
strong analgesia) for chapter 8 analysis (NorStOP data). 
Figure B.8.1: Survival estimate curves by age group 
 
Figure B.8.2: Survival estimate curves by gender 
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Figure B.8.3: Survival estimate curves by previous prescribed analgesia 
 
Figure B.8.4: Survival estimate curves by analgesia prescribed on initial consultation 
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Figure B.8.5: Survival estimate curves by age group 
 
Figure B.8.6: Survival estimate curves by over the counter medication used 
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Figure B.8.7: Survival estimate curves by patient BMI 
 
Figure B.8.8: Survival estimate curves by the presence of selected comorbidity 
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Figure B.8.9: Survival estimate curves by adequate access to GP 
 
Figure B.8.10: Survival estimate curves by age group 
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Figure B.8.11: Survival estimate curves by presence of widespread pain 
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